{
  "meta": {
    "id": "test5",
    "title": "Autonomic Nervous System",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "A patient of septic shock was given intravenous nor-epinephrine. The response to this drug is best checked by?",
      "options": [
        {
          "label": "A",
          "text": "Increase in heart rate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decrease in heart rate",
          "correct": false
        },
        {
          "label": "C",
          "text": "Increase in mean arterial pressure",
          "correct": true
        },
        {
          "label": "D",
          "text": "Decreased renal perfusion and reduced urine output",
          "correct": false
        }
      ],
      "correct_answer": "C. Increase in mean arterial pressure",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Increase in mean arterial pressure</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Increase in heart rate - Not the best indicator for the efficacy of nor-epinephrine in septic shock , as the drug may actually lead to a reflex bradycardia due to increased blood pressure.</li><li>\u2022 Option A. Increase in heart rate</li><li>\u2022 Not the best indicator</li><li>\u2022 nor-epinephrine in septic shock</li><li>\u2022 reflex bradycardia due to increased blood pressure.</li><li>\u2022 Option B. Decrease in heart rate - While nor-epinephrine can cause a reflex decrease in heart rate due to increased blood pressure, it's not the primary indicator of therapeutic response in septic shock.</li><li>\u2022 Option B. Decrease in heart rate</li><li>\u2022 nor-epinephrine</li><li>\u2022 reflex decrease in heart rate</li><li>\u2022 increased blood pressure,</li><li>\u2022 not the primary indicator</li><li>\u2022 Option D. Decreased renal perfusion and reduced urine output - These are potential adverse effects of nor-epinephrine due to its vasoconstrictive action , not indicators of a positive therapeutic response.</li><li>\u2022 Option D. Decreased renal perfusion and reduced urine output</li><li>\u2022 potential adverse effects of nor-epinephrine</li><li>\u2022 vasoconstrictive action</li><li>\u2022 not</li><li>\u2022 positive therapeutic response.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The effectiveness of nor-epinephrine in the management of septic shock is best monitored by an increase in mean arterial pressure , aiming to maintain a mean BP above 70 mm Hg and systolic BP above 90 mm Hg to ensure adequate organ perfusion .</li><li>\u2022 nor-epinephrine</li><li>\u2022 septic shock</li><li>\u2022 monitored</li><li>\u2022 increase in mean arterial pressure</li><li>\u2022 maintain a mean BP above 70 mm Hg and systolic BP above 90 mm Hg</li><li>\u2022 adequate organ perfusion</li><li>\u2022 Ref: Harrison 19 th /1761</li><li>\u2022 Ref:</li><li>\u2022 Harrison 19 th /1761</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3c827603",
      "audio": ""
    },
    {
      "text": "A 24-year-old farm worker is rushed to a nearby emergency department after an accidental exposure to parathion. Which of the following drugs can be given to increase the activity of his acetyl cholinesterase?",
      "options": [
        {
          "label": "A",
          "text": "Atropine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dimercaprol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Physostigmine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pralidoxime",
          "correct": true
        }
      ],
      "correct_answer": "D. Pralidoxime",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Pralidoxime</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Atropine: Atropine is drug of choice as an antidote in organophosphate poisoning , but it does not increase the activity of acetylcholinesterase. Instead, it serves to counteract the effects of excess acetylcholine on muscarinic receptors , thereby relieving symptoms such as bradycardia, salivation, and bronchoconstriction. Atropine does not affect the nicotinic receptor-mediated effects (e.g., muscle weakness, paralysis).</li><li>\u2022 Option</li><li>\u2022 A.</li><li>\u2022 Atropine:</li><li>\u2022 Atropine</li><li>\u2022 drug of choice</li><li>\u2022 antidote in organophosphate poisoning</li><li>\u2022 does not increase</li><li>\u2022 acetylcholinesterase.</li><li>\u2022 serves to counteract the effects</li><li>\u2022 acetylcholine on muscarinic receptors</li><li>\u2022 bradycardia, salivation, and bronchoconstriction. Atropine does not</li><li>\u2022 nicotinic receptor-mediated</li><li>\u2022 effects (e.g., muscle weakness, paralysis).</li><li>\u2022 Option B. Dimercaprol: Dimercaprol is a chelating agent used in the treatment of poisoning by heavy metals , such as arsenic, lead, and mercury . It is not used in the treatment of organophosphate poisoning and does not i ncrease acetylcholinesterase activity .</li><li>\u2022 Option B.</li><li>\u2022 Dimercaprol:</li><li>\u2022 agent</li><li>\u2022 poisoning by heavy metals</li><li>\u2022 arsenic, lead, and mercury</li><li>\u2022 not</li><li>\u2022 organophosphate poisoning</li><li>\u2022 does not</li><li>\u2022 ncrease acetylcholinesterase activity</li><li>\u2022 Option C . Physostigmine: Physostigmine is a cholinesterase inhibitor, and unlike pralidoxime, it would exacerbate the effects of organophosphate poisoning by further inhibiting acetylcholinesterase. Therefore, it is not used in the treatment of organophosphate poisoning and is contraindicated in such cases.</li><li>\u2022 Option C</li><li>\u2022 Physostigmine:</li><li>\u2022 cholinesterase inhibitor,</li><li>\u2022 unlike pralidoxime,</li><li>\u2022 organophosphate poisoning</li><li>\u2022 inhibiting acetylcholinesterase.</li><li>\u2022 not used</li><li>\u2022 organophosphate poisoning</li><li>\u2022 contraindicated in such cases.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Pralidoxime is used to reactivate acetylcholinesterase inhibited by organophosphates, thereby r educing the toxic accumulation of acetylcholine . This treatment, often used in conjunction with atropine to manage muscarinic symptoms, is critical in the management of organophosphate poisoning, highlighting the importance of specific antidotes in toxicological emergencies.</li><li>\u27a4 Pralidoxime</li><li>\u27a4 reactivate acetylcholinesterase</li><li>\u27a4 educing the toxic accumulation of</li><li>\u27a4 acetylcholine</li><li>\u27a4 conjunction with atropine to manage muscarinic symptoms,</li><li>\u27a4 organophosphate poisoning,</li><li>\u27a4 specific antidotes in toxicological emergencies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c183dbfb",
      "audio": ""
    },
    {
      "text": "Which of the following acts on \u03b11, \u03b12 and \u03b21 receptors but does not stimulate \u03b22 receptors?",
      "options": [
        {
          "label": "A",
          "text": "Adrenaline",
          "correct": false
        },
        {
          "label": "B",
          "text": "Noradrenaline",
          "correct": true
        },
        {
          "label": "C",
          "text": "Isoprenaline",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dobutamine",
          "correct": false
        }
      ],
      "correct_answer": "B. Noradrenaline",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-115834.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Noradrenaline</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Noradrenaline (norepinephrine) acts on \u03b11, \u03b12, and \u03b21 adrenergic receptors. It is a naturally occurring catecholamine that functions as a neurotransmitter and hormone in the body . Noradrenaline's action on \u03b11 and \u03b12 receptors is responsible for its vasoconstrictive effects , while its action on \u03b21 receptors affects cardiac output by increasing the heart rate and myocardial contractility. It does not stimulate \u03b22 receptors , which are primarily involved in bronchodilation and vasodilation .</li><li>\u2022 Noradrenaline (norepinephrine) acts on \u03b11, \u03b12, and \u03b21 adrenergic receptors.</li><li>\u2022 catecholamine</li><li>\u2022 neurotransmitter and hormone in the body</li><li>\u2022 \u03b11 and \u03b12 receptors</li><li>\u2022 vasoconstrictive effects</li><li>\u2022 \u03b21 receptors</li><li>\u2022 cardiac output by increasing the heart rate</li><li>\u2022 myocardial</li><li>\u2022 contractility.</li><li>\u2022 does not stimulate \u03b22 receptors</li><li>\u2022 bronchodilation and vasodilation</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f21c814d",
      "audio": ""
    },
    {
      "text": "Propranolol can be used in all of the following conditions except.",
      "options": [
        {
          "label": "A",
          "text": "Thyrotoxicosis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Variant angina",
          "correct": true
        },
        {
          "label": "C",
          "text": "Migraine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hypertension",
          "correct": false
        }
      ],
      "correct_answer": "B. Variant angina",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/88.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Variant angina</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Thyrotoxicosis: Propranolol is used in thyrotoxicosis to provide symptomatic relief from hyperthyroid symptoms such as tachycardia, anxiety, and tremors . It can also inhibit peripheral conversion of T4 to T3.</li><li>\u2022 Option A. Thyrotoxicosis:</li><li>\u2022 Propranolol</li><li>\u2022 thyrotoxicosis</li><li>\u2022 symptomatic relief</li><li>\u2022 hyperthyroid symptoms</li><li>\u2022 tachycardia, anxiety, and tremors</li><li>\u2022 inhibit peripheral conversion of T4 to T3.</li><li>\u2022 Option C. Migraine: Propranolol is used as a prophylactic treatment for migraine . It helps reduce the frequency and severity of migraine attacks.</li><li>\u2022 Option C. Migraine:</li><li>\u2022 Propranolol</li><li>\u2022 prophylactic treatment for migraine</li><li>\u2022 reduce the frequency</li><li>\u2022 severity of</li><li>\u2022 migraine attacks.</li><li>\u2022 Option D. Hypertension: Propranolol can be used in the management of hypertension . It lowers blood pressure by reducing cardiac output and inhibiting renin release from the kidneys.</li><li>\u2022 Option D. Hypertension:</li><li>\u2022 Propranolol</li><li>\u2022 hypertension</li><li>\u2022 lowers blood pressure</li><li>\u2022 reducing cardiac</li><li>\u2022 output</li><li>\u2022 inhibiting</li><li>\u2022 renin</li><li>\u2022 kidneys.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the therapeutic uses and contraindications of propranolol, a non-selective beta-blocke r. Recognizing that propranolol is contraindicated in variant angina due to its potential to worsen coronary artery spasms highlights the importance of considering the specific clinical context when selecting beta-blockers for treatment.</li><li>\u27a4 therapeutic uses</li><li>\u27a4 contraindications of propranolol,</li><li>\u27a4 non-selective beta-blocke</li><li>\u27a4 propranolol is contraindicated in variant angina</li><li>\u27a4 potential to worsen coronary artery spasms</li><li>\u27a4 Indications of \u03b2-Blockers:</li><li>\u27a4 Indications of \u03b2-Blockers:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "28d161c2",
      "audio": ""
    },
    {
      "text": "Fenoldopam is used in the management of?",
      "options": [
        {
          "label": "A",
          "text": "Hypertensive emergencies",
          "correct": true
        },
        {
          "label": "B",
          "text": "Congestive heart failure",
          "correct": false
        },
        {
          "label": "C",
          "text": "Migraine prophylaxis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tachyarrhythmias",
          "correct": false
        }
      ],
      "correct_answer": "A. Hypertensive emergencies",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Hypertensive emergencies</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Congestive heart failure: Fenoldopam is not typically used in the management of congestive heart failure (CHF). Drugs commonly used in CHF include ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists , which work by different mechanisms to reduce the workload on the heart and improve cardiac output .</li><li>\u2022 Option B. Congestive heart failure:</li><li>\u2022 Fenoldopam</li><li>\u2022 not</li><li>\u2022 congestive heart failure (CHF).</li><li>\u2022 CHF include ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists</li><li>\u2022 reduce the workload on the heart</li><li>\u2022 improve cardiac output</li><li>\u2022 Option C. Migraine prophylaxis: Fenoldopam is not used for migraine prophylaxis . Medications for migraine prevention include beta-blockers (such as propranolol), calcium channel blockers, antidepressants, and antiepileptic drugs , which have different mechanisms of action aimed at reducing the frequency and severity of migraine attacks .</li><li>\u2022 Option C. Migraine prophylaxis:</li><li>\u2022 Fenoldopam</li><li>\u2022 not</li><li>\u2022 migraine prophylaxis</li><li>\u2022 beta-blockers (such as propranolol), calcium channel blockers, antidepressants, and antiepileptic drugs</li><li>\u2022 reducing the frequency and severity of migraine attacks</li><li>\u2022 Option D. Tachyarrhythmias: Fenoldopam is not indicated for the treatment of tachyarrhythmias. Drugs used to manage tachyarrhythmias include beta-blockers, calcium channel blockers, antiarrhythmic agents, and sometimes digoxin , depending on the type and cause of the arrhythmia. These medications work by modulating cardiac electrical activity to normalize heart rhythm .</li><li>\u2022 Option D. Tachyarrhythmias:</li><li>\u2022 Fenoldopam</li><li>\u2022 not</li><li>\u2022 tachyarrhythmias. Drugs used</li><li>\u2022 beta-blockers, calcium channel blockers, antiarrhythmic agents, and sometimes digoxin</li><li>\u2022 type and cause of the arrhythmia.</li><li>\u2022 modulating cardiac electrical activity</li><li>\u2022 normalize heart rhythm</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the specific indications for fenoldopam, particularly its role in managing hypertensive emergencies due to its vasodilatory effects and positive impact on renal perfusion . Additionally, recognizing that fenoldopam is not indicated for congestive heart failure, migraine prophylaxis, or tachyarrhythmias underscores the importance of selecting appropriate medications based on the clinical condition being treated.</li><li>\u27a4 specific indications for fenoldopam,</li><li>\u27a4 managing hypertensive emergencies</li><li>\u27a4 its vasodilatory effects</li><li>\u27a4 renal perfusion</li><li>\u27a4 fenoldopam is not</li><li>\u27a4 congestive heart failure, migraine prophylaxis, or tachyarrhythmias</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ccab0f5a",
      "audio": ""
    },
    {
      "text": "A 7-year-old child opened his father\u2019s drawer and ingested multiple tablets of his cardiac medication, metoprolol. The child was brought to hospital with profound hypotension and bradycardia. What is the specific antidote used in this situation?",
      "options": [
        {
          "label": "A",
          "text": "Dobutamine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glucagon",
          "correct": true
        },
        {
          "label": "C",
          "text": "Adrenaline",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nor-adrenaline",
          "correct": false
        }
      ],
      "correct_answer": "B. Glucagon",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Glucagon</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective</li><li>\u27a4 In cases of beta-blocker overdose , such as with metoprolol , the specific antidote is glucagon . It works by increasing cyclic AMP independently of the beta-adrenergic receptors , thereby improving heart rate and contractility despite the beta-blockade. Understanding the role of glucagon and its mechanism of action is crucial in managing beta-blocker toxicity effectively .</li><li>\u27a4 beta-blocker overdose</li><li>\u27a4 metoprolol</li><li>\u27a4 glucagon</li><li>\u27a4 increasing</li><li>\u27a4 cyclic AMP independently</li><li>\u27a4 beta-adrenergic receptors</li><li>\u27a4 improving heart rate and contractility</li><li>\u27a4 beta-blockade.</li><li>\u27a4 role of glucagon</li><li>\u27a4 managing beta-blocker toxicity effectively</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0d5c4f3f",
      "audio": ""
    },
    {
      "text": "Repeated administration of a drug produces the following effect on blood pressure (as shown in the diagram). What is this phenomenon known as?",
      "options": [
        {
          "label": "A",
          "text": "Tachyphylaxis",
          "correct": true
        },
        {
          "label": "B",
          "text": "Nicotinic actions of acetylcholine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Biphasic response of adrenaline",
          "correct": false
        },
        {
          "label": "D",
          "text": "Vasomotor reversal of Dale",
          "correct": false
        }
      ],
      "correct_answer": "A. Tachyphylaxis",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/picture1.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Tachyphylaxis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Nicotinic actions of acetylcholine</li><li>\u2022 Option B. Nicotinic actions of acetylcholine</li><li>\u2022 This is not the correct answer . The nicotinic actions of acetylcholine refer to the effect acetylcholine has on nicotinic acetylcholine receptors, which are ligand-gated ion channels found in the nervous system and at the neuromuscular junction . Normally acetylcholine decreases blood pressure and heart rate due to its action of muscarinic receptors. However, if we give very high dose of acetylcholine after giving atropine (to block muscarinic receptors), then it shows increase in BP and heart rate . This is due to the action of acetylcholine on nicotinic receptors present on ganglia</li><li>\u2022 not</li><li>\u2022 correct answer</li><li>\u2022 nicotinic actions</li><li>\u2022 acetylcholine</li><li>\u2022 nicotinic acetylcholine</li><li>\u2022 receptors,</li><li>\u2022 ligand-gated ion channels</li><li>\u2022 nervous system and at the neuromuscular junction</li><li>\u2022 acetylcholine decreases blood pressure and heart rate</li><li>\u2022 muscarinic receptors.</li><li>\u2022 very high dose of acetylcholine</li><li>\u2022 atropine (to block muscarinic receptors),</li><li>\u2022 increase in BP and heart rate</li><li>\u2022 acetylcholine on nicotinic receptors</li><li>\u2022 ganglia</li><li>\u2022 Option C. Biphasic response of adrenaline</li><li>\u2022 Option C. Biphasic response of adrenaline</li><li>\u2022 This option is incorrect. A biphasic response to adrenaline would involve an initial phase in which there is increase in blood pressure (due to stimulation of alpha 1 receptors) followed by a second phase in which there is fall in blood pressure (due to action on beta 2 receptors). The tracing does not show a biphasic response; it shows a series of responses that diminish over time, consistent with tachyphylaxis.</li><li>\u2022 incorrect.</li><li>\u2022 biphasic response</li><li>\u2022 adrenaline</li><li>\u2022 initial phase</li><li>\u2022 increase in blood pressure (due to stimulation of alpha 1 receptors)</li><li>\u2022 second phase</li><li>\u2022 blood pressure (due to action on beta 2 receptors).</li><li>\u2022 tracing does not</li><li>\u2022 biphasic response;</li><li>\u2022 series of responses</li><li>\u2022 diminish over time, consistent</li><li>\u2022 tachyphylaxis.</li><li>\u2022 Option D. Vasomotor reversal of Dale</li><li>\u2022 Option D. Vasomotor reversal of Dale</li><li>\u2022 Vasomotor reversal of Dale is a phenomenon where adrenaline can produce a paradoxical decrease in blood pressure due to stimulation of vasodilatory beta-adrenergic receptors , especially after pre-treatment with drugs that block alpha-adrenergic receptors. This is not what is depicted in the tracing.</li><li>\u2022 Vasomotor reversal of Dale</li><li>\u2022 adrenaline</li><li>\u2022 paradoxical decrease in blood pressure</li><li>\u2022 stimulation of vasodilatory beta-adrenergic receptors</li><li>\u2022 pre-treatment with drugs</li><li>\u2022 block alpha-adrenergic receptors.</li><li>\u2022 not</li><li>\u2022 Based on the image, the correct answer is:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Tachyphylaxis is a diminishing response to repeated administrations of the same dose of a drug over a short period. This is a common pharmacological phenomenon often seen with drugs that act on receptors or other cellular targets that can become desensitized or down-regulated with frequent stimulation .</li><li>\u2022 Tachyphylaxis is</li><li>\u2022 diminishing response</li><li>\u2022 repeated administrations</li><li>\u2022 act on receptors or other cellular targets</li><li>\u2022 desensitized or down-regulated with frequent stimulation</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4f5e6304",
      "audio": ""
    },
    {
      "text": "A 66-year-old woman with a long history of heavy smoking presents to her doctor with complaints of shortness of breath and chronic coughing that has been present for about 2 years and has been worsening in frequency. The doctor decides to prescribe a bronchodilator agent that has minimal cardiac side effects, since the patient also has an extensive cardiac history. Which medication did the doctor likely prescribe?",
      "options": [
        {
          "label": "A",
          "text": "Albuterol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Atenolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ipratropium",
          "correct": true
        },
        {
          "label": "D",
          "text": "Pseudoephedrine",
          "correct": false
        }
      ],
      "correct_answer": "C. Ipratropium",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Ipratropium</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Albuterol: Albuterol is a beta-2 agonist that effectively relieves bronchoconstriction. However, it can have cardiac side effects such as tachycardia and palpitations , especially in patients with existing cardiac conditions, due to its slight action on beta-1 adrenergic receptors.</li><li>\u2022 Option A. Albuterol: Albuterol is a beta-2 agonist that effectively relieves bronchoconstriction. However, it can have cardiac side effects such as tachycardia and palpitations , especially in patients with existing cardiac conditions, due to its slight action on beta-1 adrenergic receptors.</li><li>\u2022 Option A. Albuterol:</li><li>\u2022 beta-2 agonist</li><li>\u2022 relieves bronchoconstriction.</li><li>\u2022 cardiac side effects</li><li>\u2022 tachycardia and palpitations</li><li>\u2022 existing cardiac conditions,</li><li>\u2022 slight action on beta-1 adrenergic receptors.</li><li>\u2022 Option B. Atenolol: Atenolol is a beta-1 selective blocker used primarily in the treatment of hypertension and other cardiovascular conditions . It is not a bronchodilator and would not be appropriate for the treatment of COPD or asthma.</li><li>\u2022 Option B. Atenolol: Atenolol is a beta-1 selective blocker used primarily in the treatment of hypertension and other cardiovascular conditions . It is not a bronchodilator and would not be appropriate for the treatment of COPD or asthma.</li><li>\u2022 Option B. Atenolol:</li><li>\u2022 beta-1 selective blocker</li><li>\u2022 hypertension</li><li>\u2022 cardiovascular conditions</li><li>\u2022 not a bronchodilator</li><li>\u2022 treatment of COPD or asthma.</li><li>\u2022 Option D. Pseudoephedrine: Pseudoephedrine is a sympathomimetic drug used as a decongestant. It can increase blood pressure and heart rate, making it unsuitable for a patient with an extensive cardiac history requiring bronchodilation.</li><li>\u2022 Option D. Pseudoephedrine: Pseudoephedrine is a sympathomimetic drug used as a decongestant. It can increase blood pressure and heart rate, making it unsuitable for a patient with an extensive cardiac history requiring bronchodilation.</li><li>\u2022 Option D. Pseudoephedrine:</li><li>\u2022 sympathomimetic drug</li><li>\u2022 decongestant.</li><li>\u2022 increase</li><li>\u2022 blood pressure</li><li>\u2022 heart rate,</li><li>\u2022 unsuitable</li><li>\u2022 extensive cardiac history</li><li>\u2022 bronchodilation.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to understand the selection of bronchodilators in the management of respiratory conditions like COPD, especially in patients with comorbid cardiac conditions. Recognizing the pharmacological profiles of different classes of bronchodilators and their systemic effects is crucial for minimizing adverse effects and optimizing patient care.</li><li>\u27a4 selection of bronchodilators</li><li>\u27a4 respiratory conditions like COPD,</li><li>\u27a4 comorbid cardiac conditions.</li><li>\u27a4 pharmacological profiles</li><li>\u27a4 different classes of bronchodilators</li><li>\u27a4 systemic effects</li><li>\u27a4 minimizing adverse effects</li><li>\u27a4 optimizing patient care.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6d67d3c0",
      "audio": ""
    },
    {
      "text": "Which of the following patients would not benefit from the use of beta blockers?",
      "options": [
        {
          "label": "A",
          "text": "64-year-old female with frequent attacks of migraine",
          "correct": false
        },
        {
          "label": "B",
          "text": "35-year-old female with hyperthyroidism and symptomatic tachycardia and tremors",
          "correct": false
        },
        {
          "label": "C",
          "text": "56-year-old male with erectile dysfunction",
          "correct": true
        },
        {
          "label": "D",
          "text": "74-year-old male with history of compensated heart failure",
          "correct": false
        }
      ],
      "correct_answer": "C. 56-year-old male with erectile dysfunction",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 56-year-old male with erectile dysfunction</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. 64-year-old female with frequent attacks of migraine: Beta-blockers are often used for the prophylaxis of migraines . They can help reduce the frequency and severity of migraine attacks.</li><li>\u2022 Option A. 64-year-old female with frequent attacks of migraine: Beta-blockers are often used for the prophylaxis of migraines . They can help reduce the frequency and severity of migraine attacks.</li><li>\u2022 Option A. 64-year-old female with frequent attacks of migraine:</li><li>\u2022 Beta-blockers</li><li>\u2022 prophylaxis of</li><li>\u2022 migraines</li><li>\u2022 reduce the frequency</li><li>\u2022 severity of migraine attacks.</li><li>\u2022 Option B. 35-year-old female with hyperthyroidism and symptomatic tachycardia and tremors: Beta-blockers are useful in managing symptoms of hyperthyroidism such as tachycardia and tremors by blocking the effects of excess t hyroid hormones on the heart and other tissues.</li><li>\u2022 Option B. 35-year-old female with hyperthyroidism and symptomatic tachycardia and tremors: Beta-blockers are useful in managing symptoms of hyperthyroidism such as tachycardia and tremors by blocking the effects of excess t hyroid hormones on the heart and other tissues.</li><li>\u2022 Option B. 35-year-old female with hyperthyroidism and symptomatic tachycardia and tremors:</li><li>\u2022 Beta-blockers</li><li>\u2022 useful</li><li>\u2022 hyperthyroidism</li><li>\u2022 tachycardia and tremors</li><li>\u2022 blocking the effects</li><li>\u2022 excess</li><li>\u2022 hyroid hormones on the heart and other tissues.</li><li>\u2022 Option D. 74-year-old male with history of compensated heart failure: Certain beta-blockers are indicated in the management of heart failure . They can i mprove survival and reduce the need for hospitalization in patients with heart failure, especially those with a history of compensated heart failure, provided they are carefully selected and dosed.</li><li>\u2022 Option D. 74-year-old male with history of compensated heart failure: Certain beta-blockers are indicated in the management of heart failure . They can i mprove survival and reduce the need for hospitalization in patients with heart failure, especially those with a history of compensated heart failure, provided they are carefully selected and dosed.</li><li>\u2022 Option D. 74-year-old male with history of compensated heart failure:</li><li>\u2022 beta-blockers</li><li>\u2022 heart failure</li><li>\u2022 mprove survival and reduce</li><li>\u2022 hospitalization</li><li>\u2022 heart</li><li>\u2022 failure,</li><li>\u2022 history of compensated heart failure,</li><li>\u2022 carefully selected and dosed.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to understand the indications and contraindications for beta-blocker therapy . While beta-blockers are versatile medications with a broad range of clinical applications , their potential side effects, such as exacerbating erectile dysfunction , must be considered when prescribing these drugs to ensure they align with the patient's overall health status and medical needs.</li><li>\u27a4 indications and contraindications</li><li>\u27a4 beta-blocker therapy</li><li>\u27a4 beta-blockers are versatile</li><li>\u27a4 medications</li><li>\u27a4 broad range of clinical applications</li><li>\u27a4 potential side effects,</li><li>\u27a4 exacerbating erectile dysfunction</li><li>\u27a4 prescribing these drugs to ensure they align</li><li>\u27a4 health status and medical needs.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ba251c9b",
      "audio": ""
    },
    {
      "text": "A child on formoterol inhaler for treatment of bronchial asthma may exhibit all of the following features except?",
      "options": [
        {
          "label": "A",
          "text": "Tremors",
          "correct": false
        },
        {
          "label": "B",
          "text": "Hypoglycemia",
          "correct": true
        },
        {
          "label": "C",
          "text": "Hypokalemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bronchodilation",
          "correct": false
        }
      ],
      "correct_answer": "B. Hypoglycemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Hypoglycemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Tremors - A known side effect due to the stimulation of \u03b22 receptors by \u03b22 agonists.</li><li>\u2022 Option A.</li><li>\u2022 Tremors</li><li>\u2022 side effect</li><li>\u2022 \u03b22 receptors by \u03b22 agonists.</li><li>\u2022 Option C. Hypokalemia - Can occur as \u03b22 agonists increase intracellular potassium uptake .</li><li>\u2022 Option C.</li><li>\u2022 Hypokalemia</li><li>\u2022 \u03b22 agonists</li><li>\u2022 intracellular potassium uptake</li><li>\u2022 Option D. Bronchodilation - The primary therapeutic action of formoterol in bronchial asthma .</li><li>\u2022 Option D.</li><li>\u2022 Bronchodilation</li><li>\u2022 formoterol in bronchial asthma</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Formoterol, a \u03b22 agonist, does not cause hypoglycemia . Instead, it can cause side effects such as tremors, hypokalemia due to increased potassium uptake into cells , and the desired effect of bronchodilation for the management of asthma.</li><li>\u27a4 Formoterol, a \u03b22 agonist, does not</li><li>\u27a4 hypoglycemia</li><li>\u27a4 tremors, hypokalemia</li><li>\u27a4 increased potassium uptake into cells</li><li>\u27a4 bronchodilation</li><li>\u27a4 asthma.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a7d8dd8d",
      "audio": ""
    },
    {
      "text": "Cholinomimetic drugs can be used for the treatment of all the following conditions except ?",
      "options": [
        {
          "label": "A",
          "text": "Closed angle glaucoma",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bradycardia",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cobra bite",
          "correct": false
        },
        {
          "label": "D",
          "text": "Myasthenia gravis",
          "correct": false
        }
      ],
      "correct_answer": "B. Bradycardia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-120058.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Bradycardia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Correct Usage - Closed angle glaucoma : is treated with drugs like Physostigmine and Pilocarpine to increase aqueous humor outflow .</li><li>\u2022 Option A. Correct Usage - Closed angle glaucoma</li><li>\u2022 Physostigmine and Pilocarpine to increase aqueous humor outflow</li><li>\u2022 Option C. Correct Usage - For a cobra bite: Neostigmine plus atropine is used to counteract the neuromuscular blockade caused by the venom .</li><li>\u2022 Option C. Correct Usage - For a cobra bite:</li><li>\u2022 Neostigmine plus atropine</li><li>\u2022 counteract the neuromuscular blockade</li><li>\u2022 venom</li><li>\u2022 Option D. Correct Usage - In Myasthenia gravis: drugs such as Neostigmine are used to enhance neuromuscular transmission by preventing the breakdown of acetylcholine.</li><li>\u2022 Option D. Correct Usage - In Myasthenia gravis:</li><li>\u2022 Neostigmine</li><li>\u2022 neuromuscular transmission</li><li>\u2022 breakdown of acetylcholine.</li><li>\u2022 Additional Uses of Cholinergic Drugs:</li><li>\u2022 Additional Uses of Cholinergic Drugs:</li><li>\u2022 Alzheimer\u2019s disease treatment with Donepezil, Rivastigmine, and Galantamine to increase acetylcholine in the brain. Management of xerostomia with drugs like Cevimeline to stimulate salivary gland secretion . Postoperative urinary retention and paralytic ileus managed with drugs like Bethanechol and Neostigmine to stimulate the bladder detrusor muscle and GI motility . Antidote for anticholinergic poisoning with Physostigmine to counteract muscarinic receptor blockade.</li><li>\u2022 Alzheimer\u2019s disease treatment with Donepezil, Rivastigmine, and Galantamine to increase acetylcholine in the brain.</li><li>\u2022 Alzheimer\u2019s disease</li><li>\u2022 Donepezil, Rivastigmine, and Galantamine</li><li>\u2022 increase acetylcholine</li><li>\u2022 Management of xerostomia with drugs like Cevimeline to stimulate salivary gland secretion .</li><li>\u2022 xerostomia</li><li>\u2022 Cevimeline</li><li>\u2022 salivary gland secretion</li><li>\u2022 Postoperative urinary retention and paralytic ileus managed with drugs like Bethanechol and Neostigmine to stimulate the bladder detrusor muscle and GI motility .</li><li>\u2022 Postoperative urinary retention</li><li>\u2022 paralytic ileus</li><li>\u2022 Bethanechol and Neostigmine</li><li>\u2022 bladder detrusor muscle and GI motility</li><li>\u2022 Antidote for anticholinergic poisoning with Physostigmine to counteract muscarinic receptor blockade.</li><li>\u2022 Antidote for anticholinergic poisoning</li><li>\u2022 Physostigmine</li><li>\u2022 muscarinic receptor blockade.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Cholinomimetic drugs are not used for the treatment of bradycardia due to their potential to cause a decrease in heart rate . They are, however, useful in treating various other conditions where increased cholinergic action is beneficial, such as closed angle glaucoma, cobra bites, Myasthenia gravis, and Alzheimer\u2019s disease.</li><li>\u2022 Cholinomimetic drugs</li><li>\u2022 not used</li><li>\u2022 bradycardia</li><li>\u2022 decrease in heart rate</li><li>\u2022 increased cholinergic action</li><li>\u2022 closed angle glaucoma, cobra bites, Myasthenia gravis, and Alzheimer\u2019s disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5fd52a07",
      "audio": ""
    },
    {
      "text": "Treatment of choice for anaphylactic shock is",
      "options": [
        {
          "label": "A",
          "text": "Adrenaline 0.5 ml of 1:1000 solution by intramuscular route",
          "correct": true
        },
        {
          "label": "B",
          "text": "Adrenaline 1 ml of 1:10000 by intravenous route",
          "correct": false
        },
        {
          "label": "C",
          "text": "Atropine 3 mg intravenously",
          "correct": false
        },
        {
          "label": "D",
          "text": "Adenosine 12 mg intravenously",
          "correct": false
        }
      ],
      "correct_answer": "A. Adrenaline 0.5 ml of 1:1000 solution by intramuscular route",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Adrenaline 0.5 ml of 1:1000 solution by intramuscular route</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Adrenaline 1 ml of 1 :10000 by intravenous route: This is less preferred initially due to the risk of adverse effects with intravenous administration unless absolutely necessary and under close monitoring.</li><li>\u2022 Option B. Adrenaline 1 ml of 1</li><li>\u2022 :10000 by intravenous route:</li><li>\u2022 less</li><li>\u2022 risk of adverse effects</li><li>\u2022 intravenous administration</li><li>\u2022 absolutely necessary and under close monitoring.</li><li>\u2022 Option C. Atropine 3 mg intravenously: Not used in anaphylaxis , as it does not address the pathophysiological changes involved in anaphylactic shock.</li><li>\u2022 Option C. Atropine 3 mg intravenously:</li><li>\u2022 Not used in anaphylaxis</li><li>\u2022 Option D. Adenosine 12 mg intravenously: Not indicated for anaphylaxis as it's primarily used for certain types of supraventricular tachycardias.</li><li>\u2022 Option D. Adenosine 12 mg intravenously:</li><li>\u2022 Not indicated for anaphylaxis</li><li>\u2022 used for</li><li>\u2022 supraventricular tachycardias.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 For anaphylactic shock , adrenaline is administered intramuscularly in a 1:1000 concentration as the first-line treatment . This route is preferred over subcutaneous or intravenous administration due to its effectiveness and safety profile .</li><li>\u2022 anaphylactic shock</li><li>\u2022 adrenaline</li><li>\u2022 intramuscularly in a 1:1000 concentration as the first-line treatment</li><li>\u2022 subcutaneous or intravenous administration</li><li>\u2022 effectiveness and safety profile</li><li>\u2022 Ref : Harrison 19 th /2117</li><li>\u2022 Ref : Harrison 19 th /2117</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7099d4f9",
      "audio": ""
    },
    {
      "text": "All of the following are non-selective \u03b2-blockers except:",
      "options": [
        {
          "label": "A",
          "text": "Carvedilol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Betaxolol",
          "correct": true
        },
        {
          "label": "C",
          "text": "Oxprenolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Labetalol",
          "correct": false
        }
      ],
      "correct_answer": "B. Betaxolol",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/33.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Betaxolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Carvedilol: A non-selective beta-blocker that also has alpha-blocking activity, used for the treatment of high blood p ressure and heart failure.</li><li>\u2022 Option A.</li><li>\u2022 Carvedilol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 alpha-blocking activity,</li><li>\u2022 high blood</li><li>\u2022 ressure and heart failure.</li><li>\u2022 Option C. Oxprenolol: A non-selective beta-blocker with intrinsic sympathomimetic activity.</li><li>\u2022 Option C.</li><li>\u2022 Oxprenolol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 intrinsic sympathomimetic activity.</li><li>\u2022 Option D. Labetalol: A non-selective beta-blocker that also blocks alpha-1 receptors and is commonly used in pregnancy-induced hypertension.</li><li>\u2022 Option D.</li><li>\u2022 Labetalol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 blocks alpha-1 receptors</li><li>\u2022 pregnancy-induced</li><li>\u2022 hypertension.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Betaxolol is a cardioselective beta-blocker that selectively blocks beta-1 adrenergic receptors in the heart , while Carvedilol, Oxprenolol, and Labetalol are non-selective beta-blockers affecting both beta-1 and beta-2 adrenergic receptors.</li><li>\u2022 Betaxolol</li><li>\u2022 cardioselective beta-blocker</li><li>\u2022 blocks beta-1 adrenergic receptors in the heart</li><li>\u2022 Carvedilol,</li><li>\u2022 Oxprenolol, and Labetalol</li><li>\u2022 non-selective beta-blockers</li><li>\u2022 both</li><li>\u2022 beta-1 and beta-2 adrenergic receptors.</li><li>\u2022 Cardio-selective beta blockers:</li><li>\u2022 Cardio-selective beta blockers:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b1a73076",
      "audio": ""
    },
    {
      "text": "What is the usual weight of rabbit used in ophthalmological experiments?",
      "options": [
        {
          "label": "A",
          "text": "0.5\u20131 kg",
          "correct": false
        },
        {
          "label": "B",
          "text": "1.5\u20132.5 kg",
          "correct": true
        },
        {
          "label": "C",
          "text": "5\u20137 kg",
          "correct": false
        },
        {
          "label": "D",
          "text": "10\u201312 kg",
          "correct": false
        }
      ],
      "correct_answer": "B. 1.5\u20132.5 kg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 1.5\u20132.5 kg</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "65bc55a7",
      "audio": ""
    },
    {
      "text": "In an animal model, the phenomenon of vasomotor reversal of Dale can be demonstrated by?",
      "options": [
        {
          "label": "A",
          "text": "Beta-2 stimulation by epinephrine following beta 1-stimulation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Stimulation of beta-1 receptors following blocking of beta 2 receptors",
          "correct": false
        },
        {
          "label": "C",
          "text": "Stimulation of beta-2 receptors following blocking of alpha receptors",
          "correct": true
        },
        {
          "label": "D",
          "text": "Beta-2 stimulation by norepinephrine following beta-1 blockade",
          "correct": false
        }
      ],
      "correct_answer": "C. Stimulation of beta-2 receptors following blocking of alpha receptors",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/picture2.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Stimulation of beta-2 receptors following blocking of alpha receptors</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Options A. Beta-2 stimulation by epinephrine following beta 1-stimulation: This option does not describe vasomotor reversal of Dale . Beta-1 stimulation typically affects heart rate and contractility , not vasomotor responses.</li><li>\u2022 Options A. Beta-2 stimulation by epinephrine following beta 1-stimulation:</li><li>\u2022 does not</li><li>\u2022 vasomotor reversal of Dale</li><li>\u2022 Beta-1 stimulation</li><li>\u2022 heart rate and contractility</li><li>\u2022 Options B. Stimulation of beta-1 receptors following blocking of beta 2 receptors: This also does not lead to vasomotor reversal of Dale . Blocking beta-2 receptors would typically enhance the alpha receptor-mediated vasoconstrictive effect of catecholamines, not reverse it.</li><li>\u2022 Options B. Stimulation of beta-1 receptors following blocking of beta 2 receptors:</li><li>\u2022 does not</li><li>\u2022 vasomotor reversal of Dale</li><li>\u2022 Blocking beta-2 receptors</li><li>\u2022 enhance</li><li>\u2022 alpha receptor-mediated vasoconstrictive</li><li>\u2022 catecholamines,</li><li>\u2022 Options C. Stimulation of beta-2 receptors following blocking of alpha receptors: This is the correct option for demonstrating vasomotor reversal of Dale. When alpha receptors are blocked, the administration of a catecholamine will primarily stimulate the beta-2 adrenergic receptors , leading to vasodilation, which is the opposite of the usual vasoconstrictive effect of catecholamines on blood vessels.</li><li>\u2022 Options C. Stimulation of beta-2 receptors following blocking of alpha receptors:</li><li>\u2022 correct option</li><li>\u2022 vasomotor reversal of Dale.</li><li>\u2022 alpha receptors are blocked,</li><li>\u2022 catecholamine</li><li>\u2022 stimulate the</li><li>\u2022 beta-2 adrenergic receptors</li><li>\u2022 vasodilation,</li><li>\u2022 opposite</li><li>\u2022 vasoconstrictive effect of catecholamines</li><li>\u2022 blood vessels.</li><li>\u2022 Options D. Beta-2 stimulation by norepinephrine following beta-1 blockade: Norepinephrine (noradrenaline) has a much weaker effect on beta-2 receptors compared to alpha receptors , so blocking beta-1 receptors would not typically result in a vasomotor reversal. Norepinephrine is more known for its strong alpha receptor affinity , leading to vasoconstriction.</li><li>\u2022 Options D. Beta-2 stimulation by norepinephrine following beta-1 blockade:</li><li>\u2022 Norepinephrine (noradrenaline)</li><li>\u2022 weaker effect on beta-2 receptors</li><li>\u2022 alpha receptors</li><li>\u2022 blocking beta-1 receptors would not</li><li>\u2022 vasomotor reversal. Norepinephrine</li><li>\u2022 strong alpha receptor affinity</li><li>\u2022 vasoconstriction.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The vasomotor reversal of Dale, characterized by a switch from vasoconstriction to vasodilation, is demonstrated by the stimulation of beta-2 receptors after alpha receptors have been blocked, showcasing the unique and sometimes counterintuitive effect s that can result from the complex interplay of the autonomic nervous system's receptors.</li><li>\u27a4 vasomotor reversal of Dale,</li><li>\u27a4 switch from vasoconstriction to vasodilation,</li><li>\u27a4 stimulation</li><li>\u27a4 beta-2 receptors</li><li>\u27a4 alpha receptors have been blocked,</li><li>\u27a4 unique and sometimes counterintuitive effect</li><li>\u27a4 complex interplay of the autonomic nervous system's receptors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bb1952b3",
      "audio": ""
    },
    {
      "text": "A patient present with diabetic macular edema with glaucoma. Which of the following drug should be avoided in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Alpha agonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "Acetazolamide",
          "correct": false
        },
        {
          "label": "C",
          "text": "Beta blockers",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prostaglandin analogues",
          "correct": true
        }
      ],
      "correct_answer": "D. Prostaglandin analogues",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-115656.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Prostaglandin analogues</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Alpha agonists: These are not primarily associated with exacerbation of macular edema .</li><li>\u2022 Option A. Alpha agonists:</li><li>\u2022 not primarily</li><li>\u2022 exacerbation of macular edema</li><li>\u2022 Option B. Acetazolamide :  A carbonic anhydrase inhibitor, not typically associated with causing or worsening macular edema .</li><li>\u2022 Option B. Acetazolamide</li><li>\u2022 carbonic anhydrase inhibitor, not</li><li>\u2022 causing or worsening macular edema</li><li>\u2022 Option C. Beta blockers: Commonly used in glaucoma to reduce intraocular pressure without affecting macular edema.</li><li>\u2022 Option C. Beta blockers:</li><li>\u2022 Commonly used in glaucoma</li><li>\u2022 reduce intraocular pressure</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Prostaglandin analogues can worsen macular edema and therefore should be avoided in patients with diabetic macular edema.</li><li>\u27a4 Prostaglandin analogues</li><li>\u27a4 worsen macular edema</li><li>\u27a4 avoided in patients with diabetic macular edema.</li><li>\u27a4 Important adverse effects of anti-glaucoma drugs</li><li>\u27a4 adverse effects of anti-glaucoma drugs</li><li>\u27a4 Ref : KDT 8 th /169</li><li>\u27a4 Ref</li><li>\u27a4 : KDT 8 th /169</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fc507e9e",
      "audio": ""
    },
    {
      "text": "Acetylcholine decrease heart rate by which of the following mechanisms?",
      "options": [
        {
          "label": "A",
          "text": "By decreasing the rate of diastolic depolarization of SA node",
          "correct": true
        },
        {
          "label": "B",
          "text": "By causing delay through AV node",
          "correct": false
        },
        {
          "label": "C",
          "text": "By blocking calcium channels and prolonging the plateau phase",
          "correct": false
        },
        {
          "label": "D",
          "text": "By reducing the rate of ventricular repolarization",
          "correct": false
        }
      ],
      "correct_answer": "A. By decreasing the rate of diastolic depolarization of SA node",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) By decreasing the rate of diastolic depolarization of SA node</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. By causing delay through AV node: While acetylcholine does cause a delay in conduction through the atrioventricular (AV) node, this is not the primary mechanism by which it decreases the heart rate. However, this effect can contribute to a reduction in the ventricular rate , especially during conditions such as atrial fibrillation, by limiting the number of impulses t hat reach the ventricles.</li><li>\u2022 Option B. By causing delay through AV node:</li><li>\u2022 While acetylcholine</li><li>\u2022 delay in conduction</li><li>\u2022 atrioventricular (AV) node,</li><li>\u2022 not</li><li>\u2022 decreases the heart rate.</li><li>\u2022 reduction in the ventricular rate</li><li>\u2022 atrial fibrillation,</li><li>\u2022 limiting the number of impulses t</li><li>\u2022 ventricles.</li><li>\u2022 Option C. By blocking calcium channels and prolonging the plateau phase: This option is incorrect with respect to heart rate . Blocking calcium channels and prolonging the plateau phase of the cardiac action potential would affect the force of cardiac muscle contraction and potentially the duration of the action potential, but it is not the primary mechanism by which acetylcholine decreases heart rate .</li><li>\u2022 Option C. By blocking calcium channels and prolonging the plateau phase:</li><li>\u2022 option is incorrect</li><li>\u2022 heart rate</li><li>\u2022 Blocking calcium channels</li><li>\u2022 prolonging the plateau phase</li><li>\u2022 cardiac action potential</li><li>\u2022 force of cardiac muscle</li><li>\u2022 contraction</li><li>\u2022 duration of the action potential,</li><li>\u2022 not</li><li>\u2022 acetylcholine decreases heart rate</li><li>\u2022 Option D. By reducing the rate of ventricular repolarization: This mechanism is not associated with acetylcholine . Acetylcholine does not typically reduce the rate of ventricular repolarization; instead, it would affect the repolarization phase of the atria more than the ventricles.</li><li>\u2022 Option D. By reducing the rate of ventricular repolarization:</li><li>\u2022 not</li><li>\u2022 acetylcholine</li><li>\u2022 does not</li><li>\u2022 reduce the rate of ventricular repolarization;</li><li>\u2022 repolarization phase of the atria more</li><li>\u2022 ventricles.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Aetylcholine decreases heart rate by decreasing the rate of diastolic depolarization of the SA node , which reduces the frequency of action potentials generated and hence lowers the heart rate .</li><li>\u27a4 Aetylcholine decreases heart rate</li><li>\u27a4 decreasing the rate of diastolic depolarization of the SA node</li><li>\u27a4 reduces</li><li>\u27a4 action potentials generated</li><li>\u27a4 lowers the heart rate</li><li>\u27a4 Ref : KDT 8th/114</li><li>\u27a4 Ref</li><li>\u27a4 : KDT 8th/114</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a3359b55",
      "audio": ""
    },
    {
      "text": "A 58-year-old male with a history of hypertension has been managing his condition with metoprolol, a beta-blocker, to control his heart rate and blood pressure. Despite this treatment, his blood pressure remains above the target range. His physician decides to add verapamil, a calcium channel blocker, to his regimen to further control his blood pressure. Shortly after initiating verapamil, the patient reports symptoms of fatigue and dizziness. What complication can result from the addition of verapamil to a patient already on metoprolol treatment?",
      "options": [
        {
          "label": "A",
          "text": "Atrial fibrillation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Bradycardia with AV block",
          "correct": true
        },
        {
          "label": "C",
          "text": "Torsades\u2019 de pointes",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tachycardia",
          "correct": false
        }
      ],
      "correct_answer": "B. Bradycardia with AV block",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Bradycardia with AV block.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Atrial fibrillation: is not the most likely outcome of adding verapamil to metoprolol therapy, although verapamil is sometimes used to control ventricular rate i n patients with atrial fibrillation.</li><li>\u2022 Option A</li><li>\u2022 Atrial fibrillation:</li><li>\u2022 not</li><li>\u2022 adding verapamil to metoprolol therapy,</li><li>\u2022 verapamil is</li><li>\u2022 control ventricular rate i</li><li>\u2022 with atrial fibrillation.</li><li>\u2022 Option C. Torsades\u2019 de pointes: are a specific type of ventricular tachycardia often associated with a prolonged QT interval, which is not a typical side effect of either metoprolol or verapamil.</li><li>\u2022 Option</li><li>\u2022 C. Torsades\u2019 de pointes:</li><li>\u2022 ventricular tachycardia</li><li>\u2022 prolonged QT interval,</li><li>\u2022 not</li><li>\u2022 side effect of either metoprolol or verapamil.</li><li>\u2022 Option D. Tachycardia: or increased heart rate , would be unlikely as both drugs work to slow the heart rate .</li><li>\u2022 Option</li><li>\u2022 D. Tachycardia:</li><li>\u2022 increased heart rate</li><li>\u2022 both drugs</li><li>\u2022 slow the heart rate</li><li>\u2022 Therefore, the most appropriate answer in the context of this clinical scenario is b. Bradycardia with AV block , considering the pharmacological actions of both metoprolol and verapamil and the symptoms reported by the patient.</li><li>\u2022 Bradycardia with AV block</li><li>\u2022 both metoprolol and verapamil</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 When combining metoprolol , a beta-blocker, with verapamil, a calcium channel blocker, there is a significant risk of developing bradycardia with AV block due to their combined effect on slowing heart rate and impairing AV nodal conduction.</li><li>\u2022 metoprolol</li><li>\u2022 beta-blocker, with verapamil, a calcium channel blocker,</li><li>\u2022 risk of developing</li><li>\u2022 bradycardia with AV block</li><li>\u2022 combined effect</li><li>\u2022 slowing heart rate and impairing AV nodal conduction.</li><li>\u2022 Ref : KDT 8th/160</li><li>\u2022 Ref</li><li>\u2022 : KDT 8th/160</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "372f6f7b",
      "audio": ""
    },
    {
      "text": "A pharmacological experiment was conducted to study effect of three drugs on heart rate and blood pressure. The following graphs were obtained before and after giving the drug. Which of the following statements is correct?",
      "options": [
        {
          "label": "A",
          "text": "Drug A in the graph is epinephrine",
          "correct": false
        },
        {
          "label": "B",
          "text": "The effect on heart rate in graph A can be prevented by anti-muscarinic agents",
          "correct": true
        },
        {
          "label": "C",
          "text": "Drug acting on graph B is isoprenaline",
          "correct": false
        },
        {
          "label": "D",
          "text": "Drug acting in the graph C is nor-epinephrine",
          "correct": false
        }
      ],
      "correct_answer": "B. The effect on heart rate in graph A can be prevented by anti-muscarinic agents",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/picture11.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) The effect on heart rate in graph A can be prevented by anti-muscarinic agents</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Drug A in the graph can be epinephrine: This is incorrect since epinephrine usually increases heart rate due to its beta-1 stimulatory effect.</li><li>\u2022 Option A. Drug A in the graph can be epinephrine:</li><li>\u2022 incorrect</li><li>\u2022 epinephrine</li><li>\u2022 increases heart rate</li><li>\u2022 beta-1</li><li>\u2022 stimulatory effect.</li><li>\u2022 Option C. The drug acting on graph B is isoprenaline: This statement is incorrect because isoprenaline (also known as isoproterenol) is a non-selective beta-adrenergic agonist that can increase SBP but decrease DBP and MBP. Rather the graph shown is typically present in epinephrine.</li><li>\u2022 Option C. The drug acting on graph B is isoprenaline:</li><li>\u2022 incorrect</li><li>\u2022 isoprenaline (also known as isoproterenol)</li><li>\u2022 non-selective beta-adrenergic agonist</li><li>\u2022 increase SBP</li><li>\u2022 decrease DBP</li><li>\u2022 MBP.</li><li>\u2022 Option D. The drug acting in graph C is norepinephrine: This statement is incorrect because norepinephrine primarily increases SBP, DBP and MBP and cause reflex tachycardia. The graph shown is typically present in isoprenaline.</li><li>\u2022 Option D. The drug acting in graph C is norepinephrine:</li><li>\u2022 incorrect</li><li>\u2022 norepinephrine</li><li>\u2022 increases SBP,</li><li>\u2022 DBP and MBP</li><li>\u2022 reflex tachycardia.</li><li>\u2022 graph shown</li><li>\u2022 isoprenaline.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Anti-muscarinic agents can prevent the reflex bradycardia induced by vasoconstrictive drugs like norepinephrine by inhibiting the parasympathetic nervous system's control over the heart.</li><li>\u2022 Anti-muscarinic agents</li><li>\u2022 reflex bradycardia</li><li>\u2022 vasoconstrictive drugs</li><li>\u2022 norepinephrine</li><li>\u2022 parasympathetic nervous system's</li><li>\u2022 over the heart.</li><li>\u2022 Ref : Goodman and Gilman 12th/283</li><li>\u2022 Ref</li><li>\u2022 : Goodman and Gilman 12th/283</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "56a6078b",
      "audio": ""
    },
    {
      "text": "Which of the following statements is not true about clonidine?",
      "options": [
        {
          "label": "A",
          "text": "It is a selective alpha 2 receptor agonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "It decreases central sympathetic outflow",
          "correct": false
        },
        {
          "label": "C",
          "text": "It increases the release of renin",
          "correct": true
        },
        {
          "label": "D",
          "text": "It can be used for treatment of hypertension.",
          "correct": false
        }
      ],
      "correct_answer": "C. It increases the release of renin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) It increases the release of renin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Acts as a selective \u03b12 receptor agonist.</li><li>\u2022 Option A.</li><li>\u2022 selective \u03b12 receptor agonist.</li><li>\u2022 Option B. Stimulation of alpha 2A receptors in brainstem result in decrease sympathetic outflow \u2014, fall in BP and bradycardia (also due to enhanced vagal tone).</li><li>\u2022 Option B.</li><li>\u2022 Stimulation of alpha 2A receptors</li><li>\u2022 brainstem</li><li>\u2022 decrease sympathetic outflow</li><li>\u2022 fall in BP and bradycardia</li><li>\u2022 Option D. Used to treat various conditions including hypertension, menopausal syndrome, and withdrawal syndromes .</li><li>\u2022 Option D.</li><li>\u2022 hypertension, menopausal syndrome, and withdrawal syndromes</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Noradrenaline is specific to \u03b11, \u03b12, and \u03b21 receptors and does not activate \u03b22 receptors . Clonidine, an \u03b12 receptor agonist , decreases sympathetic outflow and renin release , contrary to increasing it, which is an important consideration in its pharmacological profile and clinical use.</li><li>\u2022 Noradrenaline is specific to \u03b11, \u03b12, and \u03b21 receptors and does not activate \u03b22 receptors .</li><li>\u2022 Noradrenaline</li><li>\u2022 \u03b11, \u03b12, and \u03b21 receptors</li><li>\u2022 does not activate \u03b22 receptors</li><li>\u2022 Clonidine, an \u03b12 receptor agonist , decreases sympathetic outflow and renin release , contrary to increasing it, which is an important consideration in its pharmacological profile and clinical use.</li><li>\u2022 Clonidine, an \u03b12 receptor agonist</li><li>\u2022 decreases sympathetic outflow</li><li>\u2022 renin release</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3fd6bd97",
      "audio": ""
    },
    {
      "text": "True statements about neostigmine are?",
      "options": [
        {
          "label": "A",
          "text": "It is a quaternary ammonium compound",
          "correct": true
        },
        {
          "label": "B",
          "text": "It is metabolized by liver",
          "correct": false
        },
        {
          "label": "C",
          "text": "It can cross the blood brain barrier",
          "correct": false
        },
        {
          "label": "D",
          "text": "It has no direct agonistic action on N M receptors",
          "correct": false
        }
      ],
      "correct_answer": "A. It is a quaternary ammonium compound",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) It is a quarternary ammonium compound</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of other options:</li><li>\u2022 Option B . It is metabolized by liver: Neostigmine is primarily hydrolysed by cholinesterases in the plasma and, to a lesser extent, in the liver. Its metabolism is not predominantly hepatic, which is a common misconception. The role of the liver in its metabolism is limited compared to the hydrolysis happening in the plasma.</li><li>\u2022 Option</li><li>\u2022 B</li><li>\u2022 It is metabolized by liver: Neostigmine</li><li>\u2022 hydrolysed by cholinesterases</li><li>\u2022 not predominantly hepatic,</li><li>\u2022 hydrolysis happening in the plasma.</li><li>\u2022 Option C . It can cross the blood brain barrier: As a quaternary ammonium compound, neostigmine is charged and polar, making it poorly lipid-soluble. This property significantly limits its ability to cross the blood-brain barrier. Therefore, neostigmine has minimal c entral nervous system effects under normal therapeutic conditions.</li><li>\u2022 Option</li><li>\u2022 C</li><li>\u2022 It can cross the blood brain barrier:</li><li>\u2022 quaternary ammonium compound, neostigmine</li><li>\u2022 charged and polar,</li><li>\u2022 poorly lipid-soluble.</li><li>\u2022 limits its ability to cross the blood-brain barrier.</li><li>\u2022 neostigmine</li><li>\u2022 minimal</li><li>\u2022 entral nervous system effects</li><li>\u2022 Option D . It has no direct agonistic action on NM receptors: This statement is not completely true. Neostigmine works primarily by inhibiting acetylcholinesterase, the enzyme responsible for breaking down acetylcholine in the neuromuscular junction. This inhibition leads to an increase in acetylcholine concentration at the neuromuscular junction, thereby enhancing cholinergic transmission , which can stimulate muscle contraction. Its action is thus primarily indirect as it increases the action of acetylcholine. However, neostigmine and pyridostigmine (unlike physostigmine) have been found to have some direct agonist action on neuromuscular (NM) receptors also.</li><li>\u2022 Option</li><li>\u2022 D</li><li>\u2022 It has no direct agonistic action on NM receptors:</li><li>\u2022 not completely true.</li><li>\u2022 inhibiting acetylcholinesterase,</li><li>\u2022 breaking down acetylcholine</li><li>\u2022 increase in acetylcholine concentration</li><li>\u2022 neuromuscular junction,</li><li>\u2022 cholinergic</li><li>\u2022 transmission</li><li>\u2022 muscle contraction.</li><li>\u2022 indirect</li><li>\u2022 increases the action of acetylcholine.</li><li>\u2022 neostigmine and pyridostigmine (unlike physostigmine)</li><li>\u2022 direct agonist action</li><li>\u2022 neuromuscular (NM) receptors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Neostigmine is a quaternary ammonium compound that inhibits acetylcholinesterase, thereby increasing acetylcholine levels at the neuromuscular junction and enhancing cholinergic transmission . Neostigmine also act as direct agonist of Nm receptors and has limited ability to cross the blood-brain barrier due to its quaternary ammonium structure . Its metabolism mainly involves hydrolysis by cholinesterase rather than liver metabolism.</li><li>\u27a4 Neostigmine</li><li>\u27a4 quaternary ammonium</li><li>\u27a4 inhibits acetylcholinesterase,</li><li>\u27a4 increasing acetylcholine levels</li><li>\u27a4 neuromuscular junction</li><li>\u27a4 cholinergic transmission</li><li>\u27a4 Neostigmine</li><li>\u27a4 direct agonist of Nm receptors</li><li>\u27a4 limited ability</li><li>\u27a4 cross the blood-brain barrier</li><li>\u27a4 quaternary ammonium structure</li><li>\u27a4 metabolism</li><li>\u27a4 hydrolysis by cholinesterase</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cd041948",
      "audio": ""
    },
    {
      "text": "A patient requires mild cholinomimetic stimulation following surgery. Physostigmine and bethanechol in small doses have significantly different effects on which of the following?",
      "options": [
        {
          "label": "A",
          "text": "Gastric secretion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Neuromuscular junction",
          "correct": true
        },
        {
          "label": "C",
          "text": "Sweat glands",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ureteral tone",
          "correct": false
        }
      ],
      "correct_answer": "B. Neuromuscular junction",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Neuromuscular junction</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Gastric secretion: is mediated by muscarinic receptors ; thus, both drugs would enhance secretion.</li><li>\u2022 Option A. Gastric secretion:</li><li>\u2022 muscarinic receptors</li><li>\u2022 both drugs</li><li>\u2022 enhance secretion.</li><li>\u2022 Option C. Sweat glands: are also regulated by muscarinic receptors, so both physostigmine and bethanechol would stimulate sweating.</li><li>\u2022 Option C. Sweat glands:</li><li>\u2022 muscarinic receptors,</li><li>\u2022 both physostigmine and bethanechol</li><li>\u2022 sweating.</li><li>\u2022 Option D. Ureteral tone: is under the control of muscarinic receptors, hence both drugs could increase ureteral tone.</li><li>\u2022 Option D. Ureteral tone:</li><li>\u2022 control of muscarinic receptors,</li><li>\u2022 both drugs</li><li>\u2022 increase ureteral tone.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Physostigmine can affect both muscarinic and nicotinic receptors, making it effective at the neuromuscular junction, while bethanechol's action is limited to muscarinic receptors and does not influence neuromuscular transmission.</li><li>\u27a4 Physostigmine</li><li>\u27a4 both muscarinic and nicotinic receptors,</li><li>\u27a4 at the neuromuscular junction,</li><li>\u27a4 bethanechol's</li><li>\u27a4 muscarinic receptors</li><li>\u27a4 does not</li><li>\u27a4 neuromuscular transmission.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "343d363c",
      "audio": ""
    },
    {
      "text": "All of the following are actions of a muscarinic antagonist except?",
      "options": [
        {
          "label": "A",
          "text": "Decreases gastric secretion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prolongs A-V conduction",
          "correct": true
        },
        {
          "label": "C",
          "text": "Decreases tracheobronchial secretions",
          "correct": false
        },
        {
          "label": "D",
          "text": "Results in unopposed contraction of radial muscle of iris",
          "correct": false
        }
      ],
      "correct_answer": "B. Prolongs A-V conduction",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Prolongs A-V conduction</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A . Decreases gastric secretion: Correct. Muscarinic antagonists reduce gastric acid secretion by blocking the muscarinic M3 receptors on the gastric parietal cells.</li><li>\u2022 Option A</li><li>\u2022 Decreases gastric secretion:</li><li>\u2022 Correct. Muscarinic antagonists reduce gastric acid secretion</li><li>\u2022 muscarinic M3</li><li>\u2022 receptors</li><li>\u2022 Option C . Decreases tracheobronchial secretions: Correct. These agents reduce secretions in the airway by inhibiting muscarinic receptors in the bronchial glands.</li><li>\u2022 Option C</li><li>\u2022 Decreases tracheobronchial secretions:</li><li>\u2022 Correct.</li><li>\u2022 reduce secretions</li><li>\u2022 airway</li><li>\u2022 inhibiting muscarinic</li><li>\u2022 receptors</li><li>\u2022 Option D . Causes unopposed contraction of radial muscle of iris: Muscarinic antagonists cause pupil dilation (mydriasis) by blocking the M3 receptors on the sphincter pupillae muscle . However, the pupil is also supplied by the radial muscle, which is controlled by sympathetic innervation. Therefore, when M3 receptors are blocked by anticholinergic drugs , sphincter pupillae cannot contrac t and there is unopposed contraction of radial muscles via sympathetic system leading to dilation of pupil . This is known as passive mydriasis.</li><li>\u2022 Option D</li><li>\u2022 Causes unopposed contraction of radial muscle of iris:</li><li>\u2022 Muscarinic antagonists</li><li>\u2022 pupil dilation (mydriasis)</li><li>\u2022 M3 receptors</li><li>\u2022 sphincter pupillae muscle</li><li>\u2022 pupil</li><li>\u2022 radial muscle,</li><li>\u2022 sympathetic innervation.</li><li>\u2022 M3 receptors are blocked by anticholinergic drugs</li><li>\u2022 sphincter pupillae</li><li>\u2022 cannot contrac</li><li>\u2022 contraction of radial muscles</li><li>\u2022 sympathetic system</li><li>\u2022 dilation of pupil</li><li>\u2022 passive mydriasis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Muscarinic antagonists shorten A-V conduction time rather than prolonging it, which reflects their overall effect of reducing parasympathetic activity on the heart .</li><li>\u27a4 Muscarinic antagonists shorten A-V conduction</li><li>\u27a4 reducing parasympathetic activity on the heart</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cd1d6c4e",
      "audio": ""
    },
    {
      "text": "Which one of the following drugs increases gastrointestinal motility?",
      "options": [
        {
          "label": "A",
          "text": "Glycopyrrolate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Atropine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Neostigmine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Fentanyl",
          "correct": false
        }
      ],
      "correct_answer": "C. Neostigmine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Neostigmine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Glycopyrrolate: Glycopyrrolate is an anticholinergic drug that decreases gastrointestinal motility. It works by blocking acetylcholine receptors in the gastrointestinal tract , reducing smooth muscle contractions and secretions . Glycopyrrolate is often used preoperatively to reduce salivary, tracheobronchial, and pharyngeal secretions .</li><li>\u2022 Option A.</li><li>\u2022 Glycopyrrolate:</li><li>\u2022 anticholinergic drug</li><li>\u2022 decreases gastrointestinal motility.</li><li>\u2022 acetylcholine receptors</li><li>\u2022 gastrointestinal tract</li><li>\u2022 reducing smooth muscle contractions and secretions</li><li>\u2022 Glycopyrrolate</li><li>\u2022 preoperatively to reduce salivary, tracheobronchial, and pharyngeal secretions</li><li>\u2022 Option B. Atropine: Atropine is another anticholinergic drug that reduces gastrointestinal motility by inhibiting the action of acetylcholine on muscarinic receptors in the gut . This results in decreased muscle tone and motility in the digestive tract. Atropine is used in various clinical settings, including pre-anesthetic medication to reduce salivation and increase heart rate.</li><li>\u2022 Option B.</li><li>\u2022 Atropine:</li><li>\u2022 anticholinergic drug</li><li>\u2022 reduces gastrointestinal motility</li><li>\u2022 acetylcholine on muscarinic receptors in the gut</li><li>\u2022 decreased muscle tone and motility</li><li>\u2022 digestive tract.</li><li>\u2022 pre-anesthetic medication</li><li>\u2022 reduce salivation and increase heart rate.</li><li>\u2022 Option D. Fentanyl: Fentanyl is a synthetic opioid analgesic, which does not directly affect gastrointestinal motility as its primary action . However, opioids , in general, are known to reduce gastrointestinal motility due to their inhibitory effects on the enteric nervous system , leading to constipation as a common side effect. Fentanyl's main use is for pain management , not for modulating gastrointestinal motility .</li><li>\u2022 Option D.</li><li>\u2022 Fentanyl:</li><li>\u2022 synthetic opioid analgesic,</li><li>\u2022 does not</li><li>\u2022 gastrointestinal motility</li><li>\u2022 its primary action</li><li>\u2022 opioids</li><li>\u2022 reduce gastrointestinal motility</li><li>\u2022 inhibitory effects</li><li>\u2022 enteric nervous system</li><li>\u2022 constipation</li><li>\u2022 Fentanyl's main</li><li>\u2022 pain management</li><li>\u2022 not for modulating gastrointestinal motility</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Neostigmine , a parasympathomimetic agent , increases gastrointestinal motility by inhibiting acetylcholinesterase and increasing acetylcholine levels . In contrast, anticholinergic drugs like glycopyrrolate and atropine decrease gastrointestinal motility by blocking acetylcholine receptors. Fentanyl, an opioid analgesic, can indirectly decrease gastrointestinal motility as a side effect of its analgesic use.</li><li>\u27a4 Neostigmine</li><li>\u27a4 parasympathomimetic agent</li><li>\u27a4 increases gastrointestinal motility</li><li>\u27a4 inhibiting acetylcholinesterase</li><li>\u27a4 increasing</li><li>\u27a4 acetylcholine levels</li><li>\u27a4 anticholinergic drugs like glycopyrrolate and atropine decrease gastrointestinal motility</li><li>\u27a4 acetylcholine receptors.</li><li>\u27a4 Fentanyl, an opioid analgesic,</li><li>\u27a4 indirectly decrease gastrointestinal motility</li><li>\u27a4 analgesic use.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "457651d6",
      "audio": ""
    },
    {
      "text": "Which of the following alpha-blocker drugs is used in the treatment of benign hypertrophy of the prostate without producing significant hypotension?",
      "options": [
        {
          "label": "A",
          "text": "Doxazosin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Phentolamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tamsulosin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Terazosin",
          "correct": false
        }
      ],
      "correct_answer": "C. Tamsulosin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Tamsulosin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Doxazosin: Doxazosin is a non-selective alpha-1 antagonist. It is used to treat hypertension and BPH , but it does not have the same degree of selectivity for the alpha-1A receptors as tamsulosin and can cause more pronounced hypotension as a side effect.</li><li>\u2022 Option A. Doxazosin:</li><li>\u2022 non-selective alpha-1 antagonist.</li><li>\u2022 hypertension and BPH</li><li>\u2022 does not</li><li>\u2022 alpha-1A receptors as tamsulosin</li><li>\u2022 pronounced hypotension</li><li>\u2022 Option B. Phentolamine: Phentolamine is a non-selective alpha-adrenergic antagonist , blocking both alpha-1 and alpha-2 receptors. It is primarily used in the management of hypertensive emergencies related to pheochromocytoma and is not commonly used in the treatment of BPH . Due to its non-selectivity, it can cause significant hypotension.</li><li>\u2022 Option B. Phentolamine:</li><li>\u2022 non-selective alpha-adrenergic antagonist</li><li>\u2022 alpha-1 and alpha-2 receptors.</li><li>\u2022 hypertensive emergencies</li><li>\u2022 pheochromocytoma</li><li>\u2022 not</li><li>\u2022 BPH</li><li>\u2022 non-selectivity,</li><li>\u2022 hypotension.</li><li>\u2022 Option D. Terazosin: Terazosin is another non-selective alpha-1 antagonist used to treat hypertension and symptoms of BPH . While it is effective in relieving urinary symptoms related to BPH, its non-selective action on alpha-1 receptors can also lead to more pronounced hypotension compared to tamsulosin.</li><li>\u2022 Option D. Terazosin:</li><li>\u2022 non-selective alpha-1 antagonist</li><li>\u2022 hypertension and symptoms of BPH</li><li>\u2022 relieving urinary symptoms</li><li>\u2022 BPH,</li><li>\u2022 non-selective</li><li>\u2022 alpha-1 receptors</li><li>\u2022 pronounced hypotension</li><li>\u2022 tamsulosin.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tamsulosin, with its selectivity for alpha-1A receptors, is preferable for treating BPH symptoms as it minimizes the risk of hypotension . In contrast, non-selective alpha-blockers like doxazosin, terazosin, and phentolamine can be used in BPH but may have a higher risk of causing hypotension .</li><li>\u27a4 Tamsulosin,</li><li>\u27a4 alpha-1A receptors,</li><li>\u27a4 BPH symptoms</li><li>\u27a4 minimizes</li><li>\u27a4 hypotension</li><li>\u27a4 non-selective alpha-blockers</li><li>\u27a4 doxazosin, terazosin, and phentolamine</li><li>\u27a4 BPH</li><li>\u27a4 higher risk</li><li>\u27a4 hypotension</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "713aff3e",
      "audio": ""
    },
    {
      "text": "All of the following beta-blockers can be used in glaucoma except?",
      "options": [
        {
          "label": "A",
          "text": "Propranolol",
          "correct": true
        },
        {
          "label": "B",
          "text": "Timolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Betaxolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Levobunolol",
          "correct": false
        }
      ],
      "correct_answer": "A. Propranolol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) \u00a0Propranolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . Timolol: Timolol is a non-selective beta-blocker effectively used in glaucoma treatment by lowering intraocular pressure through decreased aqueous humor production . Unlike propranolol, timolol is preferred for ocular use due to its minimal systemic side effects and lack of significant membrane-stabilizing activity that could lead to corneal anesthesia.</li><li>\u2022 Option B</li><li>\u2022 Timolol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 glaucoma</li><li>\u2022 lowering intraocular pressure</li><li>\u2022 decreased aqueous humor production</li><li>\u2022 Unlike propranolol,</li><li>\u2022 timolol</li><li>\u2022 ocular use</li><li>\u2022 minimal systemic</li><li>\u2022 side effects</li><li>\u2022 lack of significant membrane-stabilizing activity</li><li>\u2022 corneal anesthesia.</li><li>\u2022 Option C. Betaxolol: Betaxolol is a beta-1 selective adrenergic receptor blocker . Its selectivity is beneficial in patients with respiratory issues, as it minimally affects beta-2 receptors associated with bronchial smooth muscle . Betaxolol is used in glaucoma treatment to reduce intraocular pressure and is noted for having less membrane-stabilizing activity compared to non-selective beta-blockers , making it safer for the cornea.</li><li>\u2022 Option C.</li><li>\u2022 Betaxolol:</li><li>\u2022 beta-1 selective adrenergic receptor blocker</li><li>\u2022 beneficial</li><li>\u2022 respiratory issues,</li><li>\u2022 beta-2 receptors associated with bronchial smooth muscle</li><li>\u2022 Betaxolol</li><li>\u2022 glaucoma</li><li>\u2022 reduce intraocular pressure</li><li>\u2022 less membrane-stabilizing activity</li><li>\u2022 non-selective beta-blockers</li><li>\u2022 Option D. Levobunolol: Levobunolol is another non-selective beta-blocker used for lowering intraocular pressure in glaucoma patients. It shares similar benefits with timolol in terms of efficacy in glaucoma treatment and has a l ow risk of causing corneal anesthesia due to its minimal membrane-stabilizing effect.</li><li>\u2022 Option D.</li><li>\u2022 Levobunolol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 lowering intraocular pressure in glaucoma</li><li>\u2022 similar benefits with timolol</li><li>\u2022 efficacy</li><li>\u2022 ow risk of causing corneal</li><li>\u2022 anesthesia</li><li>\u2022 minimal membrane-stabilizing effect.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 While timolol, betaxolol, and levobunolol are suitable to be used in glaucoma due to their specific ocular effects and minimal membrane-stabilizing activity , propranolol is not commonly used in glaucoma due to its non-selective action and potential for causing corneal anesthesia .</li><li>\u27a4 timolol, betaxolol, and levobunolol</li><li>\u27a4 glaucoma</li><li>\u27a4 ocular effects</li><li>\u27a4 minimal membrane-stabilizing activity</li><li>\u27a4 propranolol</li><li>\u27a4 not</li><li>\u27a4 glaucoma</li><li>\u27a4 non-selective action</li><li>\u27a4 potential</li><li>\u27a4 corneal anesthesia</li><li>\u27a4 Beta-blockers with Membrane Stabilizing Activity</li><li>\u27a4 Beta-blockers with Membrane Stabilizing Activity</li><li>\u27a4 These drugs possess Na+ channel blocking (local anesthetic) activity. It can contribute to anti-arrhythmic action. These drugs should be avoided in glaucoma due to the risk of corneal anesthesia.</li><li>\u27a4 These drugs possess Na+ channel blocking (local anesthetic) activity. It can contribute to anti-arrhythmic action.</li><li>\u27a4 These drugs should be avoided in glaucoma due to the risk of corneal anesthesia.</li><li>\u27a4 Examples :</li><li>\u27a4 Examples</li><li>\u27a4 P ossess: P ropranolol (maximum)</li><li>\u27a4 P</li><li>\u27a4 P</li><li>\u27a4 Me mbrane stabilizing or: Me toprolol</li><li>\u27a4 Me</li><li>\u27a4 Me</li><li>\u27a4 L ocal: L abetalol</li><li>\u27a4 L</li><li>\u27a4 L</li><li>\u27a4 A naesthetic: A cebutolol</li><li>\u27a4 A</li><li>\u27a4 A</li><li>\u27a4 P roperty: P indolol</li><li>\u27a4 P</li><li>\u27a4 P</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7cfe8a8f",
      "audio": ""
    },
    {
      "text": "Properties making cardio-selective beta-blockers desirable are?",
      "options": [
        {
          "label": "A",
          "text": "Less bronchoconstriction",
          "correct": false
        },
        {
          "label": "B",
          "text": "Less adverse effect on lipid profile",
          "correct": false
        },
        {
          "label": "C",
          "text": "Less likely to cause glucose intolerance",
          "correct": false
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": true
        }
      ],
      "correct_answer": "D. All of the above",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) All of the above</strong></p>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The benefits of cardio-selective beta-blockers over non-selective beta-blockers include:</li><li>\u27a4 cardio-selective beta-blockers</li><li>\u27a4 non-selective beta-blockers</li><li>\u27a4 Lower propensity to cause bronchoconstriction. Less interference with carbohydrate metabolism and safer in diabetes mellitus. Less chances of precipitating Raynaud\u2019s phenomenon. No deleterious effect on blood lipid profile. Ineffective in suppressing essential tremor . Less liable to impair exercise capacity.</li><li>\u27a4 Lower propensity to cause bronchoconstriction.</li><li>\u27a4 Lower propensity</li><li>\u27a4 bronchoconstriction.</li><li>\u27a4 Less interference with carbohydrate metabolism and safer in diabetes mellitus.</li><li>\u27a4 Less interference</li><li>\u27a4 carbohydrate metabolism</li><li>\u27a4 safer in diabetes mellitus.</li><li>\u27a4 Less chances of precipitating Raynaud\u2019s phenomenon.</li><li>\u27a4 Less chances</li><li>\u27a4 Raynaud\u2019s phenomenon.</li><li>\u27a4 No deleterious effect on blood lipid profile.</li><li>\u27a4 No deleterious effect</li><li>\u27a4 blood lipid profile.</li><li>\u27a4 Ineffective in suppressing essential tremor .</li><li>\u27a4 Ineffective</li><li>\u27a4 suppressing essential tremor</li><li>\u27a4 Less liable to impair exercise capacity.</li><li>\u27a4 Less liable</li><li>\u27a4 impair exercise capacity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0b5ea091",
      "audio": ""
    },
    {
      "text": "Cycloplegic action of atropine lasts upto?",
      "options": [
        {
          "label": "A",
          "text": "6 hours",
          "correct": false
        },
        {
          "label": "B",
          "text": "12 hours",
          "correct": false
        },
        {
          "label": "C",
          "text": "1 day",
          "correct": false
        },
        {
          "label": "D",
          "text": "1-2 weeks",
          "correct": true
        }
      ],
      "correct_answer": "D. 1-2 weeks",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-120249.jpg"
      ],
      "explanation": "<p><strong>Ans. D) 1-2 weeks</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Atropine is a potent muscarinic antagonist with a broad range of pharmacological effects, including cycloplegia , which is paralysis of the ciliary muscle of the eye , resulting in a loss of accommodation, and mydriasis , which is dilation of the pupil . The cycloplegic action of atropine is particularly long-lasting . When administered in the eye , atropine can cause cycloplegia that lasts up to 1-2 weeks . This extended duration is due to its strong affinity for muscarinic receptors and its relatively slow rate of dissociation from these receptors , leading to prolonged effects.</li><li>\u2022 Atropine</li><li>\u2022 potent muscarinic antagonist</li><li>\u2022 cycloplegia</li><li>\u2022 paralysis</li><li>\u2022 ciliary muscle of the eye</li><li>\u2022 loss of accommodation, and mydriasis</li><li>\u2022 dilation of the pupil</li><li>\u2022 cycloplegic action of atropine</li><li>\u2022 long-lasting</li><li>\u2022 administered in the eye</li><li>\u2022 atropine</li><li>\u2022 cycloplegia</li><li>\u2022 1-2 weeks</li><li>\u2022 extended duration</li><li>\u2022 due to its strong affinity</li><li>\u2022 muscarinic receptors</li><li>\u2022 relatively slow rate of dissociation</li><li>\u2022 receptors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to recognize the duration of the cycloplegic effect of different drugs used in ophthalmic applications . Understanding the long-lasting action of atropine is crucial for healthcare providers in managing conditions requiring cycloplegia, such as uveitis , where prolonged pupil dilation and paralysis of accommodation are beneficial .</li><li>\u27a4 educational objective</li><li>\u27a4 duration of the cycloplegic effect</li><li>\u27a4 ophthalmic applications</li><li>\u27a4 long-lasting action of atropine</li><li>\u27a4 healthcare</li><li>\u27a4 cycloplegia, such as uveitis</li><li>\u27a4 prolonged pupil dilation and paralysis of accommodation are beneficial</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5c0e0541",
      "audio": ""
    },
    {
      "text": "Rate limiting step in catecholamine synthesis is?",
      "options": [
        {
          "label": "A",
          "text": "Phenylalanine hydroxylase",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tyrosine hydroxylase",
          "correct": true
        },
        {
          "label": "C",
          "text": "Dopa Decarboxylase",
          "correct": false
        },
        {
          "label": "D",
          "text": "Dopamine \u03b2 hydroxylase",
          "correct": false
        }
      ],
      "correct_answer": "B. Tyrosine hydroxylase",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/picture21_jXwtz1W.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Tyrosine hydroxylase</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Phenylalanine hydroxylase - Not the rate-limiting step in catecholamine synthesis, but it is involved in the conversion of phenylalanine to tyrosine.</li><li>\u2022 Option A. Phenylalanine hydroxylase</li><li>\u2022 Not the rate-limiting</li><li>\u2022 catecholamine synthesis,</li><li>\u2022 conversion of</li><li>\u2022 phenylalanine to tyrosine.</li><li>\u2022 Option C. Dopa Decarboxylase - Catalyzes the conversion of DOPA to dopamine but is not the rate-limiting step.</li><li>\u2022 Option C. Dopa Decarboxylase</li><li>\u2022 Catalyzes the conversion of DOPA to dopamine</li><li>\u2022 Option D.  Dopamine \u03b2 hydroxylase - Converts dopamine to norepinephrine, not the rate-limiting step in catecholamine synthesis.</li><li>\u2022 Option D.  Dopamine \u03b2 hydroxylase</li><li>\u2022 Converts dopamine to norepinephrine,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tyrosine hydroxylase is the rate-limiting enzyme in the synthesis of catecholamines , determining the overall rate at which these critical neurotransmitters and hormones are produced in the body.</li><li>\u27a4 Tyrosine hydroxylase</li><li>\u27a4 rate-limiting enzyme</li><li>\u27a4 catecholamines</li><li>\u27a4 overall rate</li><li>\u27a4 neurotransmitters and hormones</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "44c4f9b2",
      "audio": ""
    },
    {
      "text": "A male with insulin dependent diabetes having macular edema develops glaucoma. Which of the following anti-glaucoma drugs should be avoided in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Prostaglandin analogues",
          "correct": true
        },
        {
          "label": "B",
          "text": "Alpha agonist",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pilocarpine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Beta blocker",
          "correct": false
        }
      ],
      "correct_answer": "A. Prostaglandin analogues",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/2000_vzyqPnB.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Prostaglandin analogues</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B . Alpha agonist: Alpha agonists, such as brimonidine, work by decreasing aqueous humor production and increasing uveoscleral outflow . They are not specifically contraindicated in patients with diabetic macular edema and can be used in the management of glaucoma in such patients.</li><li>\u2022 Option B</li><li>\u2022 Alpha agonist:</li><li>\u2022 brimonidine,</li><li>\u2022 decreasing aqueous humor production</li><li>\u2022 increasing uveoscleral outflow</li><li>\u2022 not</li><li>\u2022 contraindicated in patients</li><li>\u2022 diabetic macular edema</li><li>\u2022 glaucoma</li><li>\u2022 Option C . Pilocarpine: Pilocarpine is a cholinergic agonist that works by constricting the pupil and pulling the iris away from the trabecular meshwork , thus improving the outflow of aqueous humor . While it is less commonly used due to its side effects and the availability of more effective treatments , pilocarpine is not specifically contraindicated in patients with diabetic macular edema.</li><li>\u2022 Option C</li><li>\u2022 Pilocarpine:</li><li>\u2022 cholinergic agonist</li><li>\u2022 works by constricting the pupil</li><li>\u2022 pulling the iris away from the trabecular meshwork</li><li>\u2022 improving the outflow of aqueous humor</li><li>\u2022 less commonly</li><li>\u2022 side effects</li><li>\u2022 availability of more effective treatments</li><li>\u2022 pilocarpine</li><li>\u2022 not</li><li>\u2022 contraindicated in patients with diabetic macular edema.</li><li>\u2022 Option D . Beta blocker: Beta blockers, such as timolol , work by decreasing the production of aqueous humor. They are a common choice for the treatment of glaucoma and do not directly affect the retina or exacerbate macular edema . Therefore, beta blockers can be considered for use in patients with both glaucoma and diabetic macular edema , provided there are no other contraindications (e.g., respiratory conditions).</li><li>\u2022 Option D</li><li>\u2022 Beta blocker:</li><li>\u2022 timolol</li><li>\u2022 decreasing the production of aqueous humor.</li><li>\u2022 treatment of glaucoma</li><li>\u2022 retina or exacerbate macular edema</li><li>\u2022 beta blockers</li><li>\u2022 both glaucoma and diabetic macular edema</li><li>\u2022 no other contraindications (e.g., respiratory conditions).</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In patients with macular edema, prostaglandin analogues may exacerbate macular edema and should be used cautiously or avoided . It is important to consider the systemic and ocular side effects of glaucoma medications , especially in patients with pre-existing conditions such as diabetic retinopathy.</li><li>\u27a4 macular edema, prostaglandin analogues</li><li>\u27a4 macular edema</li><li>\u27a4 cautiously or avoided</li><li>\u27a4 systemic and ocular side effects of glaucoma medications</li><li>\u27a4 pre-existing</li><li>\u27a4 diabetic retinopathy.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "d8a70b48",
      "audio": ""
    },
    {
      "text": "Which of the following drugs acting on dilator pupillae has an action analogous to that of pilocarpine on sphincter pupillae?",
      "options": [
        {
          "label": "A",
          "text": "Timolol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Phenylephrine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Neostigmine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tropicamide",
          "correct": false
        }
      ],
      "correct_answer": "B. Phenylephrine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Phenylephrine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Timolol: Timolol is a n on-selective beta-adrenergic receptor blocker used in the treatment of glaucoma to lower intraocular pressure. It does not have a direct effect on the muscles of the iris and thus does not cause analogous action to pilocarpine on sphincter pupillae.</li><li>\u2022 Option A. Timolol:</li><li>\u2022 on-selective beta-adrenergic receptor blocker</li><li>\u2022 glaucoma to lower</li><li>\u2022 intraocular pressure.</li><li>\u2022 does not</li><li>\u2022 muscles of the iris</li><li>\u2022 does not cause analogous action</li><li>\u2022 pilocarpine on sphincter pupillae.</li><li>\u2022 Option C. Neostigmine: Neostigmine is a cholinesterase inhibitor that increases the concentration of acetylcholine at cholinergic synapses , indirectly causing miosis by enhancing the effect of acetylcholine on the sphincter pupillae . Its mechanism of action is indirect, unlike the direct action of phenylephrine on the dilator pupillae.</li><li>\u2022 Option C. Neostigmine:</li><li>\u2022 cholinesterase inhibitor</li><li>\u2022 increases the concentration of acetylcholine</li><li>\u2022 cholinergic</li><li>\u2022 synapses</li><li>\u2022 miosis</li><li>\u2022 acetylcholine on the sphincter pupillae</li><li>\u2022 direct action of phenylephrine on the dilator pupillae.</li><li>\u2022 Option D. Tropicamide: Tropicamide is an anticholinergic agent used as a mydriatic to dilate the pupil. It works by blocking muscarinic receptors in the sphincter pupillae, preventing acetylcholine from contracting the muscle . While tropicamide does cause pupillary dilation, its mechanism (antagonism of cholinergic action) is not analogous to the direct stimulatory effect of pilocarpine on the sphincter pupillae . Phenylephrine's direct agonistic action on the dilator pupillae makes it the analogous agent.</li><li>\u2022 Option D. Tropicamide:</li><li>\u2022 anticholinergic agent</li><li>\u2022 mydriatic to dilate the pupil.</li><li>\u2022 blocking</li><li>\u2022 muscarinic receptors</li><li>\u2022 sphincter pupillae, preventing acetylcholine from contracting the muscle</li><li>\u2022 pupillary dilation,</li><li>\u2022 (antagonism of cholinergic action)</li><li>\u2022 not analogous</li><li>\u2022 stimulatory effect of pilocarpine</li><li>\u2022 on the sphincter pupillae</li><li>\u2022 Phenylephrine's</li><li>\u2022 agonistic</li><li>\u2022 dilator pupillae</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Phenylephrine, a sympathomimetic agent, directly stimulates the dilator pupillae to cause dilation, serving as an analogous action to pilocarpine's stimulation of the sphincter pupillae to cause constriction.</li><li>\u27a4 Phenylephrine, a sympathomimetic agent,</li><li>\u27a4 dilator pupillae to cause dilation,</li><li>\u27a4 analogous action</li><li>\u27a4 pilocarpine's</li><li>\u27a4 sphincter pupillae</li><li>\u27a4 constriction.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "99d8ceb7",
      "audio": ""
    },
    {
      "text": "A 55-year-old male patient with a history of hypertension and diabetes is brought to the emergency department in a state of acute shock. He is hypotensive with a blood pressure of 80/50 mmHg, tachycardic with a heart rate of 110 bpm, and his skin is cold and clammy. The medical team is considering the use of dopamine as part of his management. Among the following properties of dopamine. Which of them is not helpful in acute shock?",
      "options": [
        {
          "label": "A",
          "text": "Alpha-1 agonist action leading to peripheral vasoconstriction",
          "correct": false
        },
        {
          "label": "B",
          "text": "Increase in renal perfusion due to agonist action on D1 receptors",
          "correct": true
        },
        {
          "label": "C",
          "text": "Releases noradrenaline and causes positive inotropic effect",
          "correct": false
        },
        {
          "label": "D",
          "text": "Direct action on heart via beta-1 receptors",
          "correct": false
        }
      ],
      "correct_answer": "B. Increase in renal perfusion due to agonist action on D1 receptors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Increase in renal perfusion due to agonist action on D1 receptors</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Alpha-1 agonist action leading to peripheral vasoconstriction: In shock, especially distributive shock (e.g., septic shock), peripheral vasodilation is a common issue leading to hypotension. T he alpha-1 agonist action of dopamine causes peripheral vasoconstriction , which can help increase systemic vascular resistance and thereby raise blood pressure . This action is beneficial in acute shock management.</li><li>\u2022 Option A.</li><li>\u2022 Alpha-1 agonist action leading to peripheral vasoconstriction:</li><li>\u2022 In shock,</li><li>\u2022 distributive shock (e.g., septic shock),</li><li>\u2022 peripheral vasodilation</li><li>\u2022 leading to hypotension. T</li><li>\u2022 alpha-1 agonist</li><li>\u2022 dopamine</li><li>\u2022 peripheral</li><li>\u2022 vasoconstriction</li><li>\u2022 increase systemic vascular resistance</li><li>\u2022 raise blood pressure</li><li>\u2022 acute shock management.</li><li>\u2022 Option C. Releases noradrenaline and causes positive inotropic effect: Dopamine causes the release of noradrenaline (norepinephrine) and exerts a positive inotropic effect ( increasing cardiac contractility ). The release of noradrenaline can occur by three mechanisms:</li><li>\u2022 Option C.</li><li>\u2022 Releases noradrenaline and causes positive inotropic effect:</li><li>\u2022 noradrenaline</li><li>\u2022 (norepinephrine)</li><li>\u2022 positive inotropic effect</li><li>\u2022 increasing cardiac contractility</li><li>\u2022 Dopamine is a key intermediate in the biosynthesis of norepinephrine. Therefore, increased availability of dopamine leads to increased synthesis of norepinephrine. Beta 1 receptors are present presynpatically in sympathetic nerve terminals. Stimulation of these receptors by dopamine can cause the release of stored norepinephrine. Dopamine can also cause indirect release of norepinephrine by increasing intracellular calcium in sympathetic nerve terminals. This increase in calcium facilitates the exocytosis of norepinephrine-containing vesicles, leading to the release of norepinephrine into the synaptic cleft.</li><li>\u2022 Dopamine is a key intermediate in the biosynthesis of norepinephrine. Therefore, increased availability of dopamine leads to increased synthesis of norepinephrine.</li><li>\u2022 Beta 1 receptors are present presynpatically in sympathetic nerve terminals. Stimulation of these receptors by dopamine can cause the release of stored norepinephrine.</li><li>\u2022 Dopamine can also cause indirect release of norepinephrine by increasing intracellular calcium in sympathetic nerve terminals. This increase in calcium facilitates the exocytosis of norepinephrine-containing vesicles, leading to the release of norepinephrine into the synaptic cleft.</li><li>\u2022 indirect release of norepinephrine</li><li>\u2022 This action is highly beneficial in shock , particularly in cardiogenic shock, where the heart's ability to pump blood is compromised. The positive inotropic effect helps improve cardiac output.</li><li>\u2022 highly beneficial in shock</li><li>\u2022 cardiogenic shock,</li><li>\u2022 heart's ability</li><li>\u2022 pump blood is compromised.</li><li>\u2022 positive inotropic effect</li><li>\u2022 cardiac output.</li><li>\u2022 Option D. Direct action on heart via beta-1 receptors: Dopamine's direct action on beta-1 receptors in the heart increases heart rate and contractility. In acute shock , especially in cases where cardiac output is low, this action can be beneficial in improving hemodynamics.</li><li>\u2022 Option D.</li><li>\u2022 Direct action on heart via beta-1 receptors: Dopamine's</li><li>\u2022 beta-1 receptors</li><li>\u2022 increases heart</li><li>\u2022 rate and contractility.</li><li>\u2022 acute shock</li><li>\u2022 cardiac output is low,</li><li>\u2022 improving</li><li>\u2022 hemodynamics.</li><li>\u2022 Based on this analysis, the option that is \"not helpful\" in the acute management of shock is option b - \"Increase in renal perfusion due to agonist action on D1 receptors \". While it is beneficial for renal protection, it is not directly involved in the immediate hemodynamic stabiliatzion which is the primary goal.</li><li>\u2022 \"Increase in renal perfusion</li><li>\u2022 agonist action on D1 receptors</li><li>\u2022 renal protection,</li><li>\u2022 not</li><li>\u2022 immediate</li><li>\u2022 hemodynamic stabiliatzion</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In the management of acute shock, the priority is to stabilize hemodynamics , which includes improving cardiac output and increasing systemic vascular resistance. Dopamine's alpha-1 agonist action, which causes peripheral vasoconstriction, and its beta-1 effects, which increase cardiac contractility and heart rate , are the key beneficial properties in this context. The effect of dopamine on D1 receptors to increase renal perfusion , while potentially protective for kidney function, is not the primary focus during the initial management of acute shock.</li><li>\u27a4 acute shock,</li><li>\u27a4 stabilize hemodynamics</li><li>\u27a4 improving cardiac output</li><li>\u27a4 increasing systemic vascular resistance.</li><li>\u27a4 Dopamine's alpha-1 agonist</li><li>\u27a4 peripheral vasoconstriction,</li><li>\u27a4 beta-1</li><li>\u27a4 increase cardiac contractility and heart rate</li><li>\u27a4 dopamine</li><li>\u27a4 on D1 receptors</li><li>\u27a4 increase renal perfusion</li><li>\u27a4 protective for kidney function,</li><li>\u27a4 not</li><li>\u27a4 acute shock.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "219aba87",
      "audio": ""
    },
    {
      "text": "In the management of anaphylactic shock, which of the following action of adrenaline is not required?",
      "options": [
        {
          "label": "A",
          "text": "Bronchodilation by beta-2 receptors",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cardiovascular effects of beta-1 receptors",
          "correct": false
        },
        {
          "label": "C",
          "text": "Action on blood vessels by alpha-1 receptors",
          "correct": false
        },
        {
          "label": "D",
          "text": "Action on presynaptic alpha-2 receptors",
          "correct": true
        }
      ],
      "correct_answer": "D. Action on presynaptic alpha-2 receptors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Action on presynaptic alpha-2 receptors</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Bronchodilation by beta-2 receptors is vital for reversing airway constriction in anaphylaxis .</li><li>\u2022 Option A. Bronchodilation</li><li>\u2022 beta-2 receptors</li><li>\u2022 airway constriction</li><li>\u2022 anaphylaxis</li><li>\u2022 Option B. Cardiovascular effects of beta-1 receptors are crucial for supporting heart function during shock .</li><li>\u2022 Option B. Cardiovascular</li><li>\u2022 beta-1 receptors</li><li>\u2022 heart function during shock</li><li>\u2022 Option C. Vasoconstriction by alpha-1 receptors is necessary to counteract the profound vasodilation and hypotension seen in anaphylactic shock.</li><li>\u2022 Option C. Vasoconstriction</li><li>\u2022 alpha-1 receptors</li><li>\u2022 counteract</li><li>\u2022 vasodilation and hypotension</li><li>\u2022 anaphylactic shock.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The presynaptic alpha-2 receptor action of adrenaline, which would normally inhibit norepinephrine release and dampen sympathetic responses , is not desired in the treatment of anaphylactic shock , where a strong sympathetic response is needed to combat severe allergic reactions.</li><li>\u2022 presynaptic alpha-2 receptor</li><li>\u2022 adrenaline,</li><li>\u2022 inhibit norepinephrine</li><li>\u2022 dampen</li><li>\u2022 sympathetic responses</li><li>\u2022 not</li><li>\u2022 anaphylactic shock</li><li>\u2022 strong sympathetic</li><li>\u2022 allergic reactions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c44a3aef",
      "audio": ""
    },
    {
      "text": "Which of the following is a catecholamine, that can stimulate D1, D2, alpha 1 and \u03b2-1 receptors, but not \u03b2-2 receptors?",
      "options": [
        {
          "label": "A",
          "text": "Dobutamine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dopexamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dopamine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Isoprenaline",
          "correct": false
        }
      ],
      "correct_answer": "C. Dopamine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-121213.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Dopamine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Dopamine is a catecholamine neurotransmitter and hormone that exhibits activity on both dopaminergic and adrenergic receptors. It specifically stimulates D1 and D2 dopamine receptors , which are primarily involved in neurological functions and renal vasodilation , and \u03b11 and \u03b21 adrenergic receptors, which mediate vasoconstriction and increase heart rate and contractility, respectively. Importantly, dopamine does not act on \u03b22 adrenergic receptors, which are mainly responsible for bronchodilation and vasodilation .</li><li>\u2022 Dopamine</li><li>\u2022 catecholamine neurotransmitter and hormone</li><li>\u2022 both dopaminergic and adrenergic receptors.</li><li>\u2022 stimulates D1 and D2 dopamine receptors</li><li>\u2022 neurological functions</li><li>\u2022 renal vasodilation</li><li>\u2022 \u03b11 and \u03b21 adrenergic receptors,</li><li>\u2022 vasoconstriction and increase heart rate and contractility,</li><li>\u2022 dopamine does not</li><li>\u2022 \u03b22 adrenergic receptors,</li><li>\u2022 bronchodilation and vasodilation</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Dopamine is the catecholamine that meets the criteria of stimulating D1, D2, \u03b11, and \u03b21 receptors without affecting \u03b22 receptors , which is particularly relevant in treating certain cardiovascular conditions where selective receptor activation is desired</li><li>\u2022 Dopamine</li><li>\u2022 catecholamine</li><li>\u2022 D1, D2, \u03b11, and \u03b21 receptors</li><li>\u2022 \u03b22 receptors</li><li>\u2022 cardiovascular conditions</li><li>\u2022 selective receptor</li><li>\u2022 desired</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f3493758",
      "audio": ""
    },
    {
      "text": "All of the following are indications of antimuscarinic drugs except ?",
      "options": [
        {
          "label": "A",
          "text": "Angle closure glaucoma",
          "correct": true
        },
        {
          "label": "B",
          "text": "Asthma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Peptic ulcer",
          "correct": false
        },
        {
          "label": "D",
          "text": "Urinary incontinence",
          "correct": false
        }
      ],
      "correct_answer": "A. Angle closure glaucoma",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-121431.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Angle closure glaucoma</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Asthma: Antimuscarinics are used to relieve bronchospasm by inhibiting constrictive parasympathetic influences on the bronchial smooth muscle.</li><li>\u2022 Option B. Asthma:</li><li>\u2022 Antimuscarinics</li><li>\u2022 used</li><li>\u2022 bronchospasm</li><li>\u2022 inhibiting constrictive parasympathetic</li><li>\u2022 bronchial smooth muscle.</li><li>\u2022 Option C. Peptic ulcer: These drugs reduce gastric acid secretion and are used to treat peptic ulcers.</li><li>\u2022 Option C. Peptic ulcer:</li><li>\u2022 reduce gastric acid secretion</li><li>\u2022 treat peptic ulcers.</li><li>\u2022 Option D. Urinary incontinence: Antimuscarinics can relax the bladder, reducing the urgency and frequency of urination.</li><li>\u2022 Option D. Urinary incontinence:</li><li>\u2022 Antimuscarinics</li><li>\u2022 relax the bladder,</li><li>\u2022 urgency and frequency of urination.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 In the treatment of various conditions where parasympathetic inhibition is beneficial, antimuscarinic drugs are indicated; however, they are contraindicated in angle-closure glaucoma due to the risk of exacerbating the condition</li><li>\u2022 parasympathetic inhibition</li><li>\u2022 beneficial, antimuscarinic drugs</li><li>\u2022 contraindicated in angle-closure glaucoma</li><li>\u2022 exacerbating the condition</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "1f86718b",
      "audio": ""
    },
    {
      "text": "Intravenous infusion of which of the following drugs may result in decrease in heart rate?",
      "options": [
        {
          "label": "A",
          "text": "Adrenaline",
          "correct": false
        },
        {
          "label": "B",
          "text": "Isoprenaline",
          "correct": false
        },
        {
          "label": "C",
          "text": "Noradrenaline",
          "correct": true
        },
        {
          "label": "D",
          "text": "Dobutamine",
          "correct": false
        }
      ],
      "correct_answer": "C. Noradrenaline",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Noradrenaline</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Adrenaline: Adrenaline (epinephrine) acts on both alpha and beta-adrenergic receptors. Its action on beta-1 receptors in the heart typically increases heart rate and cardiac output. Thus, intravenous infusion of adrenaline is more likely to increase rather than decrease heart rate.</li><li>\u2022 Option A.</li><li>\u2022 Adrenaline:</li><li>\u2022 both alpha and beta-adrenergic receptors.</li><li>\u2022 beta-1 receptors</li><li>\u2022 increases heart rate and cardiac output.</li><li>\u2022 infusion of adrenaline</li><li>\u2022 increase rather</li><li>\u2022 decrease heart rate.</li><li>\u2022 Option B . Isoprenaline: Isoprenaline (isoproterenol) is a synthetic sympathomimetic amine that acts predominantly on beta-adrenergic receptors , including beta-1 receptors in the heart , leading to an increase in heart rate and cardiac output . It does not cause a decrease in heart rate .</li><li>\u2022 Option B</li><li>\u2022 Isoprenaline:</li><li>\u2022 synthetic sympathomimetic amine</li><li>\u2022 beta-adrenergic receptors</li><li>\u2022 beta-1 receptors in the heart</li><li>\u2022 increase in heart rate and cardiac output</li><li>\u2022 does not</li><li>\u2022 decrease in heart rate</li><li>\u2022 Option D. Dobutamine: Dobutamine is a beta-1 adrenergic agonist with strong inotropic effects but relatively mild chronotropic effects compared to isoprenaline . It primarily increases the strength of heart muscle contraction and slightly increases heart rate but is primarily used for its inotropic effect in heart failure . It is less likely to cause a decrease in heart rate compared to noradrenaline's reflex bradycardia effect .</li><li>\u2022 Option D.</li><li>\u2022 Dobutamine:</li><li>\u2022 beta-1 adrenergic agonist</li><li>\u2022 strong inotropic effects</li><li>\u2022 mild chronotropic</li><li>\u2022 isoprenaline</li><li>\u2022 increases the strength of heart muscle contraction</li><li>\u2022 increases heart rate</li><li>\u2022 its inotropic effect in heart failure</li><li>\u2022 less likely</li><li>\u2022 decrease in heart rate</li><li>\u2022 noradrenaline's reflex bradycardia effect</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to understand the cardiovascular effects of different sympathomimetic amines , particularly their impact on heart rate . While adrenaline, isoprenaline, and dobutamine generally increase heart rate due to their beta-1 adrenergic receptor activity , noradrenaline can lead to a reflex decrease in heart rate (bradycardia) through increased blood pressure and subsequent activation of the baroreceptor reflex .</li><li>\u27a4 cardiovascular effects of different sympathomimetic amines</li><li>\u27a4 heart rate</li><li>\u27a4 adrenaline, isoprenaline, and dobutamine</li><li>\u27a4 increase heart rate</li><li>\u27a4 beta-1 adrenergic receptor activity</li><li>\u27a4 noradrenaline</li><li>\u27a4 decrease in heart rate (bradycardia)</li><li>\u27a4 increased blood pressure</li><li>\u27a4 subsequent activation of the baroreceptor reflex</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c9fae811",
      "audio": ""
    },
    {
      "text": "All of the following statements are True about Dexmedetomidine except?",
      "options": [
        {
          "label": "A",
          "text": "It is an agonist at \u03b1 1A adrenergic receptors",
          "correct": true
        },
        {
          "label": "B",
          "text": "It is used to produce sedation in critically ill patients",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is used as an adjunct in anesthesia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Its route of administration is intravenous",
          "correct": false
        }
      ],
      "correct_answer": "A. It is an agonist at \u03b1 1A adrenergic receptors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) It is an agonist at \u03b11Aadrenergic receptors</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. It is used to produce sedation in critically ill patients: This is correct as dexmedetomidine is commonly used in the ICU setting for its sedative properties with minimal respiratory depression .</li><li>\u2022 Option B.</li><li>\u2022 It is used to produce sedation in critically ill patients:</li><li>\u2022 correct as dexmedetomidine</li><li>\u2022 ICU setting</li><li>\u2022 minimal respiratory depression</li><li>\u2022 Option C. It is used as an adjunct in anesthesia: This is true ; dexmedetomidine is used as an adjunct due to its sedative, anxiolytic, and analgesic properties , making it a versatile drug in anesthetic practice.</li><li>\u2022 Option C.</li><li>\u2022 It is used as an adjunct in anesthesia:</li><li>\u2022 This is true</li><li>\u2022 dexmedetomidine</li><li>\u2022 an adjunct</li><li>\u2022 sedative, anxiolytic, and analgesic properties</li><li>\u2022 Option D. Its route of administration is intravenous: This is correct; dexmedetomidine is typically administered intravenously , especially in a hospital setting .</li><li>\u2022 Option D.</li><li>\u2022 Its route of administration is intravenous:</li><li>\u2022 correct; dexmedetomidine</li><li>\u2022 intravenously</li><li>\u2022 hospital setting</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The essential fact to remember about dexmedetomidine is that it is a selective \u03b12A adrenergic receptor agonist , not \u03b11A, and is used intravenously to sedate critically ill patients and as an adjunct in anesthesia , with the benefit of causing minimal respiratory depression.</li><li>\u27a4 essential fact</li><li>\u27a4 dexmedetomidine</li><li>\u27a4 selective \u03b12A adrenergic receptor agonist</li><li>\u27a4 intravenously</li><li>\u27a4 sedate critically ill</li><li>\u27a4 adjunct in anesthesia</li><li>\u27a4 minimal respiratory depression.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "39b0e1cf",
      "audio": ""
    },
    {
      "text": "Atropine is indicated in all the following poisonings except ?",
      "options": [
        {
          "label": "A",
          "text": "Baygon",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tik 20",
          "correct": false
        },
        {
          "label": "C",
          "text": "Parathion",
          "correct": false
        },
        {
          "label": "D",
          "text": "Endrin",
          "correct": true
        }
      ],
      "correct_answer": "D. Endrin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Baygon: Contains carbaryl, a carbamate insecticide. Atropine is used to treat poisoning due to its mechanism as an acetylcholinesterase inhibitor.</li><li>\u2022 Option A. Baygon:</li><li>\u2022 carbaryl,</li><li>\u2022 insecticide. Atropine</li><li>\u2022 treat poisoning</li><li>\u2022 acetylcholinesterase inhibitor.</li><li>\u2022 Option B. Tik 20: Contains diazinon , an organophosphate insecticide. Atropine is also indicated for the same reason as Baygon.</li><li>\u2022 Option B. Tik 20:</li><li>\u2022 diazinon</li><li>\u2022 organophosphate insecticide. Atropine</li><li>\u2022 indicated</li><li>\u2022 Option C. Parathion: An organophosphate compound and atropine is indicated for its poisoning due to its acetylcholinesterase inhibitory action.</li><li>\u2022 Option C. Parathion:</li><li>\u2022 organophosphate compound</li><li>\u2022 atropine is indicated</li><li>\u2022 acetylcholinesterase</li><li>\u2022 inhibitory action.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Atropine is not indicated for poisoning by Endrin, an organochlorine insecticide, because it does not inhibit acetylcholinesterase like the other compounds listed. While atropine is effective for organophosphate and carbamate poisoning , organochlorine poisonings do not have a specific antidote and are treated supportively.</li><li>\u2022 Atropine</li><li>\u2022 not indicated</li><li>\u2022 poisoning by Endrin,</li><li>\u2022 organochlorine insecticide,</li><li>\u2022 does not inhibit acetylcholinesterase</li><li>\u2022 atropine is effective</li><li>\u2022 organophosphate and carbamate poisoning</li><li>\u2022 organochlorine poisonings do not</li><li>\u2022 specific antidote</li><li>\u2022 supportively.</li><li>\u2022 Ref : KDT 7th/105</li><li>\u2022 Ref : KDT 7th/105</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "747ec15b",
      "audio": ""
    },
    {
      "text": "Testing of a drug related to autonomic nervous system was planned. The drug and a placebo were administered in a healthy volunteer? The following effect were seen. What are the likely characteristics of the drug?",
      "options": [
        {
          "label": "A",
          "text": "Agonist at \u03b11 and \u03b21",
          "correct": false
        },
        {
          "label": "B",
          "text": "Agonist at \u03b11 and \u03b22",
          "correct": false
        },
        {
          "label": "C",
          "text": "Agonist at \u03b21 and \u03b22",
          "correct": true
        },
        {
          "label": "D",
          "text": "Agonist at \u03b21 and antagonist at \u03b11",
          "correct": false
        }
      ],
      "correct_answer": "C. Agonist at \u03b21 and \u03b22",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-121656.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Agonist at \u03b21 and \u03b22</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A.  Agonist at \u03b11 and \u03b21: Incorrect because \u03b11 stimulation would increase both systolic and diastolic blood pressure, which is not observed.</li><li>\u2022 Option A.  Agonist at \u03b11 and \u03b21:</li><li>\u2022 Incorrect</li><li>\u2022 \u03b11 stimulation</li><li>\u2022 increase both systolic and diastolic blood pressure,</li><li>\u2022 Option B. Agonist at \u03b11 and \u03b22: Incorrec t because \u03b11 agonist action would not result in decreased diastolic blood pressure.</li><li>\u2022 Option B. Agonist at \u03b11 and \u03b22:</li><li>\u2022 Incorrec</li><li>\u2022 \u03b11 agonist action</li><li>\u2022 not</li><li>\u2022 decreased diastolic blood pressure.</li><li>\u2022 Option D.  Agonist at \u03b21 and antagonist at \u03b11: Incorrect because an \u03b11 antagonist would lead to a decrease in both systolic and diastolic blood pressure, not an increase in systolic pressure.</li><li>\u2022 Option D.  Agonist at \u03b21 and antagonist at \u03b11:</li><li>\u2022 Incorrect</li><li>\u2022 \u03b11 antagonist</li><li>\u2022 decrease in both systolic and diastolic blood pressure, not an increase in systolic pressure.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The characteristic effects of tachycardia and changes in blood pressure, along with the presence of tremors , suggest that the drug has agonistic activity at \u03b21 and \u03b22 receptors, making it a likely candidate for a beta-adrenergic agonist with both cardiac and peripheral actions.</li><li>\u2022 tachycardia and changes in blood pressure,</li><li>\u2022 presence of tremors</li><li>\u2022 agonistic activity at \u03b21 and \u03b22 receptors,</li><li>\u2022 beta-adrenergic agonist</li><li>\u2022 both cardiac and</li><li>\u2022 peripheral actions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fb394694",
      "audio": ""
    },
    {
      "text": "Which of the following are receptors are present on the ganglion?",
      "options": [
        {
          "label": "A",
          "text": "Dopaminergic",
          "correct": false
        },
        {
          "label": "B",
          "text": "Cholinergic",
          "correct": true
        },
        {
          "label": "C",
          "text": "Adrenergic",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serotonergic",
          "correct": false
        }
      ],
      "correct_answer": "B. Cholinergic",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Cholinergic</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Dopaminergic : These receptors respond to dopamine and are not typically found in autonomic ganglia.</li><li>\u2022 Option A. Dopaminergic</li><li>\u2022 dopamine</li><li>\u2022 not</li><li>\u2022 found in autonomic ganglia.</li><li>\u2022 Option C. Adrenergic : These receptors respond to norepinephrine and epinephrine and are generally not found on neurons in the ganglia . They are typically located on the target organs innervated by postganglionic sympathetic neurons.</li><li>\u2022 Option C. Adrenergic</li><li>\u2022 receptors respond to norepinephrine and epinephrine</li><li>\u2022 not found on neurons in the ganglia</li><li>\u2022 located on the target organs</li><li>\u2022 postganglionic sympathetic neurons.</li><li>\u2022 Option D.  Serotonergic : These receptors respond to serotonin and are not present in the autonomic ganglia .</li><li>\u2022 Option D.  Serotonergic</li><li>\u2022 receptors</li><li>\u2022 serotonin</li><li>\u2022 not</li><li>\u2022 autonomic ganglia</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 All preganglionic fibres (Both sympathetic as well as parasympathetic) secrete Ach Post-ganglionic parasympathetic fibres secrete Ach Post-ganglionic sympathetic fibres secrete mostly noradrenaline.</li><li>\u2022 All preganglionic fibres (Both sympathetic as well as parasympathetic) secrete Ach</li><li>\u2022 preganglionic fibres (Both sympathetic as well as parasympathetic)</li><li>\u2022 Ach</li><li>\u2022 Post-ganglionic parasympathetic fibres secrete Ach</li><li>\u2022 Post-ganglionic parasympathetic fibres</li><li>\u2022 Ach</li><li>\u2022 Post-ganglionic sympathetic fibres secrete mostly noradrenaline.</li><li>\u2022 Post-ganglionic sympathetic fibres</li><li>\u2022 noradrenaline.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "48503113",
      "audio": ""
    },
    {
      "text": "A patient presents to emergency with pinpoint pupil, salivation, lacrimation, tremors and red tears. Plasma cholinesterase level was 30% of normal. Most probable Diagnosis is?",
      "options": [
        {
          "label": "A",
          "text": "Organophosphate poisoning",
          "correct": true
        },
        {
          "label": "B",
          "text": "Dhatura poisoning",
          "correct": false
        },
        {
          "label": "C",
          "text": "Opioid poisoning",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pontine hemorrhage",
          "correct": false
        }
      ],
      "correct_answer": "A. Organophosphate poisoning",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Organophosphate poisoning</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Dhatura poisoning: Dhatura , a plant containing anticholinergic tropane alkaloids (e.g., atropine, scopolamine ), would cause anticholinergic syndrome , characterized by dry skin and mucous membranes, flushed face, hyperthermia, mydriasis (dilated pupils), and hallucinations. This is opposite to the cholinergic signs seen in the patient.</li><li>\u2022 Option B. Dhatura poisoning:</li><li>\u2022 Dhatura</li><li>\u2022 plant</li><li>\u2022 anticholinergic tropane alkaloids</li><li>\u2022 atropine, scopolamine</li><li>\u2022 anticholinergic syndrome</li><li>\u2022 dry skin and mucous membranes, flushed face, hyperthermia, mydriasis (dilated pupils), and hallucinations.</li><li>\u2022 opposite to the cholinergic signs</li><li>\u2022 Option C. Opioid poisoning: Opioid poisoning can cause pinpoint pupils , but the predominant symptoms would also include respiratory depression and decreased level of consciousness , which are not mentioned in the scenario. Opioids do not cause excessive salivation or lacrimation , nor do they affect plasma cholinesterase levels.</li><li>\u2022 Option C. Opioid poisoning:</li><li>\u2022 pinpoint pupils</li><li>\u2022 respiratory depression and decreased level of consciousness</li><li>\u2022 Opioids do not</li><li>\u2022 excessive salivation or lacrimation</li><li>\u2022 plasma cholinesterase levels.</li><li>\u2022 Option D. Pontine hemorrhage: While pontine hemorrhage can lead to pinpoint pupils due to disruption of the sympathetic pathways , it would also typically present with acute neurological deficits like altered consciousness, paralysis, or other focal neurological signs , which are not described in this scenario. Additionally, pontine hemorrhage would not explain the reduced plasma cholinesterase levels or the specific combination of symptoms mentioned.</li><li>\u2022 Option D. Pontine hemorrhage:</li><li>\u2022 pinpoint pupils</li><li>\u2022 sympathetic pathways</li><li>\u2022 acute neurological deficits like altered consciousness, paralysis, or other focal neurological signs</li><li>\u2022 pontine hemorrhage</li><li>\u2022 not explain</li><li>\u2022 reduced plasma cholinesterase levels</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to recognize the clinical presentation of organophosphate poisoning, which includes signs of cholinergic excess such as miosis, excessive salivation, lacrimation, and muscle tremors, along with reduced plasma cholinesterase levels . Understanding the clinical features and laboratory findings associated with this condition is critical for prompt diagnosis and treatment .</li><li>\u27a4 clinical presentation of organophosphate poisoning,</li><li>\u27a4 cholinergic</li><li>\u27a4 miosis, excessive salivation, lacrimation, and muscle tremors,</li><li>\u27a4 reduced plasma cholinesterase levels</li><li>\u27a4 Understanding the clinical features and laboratory findings</li><li>\u27a4 prompt diagnosis and treatment</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bd29e682",
      "audio": ""
    },
    {
      "text": "A 55-year-old man came with urinary symptoms of increased frequency and hesitation. The patient was diagnosed with benign hyperplasia of prostate. Which of the drugs will help to prevent further growth and possibly reduces the size of the prostate?",
      "options": [
        {
          "label": "A",
          "text": "Tamsulosin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Finasteride",
          "correct": true
        },
        {
          "label": "C",
          "text": "Prazosin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Testosterone",
          "correct": false
        }
      ],
      "correct_answer": "B. Finasteride",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Finasteride</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Tamsulosin: This medication is an alpha-1A antagonist that relaxes the muscles in the prostate and bladder neck, improving urine flow, but does not affect prostate size.</li><li>\u2022 Option A. Tamsulosin:</li><li>\u2022 alpha-1A antagonist</li><li>\u2022 relaxes the muscles</li><li>\u2022 prostate and bladder neck,</li><li>\u2022 improving urine flow,</li><li>\u2022 does not</li><li>\u2022 prostate size.</li><li>\u2022 Option C. Prazosin: While this non-selective alpha-1 antagonist can improve symptoms of benign prostatic hyperplasia (BPH ) by relaxing prostate and bladder neck muscles, it doesn't reduce prostate size and is noted for causing postural hypotension.</li><li>\u2022 Option C. Prazosin:</li><li>\u2022 non-selective alpha-1 antagonist</li><li>\u2022 benign prostatic hyperplasia (BPH</li><li>\u2022 relaxing prostate and bladder neck muscles,</li><li>\u2022 doesn't reduce prostate size</li><li>\u2022 causing postural hypotension.</li><li>\u2022 Option D. Testosterone: Administration of testosterone can actually exacerbate BPH due to its conversion to DHT within the prostate, leading to further growth.</li><li>\u2022 Option D. Testosterone:</li><li>\u2022 exacerbate BPH</li><li>\u2022 conversion to DHT</li><li>\u2022 prostate,</li><li>\u2022 further growth.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 For a patient diagnosed with BPH, finasteride is the drug of choice to not only alleviate urinary symptoms but also potentially reduce prostate size due to its mechanism of inhibiting the enzyme 5-alpha reductase and lowering intraprostatic DHT levels.</li><li>\u27a4 BPH, finasteride</li><li>\u27a4 drug of choice</li><li>\u27a4 alleviate urinary symptoms</li><li>\u27a4 reduce prostate size</li><li>\u27a4 inhibiting the enzyme 5-alpha reductase</li><li>\u27a4 lowering intraprostatic DHT levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c377ca38",
      "audio": ""
    },
    {
      "text": "Which of the following is beta blocker with nitric oxide releasing property?",
      "options": [
        {
          "label": "A",
          "text": "Nebivolol",
          "correct": true
        },
        {
          "label": "B",
          "text": "Sotalol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Betaxolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Atenolol",
          "correct": false
        }
      ],
      "correct_answer": "A. Nebivolol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Nebivolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Sotalol: Sotalol is a non-selective beta-blocker with Class III antiarrhythmic properties due to its inhibition of potassium channels in cardiac tissue . It does not have nitric oxide-releasing properties.</li><li>\u2022 Option B. Sotalol:</li><li>\u2022 non-selective beta-blocker with Class III antiarrhythmic</li><li>\u2022 inhibition of potassium</li><li>\u2022 channels in cardiac tissue</li><li>\u2022 Option C. Betaxolol: Betaxolol is a selective beta-1 adrenergic receptor blocker used primarily in the treatment of glaucoma and ocular hypertension. It does not possess nitric oxide-releasing properties.</li><li>\u2022 Option C. Betaxolol:</li><li>\u2022 selective beta-1 adrenergic receptor blocker</li><li>\u2022 glaucoma and</li><li>\u2022 ocular hypertension.</li><li>\u2022 does not</li><li>\u2022 nitric oxide-releasing properties.</li><li>\u2022 Option D. Atenolol: Atenolol is a selective beta-1 adrenergic receptor blocker commonly used in the management of hypertension and angina. It does not have nitric oxide-releasing properties.</li><li>\u2022 Option D. Atenolol:</li><li>\u2022 selective beta-1 adrenergic receptor blocker</li><li>\u2022 hypertension</li><li>\u2022 and angina.</li><li>\u2022 does not</li><li>\u2022 nitric oxide-releasing properties.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Nebivolol stands out among beta-blockers due to its unique nitric oxide-releasing property, which contributes to its vasodilatory effects and potential advantages in the treatment of hypertension and heart failure.</li><li>\u27a4 Nebivolol</li><li>\u27a4 beta-blockers</li><li>\u27a4 nitric oxide-releasing property,</li><li>\u27a4 vasodilatory</li><li>\u27a4 effects and potential advantages</li><li>\u27a4 hypertension and heart failure.</li><li>\u27a4 Beta blockers releasing nitric oxide (NO)</li><li>\u27a4 Beta blockers releasing nitric oxide (NO)</li><li>\u27a4 Nebuvilol Nipradilol Bopindolol Carteolol</li><li>\u27a4 Nebuvilol</li><li>\u27a4 Nipradilol</li><li>\u27a4 Bopindolol</li><li>\u27a4 Carteolol</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4780ecea",
      "audio": ""
    },
    {
      "text": "Which of the following drug is used for treatment of organophosphate poisoning?",
      "options": [
        {
          "label": "A",
          "text": "Hyoscine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Physostigmine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Propantheline",
          "correct": false
        },
        {
          "label": "D",
          "text": "Atropine",
          "correct": true
        }
      ],
      "correct_answer": "D. Atropine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Atropine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Hyoscine: This drug is an antimuscarinic , similar to atropine , but is not typically used for organophosphate poisoning.</li><li>\u2022 Option A. Hyoscine:</li><li>\u2022 antimuscarinic</li><li>\u2022 atropine</li><li>\u2022 not</li><li>\u2022 organophosphate poisoning.</li><li>\u2022 Option B. Physostigmine: This is a cholinesterase inhibit or and would worsen organophosphate poisoning.</li><li>\u2022 Option B. Physostigmine:</li><li>\u2022 cholinesterase inhibit</li><li>\u2022 organophosphate poisoning.</li><li>\u2022 Option C. Propantheline: An antimuscarinic used for other indications, not typically for organophosphate poisoning.</li><li>\u2022 Option C. Propantheline:</li><li>\u2022 antimuscarinic</li><li>\u2022 other indications, not</li><li>\u2022 organophosphate poisoning.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 For organophosphate poisoning, atropine is the specific antidote used to reverse the muscarinic symptoms such as excessive salivation, lacrimation, bradycardia, and hypotension due to the increased cholinergic activity.</li><li>\u2022 organophosphate poisoning,</li><li>\u2022 atropine</li><li>\u2022 specific antidote</li><li>\u2022 reverse the muscarinic symptoms</li><li>\u2022 excessive</li><li>\u2022 salivation, lacrimation, bradycardia, and hypotension</li><li>\u2022 increased cholinergic activity.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5036aed3",
      "audio": ""
    },
    {
      "text": "Oxybutynin is a drug used for treatment of overactive bladder. It acts as?",
      "options": [
        {
          "label": "A",
          "text": "Adrenergic receptor antagonist",
          "correct": false
        },
        {
          "label": "B",
          "text": "Muscarinic receptor antagonist",
          "correct": true
        },
        {
          "label": "C",
          "text": "Histaminic antagonist",
          "correct": false
        },
        {
          "label": "D",
          "text": "Serotonergic antagonist",
          "correct": false
        }
      ],
      "correct_answer": "B. Muscarinic receptor antagonist",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Muscarinic receptor antagonist</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Adrenergic receptor antagonist: Incorrect because oxybutynin does not primarily act on adrenergic receptors.</li><li>\u2022 Option A.</li><li>\u2022 Adrenergic receptor antagonist:</li><li>\u2022 Incorrect</li><li>\u2022 oxybutynin does not</li><li>\u2022 adrenergic receptors.</li><li>\u2022 Option C. Histaminic antagonist: Incorrect as oxybutynin does not block histamine receptors.</li><li>\u2022 Option C. Histaminic antagonist:</li><li>\u2022 Incorrect</li><li>\u2022 oxybutynin</li><li>\u2022 does not</li><li>\u2022 block histamine receptors.</li><li>\u2022 Option D. Serotonergic antagonist: Incorrect since oxybutynin is not known to antagonize serotonergic receptors in the context of overactive bladder treatment.</li><li>\u2022 Option D. Serotonergic antagonist:</li><li>\u2022 Incorrect</li><li>\u2022 oxybutynin</li><li>\u2022 not</li><li>\u2022 antagonize serotonergic receptors</li><li>\u2022 overactive bladder treatment.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Remember that oxybutynin is a muscarinic receptor antagonist used in the treatment of overactive bladder due to its selective action on M1 and M3 muscarinic subtypes, which provides therapeutic benefits in conditions like detrusor instability and neurogenic bladder.</li><li>\u2022 oxybutynin is a muscarinic receptor antagonist</li><li>\u2022 overactive bladder</li><li>\u2022 selective</li><li>\u2022 action on M1 and M3 muscarinic subtypes,</li><li>\u2022 therapeutic benefits</li><li>\u2022 detrusor instability and</li><li>\u2022 neurogenic bladder.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "59469a95",
      "audio": ""
    },
    {
      "text": "Which of the following drugs can cross blood brain barrier?",
      "options": [
        {
          "label": "A",
          "text": "Glycopyrrolate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Neostigmine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Physostigmine",
          "correct": true
        },
        {
          "label": "D",
          "text": "All of the above",
          "correct": false
        }
      ],
      "correct_answer": "C. Physostigmine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) i.e. Physostigmine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Glycopyrrolate: Incorrect, as it is a potent antimuscarinic agent with rapid action but lacks central effects due to its inability to cross the BBB.</li><li>\u2022 Option A. Glycopyrrolate:</li><li>\u2022 Incorrect,</li><li>\u2022 potent antimuscarinic agent</li><li>\u2022 rapid action</li><li>\u2022 lacks central effects</li><li>\u2022 inability to cross the BBB.</li><li>\u2022 Option B. Neostigmine: Incorrect because it is a quaternary ammonium compound , which results in poor oral absorption , limited corneal penetration , and an inability to cross the BBB.</li><li>\u2022 Option B. Neostigmine:</li><li>\u2022 Incorrect</li><li>\u2022 quaternary ammonium compound</li><li>\u2022 poor oral absorption</li><li>\u2022 limited</li><li>\u2022 corneal penetration</li><li>\u2022 inability to cross the BBB.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 It is important to remember that physostigmine can cross the blood-brain barrier, distinguishing it from other anticholinesterases like neostigmine and antimuscarinics like glycopyrrolate, which cannot.</li><li>\u2022 physostigmine can cross the blood-brain barrier,</li><li>\u2022 anticholinesterases</li><li>\u2022 neostigmine</li><li>\u2022 antimuscarinics like glycopyrrolate, which cannot.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "febd1495",
      "audio": ""
    },
    {
      "text": "Most common adverse effect of short acting beta 2 agonists used in bronchial asthma is?",
      "options": [
        {
          "label": "A",
          "text": "Muscle tremors",
          "correct": true
        },
        {
          "label": "B",
          "text": "Hypokalemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hypoglycemic attacks",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sedation",
          "correct": false
        }
      ],
      "correct_answer": "A. Muscle tremors",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Muscle tremors</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Hypokalemia: Incorrect, while beta-2 agonists can cause hypokalemia due to the intracellular shift of potassium, it is not the most common adverse effect.</li><li>\u2022 Option B. Hypokalemia:</li><li>\u2022 Incorrect,</li><li>\u2022 beta-2 agonists</li><li>\u2022 hypokalemia</li><li>\u2022 intracellular shift of potassium,</li><li>\u2022 not</li><li>\u2022 adverse effect.</li><li>\u2022 Option C. Hypoglycemic attacks: Incorrect, hypoglycemia is not a typical adverse effect of beta-2 agonists.</li><li>\u2022 Option C. Hypoglycemic attacks:</li><li>\u2022 Incorrect, hypoglycemia</li><li>\u2022 not</li><li>\u2022 beta-2 agonists.</li><li>\u2022 Option D. Sedation: Incorrect, beta-2 agonists typically do no t cause sedation as an adverse effect.</li><li>\u2022 Option D. Sedation:</li><li>\u2022 Incorrect,</li><li>\u2022 beta-2 agonists</li><li>\u2022 do no</li><li>\u2022 sedation as an adverse effect.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The most common adverse effect of short-acting beta-2 agonists in the treatment of bronchial asthma is muscle tremors, which occur due to direct stimulation of the beta-2 receptors in skeletal muscles.</li><li>\u2022 short-acting beta-2 agonists</li><li>\u2022 bronchial asthma is muscle tremors,</li><li>\u2022 direct stimulation of the beta-2 receptors</li><li>\u2022 skeletal muscles.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "54f936b7",
      "audio": ""
    },
    {
      "text": "Which of the following drugs used in treatment of glaucoma is an alpha-2-agonist?",
      "options": [
        {
          "label": "A",
          "text": "Apraclonidine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Timolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Latanoprost",
          "correct": false
        },
        {
          "label": "D",
          "text": "Netarsudil",
          "correct": false
        }
      ],
      "correct_answer": "A. Apraclonidine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-121842.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Apraclonidine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Timolol: Timolol is a non-selective beta-adrenergic receptor blocker (beta-blocker) used in the treatment of glaucoma. It works by reducing the production of aqueous humor.</li><li>\u2022 Option B. Timolol:</li><li>\u2022 non-selective beta-adrenergic receptor blocker (beta-blocker)</li><li>\u2022 treatment</li><li>\u2022 of glaucoma.</li><li>\u2022 reducing the production of aqueous humor.</li><li>\u2022 Option C. Latanoprost: Latanoprost is a prostaglandin analog used in the treatment of glaucoma. It works by increasing the outflow of aqueous humor through the uveoscleral pathway.</li><li>\u2022 Option C. Latanoprost:</li><li>\u2022 prostaglandin analog</li><li>\u2022 treatment of glaucoma.</li><li>\u2022 increasing the outflow</li><li>\u2022 aqueous humor</li><li>\u2022 uveoscleral pathway.</li><li>\u2022 Option D. Netarsudil: Netarsudil is a rho kinase inhibitor used in the treatment of glaucoma . It works by increasing the outflow of aqueous humor through the trabecular meshwork and Schlemm's canal.</li><li>\u2022 Option D. Netarsudil:</li><li>\u2022 rho kinase inhibitor</li><li>\u2022 glaucoma</li><li>\u2022 increasing the outflow of</li><li>\u2022 aqueous humor</li><li>\u2022 trabecular meshwork and Schlemm's canal.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Apraclonidine, as an alpha-2 adrenergic receptor agonist, reduces intraocular pressure by decreasing the production of aqueous humor.</li><li>\u27a4 Apraclonidine,</li><li>\u27a4 alpha-2 adrenergic receptor agonist,</li><li>\u27a4 reduces intraocular pressure</li><li>\u27a4 decreasing</li><li>\u27a4 aqueous</li><li>\u27a4 humor.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e96fa3e2",
      "audio": ""
    },
    {
      "text": "After eating a plant as shown in the figure below, A child presented to emergency in comatose state. The pupils were dilated, and skin was dry. Body temperature is raised, and heart rate is high. These signs and symptoms can occur with the intake of which of the following substance?",
      "options": [
        {
          "label": "A",
          "text": "Morphine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Quinine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Atropine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Digoxin",
          "correct": false
        }
      ],
      "correct_answer": "C. Atropine",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/picture3_XXE4pf8.jpg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Atropine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A.  Morphine - Incorrect, as morphine typically causes constricted pupils (miosis), not dilation.</li><li>\u2022 Option A.  Morphine</li><li>\u2022 - Incorrect,</li><li>\u2022 constricted pupils (miosis),</li><li>\u2022 Option B. Quinine - Incorrect, as quinine is not commonly associated with these symptoms.</li><li>\u2022 Option B. Quinine</li><li>\u2022 Incorrect,</li><li>\u2022 not</li><li>\u2022 these symptoms.</li><li>\u2022 Option D.  Digoxin - Incorrect, as digoxin overdose typically does not cause hyperthermia and dry skin but can cause other symptoms such as nausea, vomiting, and heart rhythm disturbances.</li><li>\u2022 Option D.  Digoxin</li><li>\u2022 Incorrect,</li><li>\u2022 digoxin overdose</li><li>\u2022 does not cause hyperthermia</li><li>\u2022 dry skin</li><li>\u2022 nausea, vomiting, and heart rhythm disturbances.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The DHATURA acronym can be used to remember the signs of atropine poisoning: Dry mouth and Delirium, Hyperthermia, Agitation, Tachycardia, Urinary retention, Retention of stool, and lost Accommodation (dilated pupils, photophobia, blurred vision).</li><li>\u2022 DHATURA acronym</li><li>\u2022 signs of atropine poisoning: Dry mouth and Delirium, Hyperthermia, Agitation, Tachycardia, Urinary retention, Retention of stool, and lost Accommodation (dilated pupils, photophobia, blurred vision).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fa094ad0",
      "audio": ""
    },
    {
      "text": "Which of the following drug possess agonistic property on alpha 1, alpha 2, beta 1 and beta 2 adrenergic receptors?",
      "options": [
        {
          "label": "A",
          "text": "Fenoldopam",
          "correct": false
        },
        {
          "label": "B",
          "text": "Dopamine",
          "correct": false
        },
        {
          "label": "C",
          "text": "Epinephrine",
          "correct": true
        },
        {
          "label": "D",
          "text": "Phenylephrine",
          "correct": false
        }
      ],
      "correct_answer": "C. Epinephrine",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-122030.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Epinephrine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Fenoldopam: Fenoldopam is a selective dopamine-1 receptor agonist used for the management of hypertension . It does not possess agonistic properties on alpha or beta adrenergic receptors.</li><li>\u2022 Option A. Fenoldopam:</li><li>\u2022 selective dopamine-1 receptor agonist</li><li>\u2022 hypertension</li><li>\u2022 not</li><li>\u2022 agonistic properties on alpha or beta adrenergic receptors.</li><li>\u2022 Option B. Dopamine: Dopamine primarily acts on dopamine receptors, but at higher doses, it can also stimulate alpha and beta adrenergic receptors . However, dopamine is not as potent or selective as epinephrine in its actions on adrenergic receptors.</li><li>\u2022 Option B. Dopamine:</li><li>\u2022 acts on dopamine receptors,</li><li>\u2022 higher doses,</li><li>\u2022 alpha and beta</li><li>\u2022 adrenergic receptors</li><li>\u2022 not as potent</li><li>\u2022 selective as epinephrine</li><li>\u2022 adrenergic receptors.</li><li>\u2022 Option D. Phenylephrine: Phenylephrine is a selective alpha-1 adrenergic receptor agonist used primarily as a decongestant and to raise blood pressure in cases of hypotension . It does not possess agonistic properties on beta adrenergic receptors.</li><li>\u2022 Option D. Phenylephrine:</li><li>\u2022 selective alpha-1 adrenergic receptor agonist</li><li>\u2022 decongestant</li><li>\u2022 raise blood pressure</li><li>\u2022 hypotension</li><li>\u2022 does not</li><li>\u2022 agonistic properties</li><li>\u2022 beta adrenergic receptors.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Epinephrine, as a non-selective adrenergic agonist , stimulates alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors, leading to a wide range of cardiovascular and bronchodilatory effects. This knowledge guides its use in emergency situation s such as anaphylaxis, cardiac arrest, and severe asthma exacerbations.</li><li>\u27a4 Epinephrine,</li><li>\u27a4 non-selective adrenergic agonist</li><li>\u27a4 alpha-1, alpha-2, beta-1, and beta-2</li><li>\u27a4 cardiovascular and bronchodilatory effects.</li><li>\u27a4 emergency situation</li><li>\u27a4 anaphylaxis, cardiac arrest, and severe asthma exacerbations.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "54ebac3d",
      "audio": ""
    },
    {
      "text": "Which of the following is the shortest acting mydriatic drug?",
      "options": [
        {
          "label": "A",
          "text": "Atropine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tropicamide",
          "correct": true
        },
        {
          "label": "C",
          "text": "Cyclopentolate",
          "correct": false
        },
        {
          "label": "D",
          "text": "Homatropine",
          "correct": false
        }
      ],
      "correct_answer": "B. Tropicamide",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-122143.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Tropicamide</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Atropine - Incorrect because atropine has a very long duration of action in the eye, ranging from 7-14 days.</li><li>\u2022 Option A. Atropine</li><li>\u2022 Incorrect</li><li>\u2022 atropine has a very long duration of action</li><li>\u2022 7-14 days.</li><li>\u2022 Option C. Cyclopentolate - Incorrect as it has a slower onset of action and a longer duration than tropicamide.</li><li>\u2022 Option C. Cyclopentolate</li><li>\u2022 Incorrect</li><li>\u2022 slower onset of action</li><li>\u2022 longer duration</li><li>\u2022 tropicamide.</li><li>\u2022 Option D. Homatropine - Incorrect because it does not act as rapidly as tropicamide and has a longer duration of action.</li><li>\u2022 Option D. Homatropine</li><li>\u2022 Incorrect</li><li>\u2022 does not</li><li>\u2022 rapidly as tropicamide</li><li>\u2022 longer duration of action.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Tropicamide is the preferred mydriatic agen t for fundus examination due to its short acting duration , which is generally around 4-6 hours . It is especially useful over other anticholinergic agents when a quick return to normal pupil size is desired, such as in outpatient settings.</li><li>\u2022 Tropicamide</li><li>\u2022 mydriatic agen</li><li>\u2022 short acting duration</li><li>\u2022 4-6</li><li>\u2022 hours</li><li>\u2022 useful over other anticholinergic agents</li><li>\u2022 quick return to normal pupil size</li><li>\u2022 outpatient settings.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "18bd73f2",
      "audio": ""
    },
    {
      "text": "Which of the following is an indication of an anticholinesterase drug?",
      "options": [
        {
          "label": "A",
          "text": "Alzheimer\u2019s disease",
          "correct": true
        },
        {
          "label": "B",
          "text": "Parkinsonism",
          "correct": false
        },
        {
          "label": "C",
          "text": "Guillain Barre syndrome",
          "correct": false
        },
        {
          "label": "D",
          "text": "To produce mydriasis",
          "correct": false
        }
      ],
      "correct_answer": "A. Alzheimer\u2019s disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Alzheimer\u2019s disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Parkinsonism - Incorrect because the primary neurotransmitter affected in Parkinsonism is dopamine, not acetylcholine.</li><li>\u2022 Option B. Parkinsonism</li><li>\u2022 Incorrect</li><li>\u2022 primary neurotransmitter</li><li>\u2022 Parkinsonism is dopamine,</li><li>\u2022 Option C. Guillain Barre syndrome - Incorrect as this is an autoimmune condition affecting peripheral nerves , and anticholinesterase drugs are not the mainstay of treatment.</li><li>\u2022 Option C. Guillain Barre syndrome</li><li>\u2022 Incorrect</li><li>\u2022 autoimmune condition</li><li>\u2022 peripheral nerves</li><li>\u2022 anticholinesterase drugs</li><li>\u2022 Option D. To produce mydriasis - Incorrect because anticholinesterase drugs do not produce mydriasis ; they are used to treat conditions like glaucoma.</li><li>\u2022 Option D. To produce mydriasis</li><li>\u2022 Incorrect</li><li>\u2022 anticholinesterase drugs do not produce mydriasis</li><li>\u2022 treat</li><li>\u2022 glaucoma.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Anticholinesterase drugs are used in the treatment of Alzheimer\u2019s disease to increase the levels of acetylcholine in the brain, which helps in improving the cognitive symptoms of the disease.</li><li>\u2022 Anticholinesterase drugs</li><li>\u2022 Alzheimer\u2019s disease</li><li>\u2022 increase the levels of acetylcholine</li><li>\u2022 brain,</li><li>\u2022 improving the cognitive symptoms</li><li>\u2022 disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5c1e41fb",
      "audio": ""
    },
    {
      "text": "Intravenous administration of norepinephrine in a patient already taking an effective dose of atropine will often?",
      "options": [
        {
          "label": "A",
          "text": "Increase heart rate",
          "correct": true
        },
        {
          "label": "B",
          "text": "Decrease total peripheral resistance",
          "correct": false
        },
        {
          "label": "C",
          "text": "Decrease pupil size",
          "correct": false
        },
        {
          "label": "D",
          "text": "Has no effect on cardiovascular system?",
          "correct": false
        }
      ],
      "correct_answer": "A. Increase heart rate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Increase heart rate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Decrease total peripheral resistance: Norepinephrine typically increases total peripheral resistance due to its potent vasoconstrictive effects on alpha-1 adrenergic receptors.</li><li>\u2022 Option B. Decrease total peripheral resistance:</li><li>\u2022 increases total peripheral resistance</li><li>\u2022 potent</li><li>\u2022 vasoconstrictive</li><li>\u2022 alpha-1 adrenergic receptors.</li><li>\u2022 Option C. Decrease pupil size: Norepinephrine primarily acts on alpha-adrenergic receptors , leading to pupillary dilation (mydriasis), rather than constriction. Atropine , being a muscarinic receptor antagonist, also causes pupillary dilation . Therefore, the combined effect of norepinephrine and atropine would likely maintain or increase pupil size.</li><li>\u2022 Option C. Decrease pupil size:</li><li>\u2022 Norepinephrine</li><li>\u2022 alpha-adrenergic receptors</li><li>\u2022 pupillary dilation (mydriasis),</li><li>\u2022 Atropine</li><li>\u2022 muscarinic receptor antagonist,</li><li>\u2022 pupillary dilation</li><li>\u2022 combined effect of norepinephrine and atropine</li><li>\u2022 maintain</li><li>\u2022 increase pupil size.</li><li>\u2022 Option D. Has no effect on the cardiovascular system: Norepinephrine has significant effects on the cardiovascular system, including increasing blood pressure, heart rate, and cardiac contractility, primarily through its actions on alpha and beta adrenergic receptors .</li><li>\u2022 Option D. Has no effect on the cardiovascular system:</li><li>\u2022 Norepinephrine</li><li>\u2022 cardiovascular system,</li><li>\u2022 increasing blood pressure, heart rate, and cardiac contractility,</li><li>\u2022 alpha and beta adrenergic</li><li>\u2022 receptors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 In this scenario, the combined administration of norepinephrine (which has beta-1 adrenergic activity) and atropine (a muscarinic receptor antagonist) results in an increased heart rate due to the unopposed action of norepinephrine on beta-1 adrenergic receptors in the heart.</li><li>\u27a4 combined administration of norepinephrine (which has beta-1 adrenergic activity) and atropine (a muscarinic</li><li>\u27a4 receptor antagonist)</li><li>\u27a4 increased heart rate</li><li>\u27a4 unopposed action of norepinephrine</li><li>\u27a4 beta-1 adrenergic</li><li>\u27a4 receptors</li><li>\u27a4 heart.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "eb5856b1",
      "audio": ""
    },
    {
      "text": "Which of the following is an antimuscarinic drug useful in overactive bladder?",
      "options": [
        {
          "label": "A",
          "text": "Pirenzepine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Tolterodine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Tropicamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Atropine",
          "correct": false
        }
      ],
      "correct_answer": "B. Tolterodine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0 B) Tolterodine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Pirenzepine: Pirenzepine is primarily used as a selective M1 muscarinic receptor antagonist in the treatment of peptic ulcers. It is not indicated for the treatment of overactive bladder.</li><li>\u2022 Option</li><li>\u2022 A. Pirenzepine:</li><li>\u2022 selective M1 muscarinic receptor antagonist</li><li>\u2022 peptic</li><li>\u2022 ulcers.</li><li>\u2022 not indicated</li><li>\u2022 overactive bladder.</li><li>\u2022 Option C. Tropicamide: Tropicamide is a muscarinic receptor antagonist used as a mydriatic agent to induce pupillary dilation for ophthalmic examinations. It is not indicated for the treatment of overactive bladder.</li><li>\u2022 Option C.</li><li>\u2022 Tropicamide:</li><li>\u2022 muscarinic receptor antagonist</li><li>\u2022 mydriatic agent</li><li>\u2022 pupillary dilation</li><li>\u2022 ophthalmic examinations.</li><li>\u2022 not indicated</li><li>\u2022 overactive bladder.</li><li>\u2022 Option D. Atropine: Atropine is a non-selective muscarinic receptor antagonist used for various purposes, including the treatment of bradycardia, organophosphate poisoning, and as a preanesthetic medication . While it can reduce detrusor muscle activity , it is not commonly used for the treatment of overactive bladder due to its non-selective nature and potential side effects.</li><li>\u2022 Option D.</li><li>\u2022 Atropine:</li><li>\u2022 non-selective muscarinic receptor antagonist</li><li>\u2022 treatment of bradycardia, organophosphate poisoning,</li><li>\u2022 preanesthetic medication</li><li>\u2022 reduce detrusor muscle activity</li><li>\u2022 not</li><li>\u2022 treatment of overactive bladder</li><li>\u2022 non-selective nature and potential side effects.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 Tolterodine, as an antimuscarinic agent, is commonly used in the treatment of overactive bladder due to its ability to reduce urinary frequency, urgency, and urge incontinence by blocking muscarinic receptors in the bladder.</li><li>\u27a4 Tolterodine,</li><li>\u27a4 antimuscarinic agent,</li><li>\u27a4 treatment of overactive bladder</li><li>\u27a4 ability to reduce urinary frequency, urgency, and urge incontinence</li><li>\u27a4 blocking muscarinic receptors</li><li>\u27a4 bladder.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a8304509",
      "audio": ""
    },
    {
      "text": "Cholinomimetic drugs are not used in which of the following conditions?",
      "options": [
        {
          "label": "A",
          "text": "Bradycardia",
          "correct": true
        },
        {
          "label": "B",
          "text": "Glaucoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "Myasthenia gravis",
          "correct": false
        },
        {
          "label": "D",
          "text": "Post-surgical atony or ileus",
          "correct": false
        }
      ],
      "correct_answer": "A. Bradycardia",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-122644.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Bradycardia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Glaucoma - Incorrect because cholinomimetics like Pilocarpine are used to increase trabecular outflow and decrease intraocular pressure.</li><li>\u2022 Option B. Glaucoma</li><li>\u2022 Incorrect</li><li>\u2022 cholinomimetics like Pilocarpine</li><li>\u2022 increase trabecular outflow</li><li>\u2022 decrease</li><li>\u2022 intraocular pressure.</li><li>\u2022 Option C. Myasthenia gravis - Incorrect as cholinomimetics improve muscle strength by enhancing neuromuscular transmission.</li><li>\u2022 Option C. Myasthenia gravis</li><li>\u2022 Incorrect</li><li>\u2022 cholinomimetics</li><li>\u2022 muscle strength</li><li>\u2022 enhancing neuromuscular transmission.</li><li>\u2022 Option D.  Post-surgical atony or ileus - Incorrect since cholinomimetics are used to stimulate GI motility and resolve atony or ileus.</li><li>\u2022 Option D.  Post-surgical atony or ileus</li><li>\u2022 Incorrect</li><li>\u2022 cholinomimetics</li><li>\u2022 stimulate GI motility</li><li>\u2022 resolve atony or ileus.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Cholinomimetic drugs should not be used to treat bradycardia as they can slow down the heart rate furthe r, being agonists at muscarinic receptors in the heart.</li><li>\u2022 Cholinomimetic drugs</li><li>\u2022 not</li><li>\u2022 treat bradycardia</li><li>\u2022 slow down the heart rate furthe</li><li>\u2022 agonists at</li><li>\u2022 muscarinic receptors</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e3e2a8f6",
      "audio": ""
    },
    {
      "text": "Correct match of drug and mechanism of action is:",
      "options": [
        {
          "label": "A",
          "text": "Brimonidine decreases aqueous production",
          "correct": true
        },
        {
          "label": "B",
          "text": "Latanoprost is a carbonic anhydrase inhibitor",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pilocarpine increases uveoscleral outflow",
          "correct": false
        },
        {
          "label": "D",
          "text": "Betaxolol increases trabecular outflow",
          "correct": false
        }
      ],
      "correct_answer": "A. Brimonidine decreases aqueous production",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-10-122831.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Brimonidine decreases aqueous production.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Latanoprost is a carbonic anhydrase inhibitor: Latanoprost is a prostaglandin analog that increases the outflow of aqueous humor through the uveoscleral pathway by relaxing the ciliary muscle and expanding the spaces in the trabecular meshwork.</li><li>\u2022 Option B. Latanoprost is a carbonic anhydrase inhibitor:</li><li>\u2022 prostaglandin analog</li><li>\u2022 increases the outflow of</li><li>\u2022 aqueous humor</li><li>\u2022 uveoscleral pathway</li><li>\u2022 relaxing the ciliary muscle</li><li>\u2022 expanding</li><li>\u2022 trabecular</li><li>\u2022 meshwork.</li><li>\u2022 Option C. Pilocarpine increases uveoscleral outflow: Pilocarpine is a muscarinic receptor agonist that primarily works by contracting the ciliary muscle , leading to widening of the spaces between the muscle bundles and increasing trabecular outflow, rather than uveoscleral outflow.</li><li>\u2022 Option C. Pilocarpine increases uveoscleral outflow:</li><li>\u2022 muscarinic receptor agonist</li><li>\u2022 contracting</li><li>\u2022 ciliary muscle</li><li>\u2022 widening of the spaces between the muscle bundles</li><li>\u2022 increasing trabecular outflow,</li><li>\u2022 Option D. Betaxolol increases trabecular outflow: Betaxolol is a beta-blocker used in the treatment of glaucoma. It works by reducing intraocular pressure through a mechanism involving the reduction of aqueous humor production by the ciliary body.</li><li>\u2022 Option D. Betaxolol increases trabecular outflow:</li><li>\u2022 beta-blocker</li><li>\u2022 treatment of glaucoma.</li><li>\u2022 reducing intraocular pressure</li><li>\u2022 reduction of aqueous humor production</li><li>\u2022 ciliary body.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "61f3be2a",
      "audio": ""
    },
    {
      "text": "Which of the following is not a tertiary amine derivative?",
      "options": [
        {
          "label": "A",
          "text": "Atropine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glycopyrrolate",
          "correct": true
        },
        {
          "label": "C",
          "text": "Scopolamine",
          "correct": false
        },
        {
          "label": "D",
          "text": "Hyoscine",
          "correct": false
        }
      ],
      "correct_answer": "B. Glycopyrrolate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans.\u00a0B) Glycopyrrolate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Atropine - Incorrect , as it is a tertiary amine and can cross the blood-brain barrier, leading to central effects.</li><li>\u2022 Option A. Atropine</li><li>\u2022 Incorrect</li><li>\u2022 tertiary amine</li><li>\u2022 can cross the blood-brain barrier,</li><li>\u2022 central effects.</li><li>\u2022 Option C. Scopolamine - Incorrect, as it is a tertiary amine with central effects and is also known as hyoscine.</li><li>\u2022 Option C. Scopolamine</li><li>\u2022 Incorrect,</li><li>\u2022 tertiary amine</li><li>\u2022 central effects</li><li>\u2022 hyoscine.</li><li>\u2022 Option D. Hyoscine - Incorrect, as it is another name for scopolamine , a tertiary amine with central actions.</li><li>\u2022 Option D. Hyoscine</li><li>\u2022 Incorrect,</li><li>\u2022 another name for scopolamine</li><li>\u2022 tertiary amine</li><li>\u2022 central actions.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Glycopyrrolate is a quaternary ammonium compound, which cannot cross the blood-brain barrier, distinguishing it from tertiary amines like atropine and scopolamine (also known as hyoscine), which can have central nervous system effects.</li><li>\u2022 Glycopyrrolate</li><li>\u2022 quaternary ammonium compound,</li><li>\u2022 cannot cross the blood-brain barrier,</li><li>\u2022 tertiary</li><li>\u2022 amines</li><li>\u2022 atropine and scopolamine (also known as hyoscine),</li><li>\u2022 central nervous system effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e4a39876",
      "audio": ""
    },
    {
      "text": "Which of the following match of a 3 rd generation beta blocker with its mechanism of vasodilatory property is correct?",
      "options": [
        {
          "label": "A",
          "text": "Carvedilol \u2013 \u03b2 2 agonistic activity",
          "correct": false
        },
        {
          "label": "B",
          "text": "Celiprolol \u2013 Potassium channel blocker",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lebetalol \u2013 Calcium channel blocker",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nebivolol \u2013 Enhance NO production",
          "correct": true
        }
      ],
      "correct_answer": "D. Nebivolol \u2013 Enhance NO production",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/screenshot-2024-05-11-165735.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Nebivolol: Enhance NO production</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Carvedilol - Incorrect because carvedilol has alpha-blocking properties as well as antioxidant properties that contribute to its vasodilatory effects , not \u03b22 agonistic activity.</li><li>\u2022 Option A. Carvedilol</li><li>\u2022 Incorrect</li><li>\u2022 carvedilol has alpha-blocking properties</li><li>\u2022 antioxidant properties</li><li>\u2022 vasodilatory effects</li><li>\u2022 not \u03b22 agonistic activity.</li><li>\u2022 Option B. Celiprolol - Incorrect because celiprolol has some \u03b22 agonistic effects which may contribute to its vasodilatory properties, not potassium channel blocking.</li><li>\u2022 Option B. Celiprolol</li><li>\u2022 Incorrect</li><li>\u2022 celiprolol</li><li>\u2022 \u03b22 agonistic effects</li><li>\u2022 vasodilatory properties,</li><li>\u2022 not potassium channel blocking.</li><li>\u2022 Option C. Labetalol - Incorrect because l abetalol blocks both alpha and beta receptors but does not act as a calcium channel blocker.</li><li>\u2022 Option C. Labetalol</li><li>\u2022 Incorrect</li><li>\u2022 abetalol blocks both alpha and beta receptors</li><li>\u2022 does not act</li><li>\u2022 calcium channel</li><li>\u2022 blocker.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Nebivolol's mechanism of vasodilation is distinct among beta blockers because it enhances nitric oxide production, leading to vasodilation without the typical resistance seen with pure beta-blocking effects.</li><li>\u2022 Nebivolol's</li><li>\u2022 vasodilation</li><li>\u2022 beta blockers</li><li>\u2022 nitric oxide production,</li><li>\u2022 vasodilation without</li><li>\u2022 typical resistance</li><li>\u2022 pure beta-blocking effects.</li><li>\u2022 Mechanism of vasodilation in third generation beta blockers</li><li>\u2022 Mechanism of vasodilation in third generation beta blockers</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7e699650",
      "audio": ""
    },
    {
      "text": "Which is the new \u03b23 agonist approved for overactive bladder?",
      "options": [
        {
          "label": "A",
          "text": "Fesoterodine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Trospium",
          "correct": false
        },
        {
          "label": "C",
          "text": "Mirabegron",
          "correct": true
        },
        {
          "label": "D",
          "text": "Oxybutynin",
          "correct": false
        }
      ],
      "correct_answer": "C. Mirabegron",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Mirabegron</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Fesoterodine - Incorrect , it is an antimuscarinic agent used for overactive bladder but not a \u03b23 agonist.</li><li>\u2022 Option A. Fesoterodine</li><li>\u2022 Incorrect</li><li>\u2022 antimuscarinic agent</li><li>\u2022 overactive bladder</li><li>\u2022 not a \u03b23 agonist.</li><li>\u2022 Option B. Trospium - Incorrect , also an antimuscarinic , not a \u03b23 agonist .</li><li>\u2022 Option B. Trospium</li><li>\u2022 Incorrect</li><li>\u2022 antimuscarinic</li><li>\u2022 not a \u03b23 agonist</li><li>\u2022 Option D. Oxybutynin - Incorrect, this is an older antimuscarinic drug used for overactive bladder .</li><li>\u2022 Option D. Oxybutynin</li><li>\u2022 - Incorrect,</li><li>\u2022 older antimuscarinic drug</li><li>\u2022 overactive bladder</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Mirabegron is the first \u03b23 agonist approved for the treatment of overactive bladder, offering a mechanism of action different from antimuscarinic agents, and can be an option for patients who cannot tolerate or do not respond to anticholinergic medications.</li><li>\u2022 Mirabegron</li><li>\u2022 first \u03b23 agonist</li><li>\u2022 overactive bladder,</li><li>\u2022 mechanism of action different</li><li>\u2022 antimuscarinic agents,</li><li>\u2022 cannot tolerate</li><li>\u2022 do not respond to anticholinergic medications.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b710c98c",
      "audio": ""
    },
    {
      "text": "Which of the following statements is true regarding anticholinesterase?",
      "options": [
        {
          "label": "A",
          "text": "They act by increasing the concentration of Ach by preventing its degradation",
          "correct": true
        },
        {
          "label": "B",
          "text": "Reversible and irreversible anticholinesterases act by different mechanism of action",
          "correct": false
        },
        {
          "label": "C",
          "text": "Anticholinesterases act by binding to the anionic site of acetylcholinesterase",
          "correct": false
        },
        {
          "label": "D",
          "text": "All organophosphates anticholinesterases are water soluble",
          "correct": false
        }
      ],
      "correct_answer": "A. They act by increasing the concentration of Ach by preventing its degradation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) They act by increasing the concentration of Ach by preventing its degradation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Incorrect, reversible and irreversible anticholinesterases both inhibit acetylcholinesterase but differ mainly in the duration and strength of their binding to the enzyme.</li><li>\u2022 Option B. Incorrect,</li><li>\u2022 reversible and irreversible anticholinesterases</li><li>\u2022 inhibit acetylcholinesterase</li><li>\u2022 differ</li><li>\u2022 duration and strength of their binding</li><li>\u2022 Option C. Incorrect , while there is an anionic site on the enzyme, the action of anticholinesterases is primarily through binding to the esteratic site , where they prevent the hydrolysis of ACh.</li><li>\u2022 Option C. Incorrect</li><li>\u2022 anionic site on the enzyme,</li><li>\u2022 anticholinesterases</li><li>\u2022 esteratic site</li><li>\u2022 prevent the hydrolysis of ACh.</li><li>\u2022 Option D. Incorrect, not all organophosphates are water-soluble; some are highly lipid-soluble, which allows them to cross lipid membranes , including the blood-brain barrier.</li><li>\u2022 Option D. Incorrect,</li><li>\u2022 not</li><li>\u2022 organophosphates are water-soluble;</li><li>\u2022 highly lipid-soluble,</li><li>\u2022 cross lipid</li><li>\u2022 membranes</li><li>\u2022 blood-brain barrier.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Anticholinesterase drugs work by inhibiting the enzyme that breaks down acetylcholine, leading to increased levels of ACh. This has various therapeutic applications, such as treating myasthenia gravis, reversing neuromuscular blockade, and as an antidote for anticholinergic poisoning. Their ability to cross membranes and enter the CNS or the eye varies based on their molecular structure.</li><li>\u2022 Anticholinesterase</li><li>\u2022 inhibiting the enzyme</li><li>\u2022 breaks down acetylcholine,</li><li>\u2022 increased levels of ACh.</li><li>\u2022 myasthenia gravis, reversing neuromuscular blockade,</li><li>\u2022 antidote for</li><li>\u2022 anticholinergic poisoning.</li><li>\u2022 ability to cross membranes</li><li>\u2022 CNS</li><li>\u2022 eye</li><li>\u2022 molecular structure.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b04a167b",
      "audio": ""
    },
    {
      "text": "Propranolol is useful in the treatment of all of the following EXCEPT?",
      "options": [
        {
          "label": "A",
          "text": "Angina",
          "correct": false
        },
        {
          "label": "B",
          "text": "Partial atrioventricular block",
          "correct": true
        },
        {
          "label": "C",
          "text": "Idiopathic hypertrophic subaortic cardiomyopathy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Familial tremor",
          "correct": false
        }
      ],
      "correct_answer": "B. Partial atrioventricular block",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Partial atrioventricular block</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Angina: Propranolol is used in the management of angina pectoris due to its ability to reduce myocardial oxygen demand .</li><li>\u2022 Option A. Angina:</li><li>\u2022 Propranolol</li><li>\u2022 angina pectoris</li><li>\u2022 ability to reduce myocardial oxygen demand</li><li>\u2022 Option C. Idiopathic: hypertrophic subaortic cardiomyopathy (HOCM): Beta blockers like propranolol are used in HOCM to reduce the outflow obstruction and improve symptoms.</li><li>\u2022 Option C. Idiopathic:</li><li>\u2022 hypertrophic subaortic cardiomyopathy (HOCM):</li><li>\u2022 propranolol</li><li>\u2022 HOCM to reduce</li><li>\u2022 outflow obstruction</li><li>\u2022 improve symptoms.</li><li>\u2022 Option D. Familial tremor: Propranolol is effective in reducing tremors in conditions like familial or essential tremor.</li><li>\u2022 Option D. Familial tremor:</li><li>\u2022 Propranolol</li><li>\u2022 reducing tremors</li><li>\u2022 familial or essential tremor.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Propranolol is contraindicated in patients with partial atrioventricular block as it can exacerbate the condition leading to complete heart block. It is, however, beneficial in conditions such as angina, HOCM, and familial tremors . Patients with variant angina (Prinzmetal's angina) should not be treated with propranolol due to the risk of coronary vasospasm.</li><li>\u2022 Propranolol</li><li>\u2022 contraindicated</li><li>\u2022 partial atrioventricular block</li><li>\u2022 exacerbate the condition</li><li>\u2022 complete</li><li>\u2022 heart block.</li><li>\u2022 beneficial</li><li>\u2022 angina, HOCM, and familial tremors</li><li>\u2022 variant angina</li><li>\u2022 (Prinzmetal's angina)</li><li>\u2022 should not</li><li>\u2022 propranolol due to the risk of coronary vasospasm.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5de48d70",
      "audio": ""
    },
    {
      "text": "Beta adrenergic blocker having cardioselectivity, intrinsic sympathomimetic activity and membrane stabilizing property is?",
      "options": [
        {
          "label": "A",
          "text": "Carvedilol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Atenolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Acebutolol",
          "correct": true
        },
        {
          "label": "D",
          "text": "Metoprolol",
          "correct": false
        }
      ],
      "correct_answer": "C. Acebutolol",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/10.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/12.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/20.jpg"
      ],
      "explanation": "<p><strong>Ans. C) Acebutolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Carvedilol: This is a non-selective beta-blocker with alpha-1 adrenergic blocking activity, making it effective in reducing blood pressure through vasodilation . It lacks intrinsic sympathomimetic activity and does not preferentially target beta-1 receptors , making it less ideal for patients with respiratory risks. Carvedilol is often chosen for its potent antihypertensive effects and benefits in heart failure management but does no t have the combined properties mentioned in the question.</li><li>\u2022 Option A. Carvedilol: This is a non-selective beta-blocker with alpha-1 adrenergic blocking activity, making it effective in reducing blood pressure through vasodilation . It lacks intrinsic sympathomimetic activity and does not preferentially target beta-1 receptors , making it less ideal for patients with respiratory risks. Carvedilol is often chosen for its potent antihypertensive effects and benefits in heart failure management but does no t have the combined properties mentioned in the question.</li><li>\u2022 Option A. Carvedilol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 alpha-1 adrenergic blocking activity,</li><li>\u2022 reducing blood pressure</li><li>\u2022 vasodilation</li><li>\u2022 lacks intrinsic sympathomimetic activity</li><li>\u2022 does not</li><li>\u2022 beta-1 receptors</li><li>\u2022 less ideal for patients</li><li>\u2022 respiratory risks. Carvedilol</li><li>\u2022 its potent</li><li>\u2022 antihypertensive effects</li><li>\u2022 benefits in heart failure</li><li>\u2022 does no</li><li>\u2022 combined properties</li><li>\u2022 Option B. Atenolol: Atenolol is a cardioselective beta-blocker, targeting beta-1 adrenergic receptors , which reduces its risk of bronchoconstriction in patients with asthma or chronic obstructive pulmonary disease (COPD). However, it lacks intrinsic sympathomimetic activity and does not have significant membrane-stabilizing activity, limiting its use in certain clinical scenarios where these properties are desired.</li><li>\u2022 Option B. Atenolol: Atenolol is a cardioselective beta-blocker, targeting beta-1 adrenergic receptors , which reduces its risk of bronchoconstriction in patients with asthma or chronic obstructive pulmonary disease (COPD). However, it lacks intrinsic sympathomimetic activity and does not have significant membrane-stabilizing activity, limiting its use in certain clinical scenarios where these properties are desired.</li><li>\u2022 Option B. Atenolol:</li><li>\u2022 cardioselective beta-blocker,</li><li>\u2022 beta-1 adrenergic receptors</li><li>\u2022 reduces its</li><li>\u2022 bronchoconstriction</li><li>\u2022 asthma or chronic obstructive pulmonary disease (COPD).</li><li>\u2022 lacks</li><li>\u2022 intrinsic sympathomimetic activity</li><li>\u2022 does not</li><li>\u2022 membrane-stabilizing activity,</li><li>\u2022 clinical scenarios</li><li>\u2022 desired.</li><li>\u2022 Option D. Metoprolol: Similar to atenolol, metoprolol is cardioselective but does not possess intrinsic sympathomimetic activity or significant membrane-stabilizing activity. It is widely used for its cardiovascular benefits, including hypertension management, heart failure treatment , and myocardial infarction recovery, but it does not meet the criteria of having all three specified properties.</li><li>\u2022 Option D. Metoprolol: Similar to atenolol, metoprolol is cardioselective but does not possess intrinsic sympathomimetic activity or significant membrane-stabilizing activity. It is widely used for its cardiovascular benefits, including hypertension management, heart failure treatment , and myocardial infarction recovery, but it does not meet the criteria of having all three specified properties.</li><li>\u2022 Option D. Metoprolol:</li><li>\u2022 Similar to atenolol,</li><li>\u2022 does not</li><li>\u2022 intrinsic sympathomimetic</li><li>\u2022 activity</li><li>\u2022 membrane-stabilizing activity.</li><li>\u2022 cardiovascular benefits,</li><li>\u2022 hypertension management, heart failure treatment</li><li>\u2022 myocardial infarction</li><li>\u2022 does not</li><li>\u2022 all three specified properties.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to understand the pharmacological properties and clinical implications of selecting specific beta-blockers for treatment. Recognizing the u nique attributes of beta-blockers , such as cardioselectivity, intrinsic sympathomimetic activity, and membrane-stabilizing activity, is crucial in tailoring therapy to individual patient needs, especially considering potential comorbid conditions.</li><li>\u27a4 pharmacological properties</li><li>\u27a4 clinical implications</li><li>\u27a4 selecting specific beta-blockers</li><li>\u27a4 treatment.</li><li>\u27a4 nique attributes of beta-blockers</li><li>\u27a4 cardioselectivity, intrinsic sympathomimetic activity,</li><li>\u27a4 membrane-stabilizing activity,</li><li>\u27a4 tailoring therapy</li><li>\u27a4 individual patient needs,</li><li>\u27a4 potential comorbid</li><li>\u27a4 conditions.</li><li>\u27a4 Cardioselective beta blockers:</li><li>\u27a4 Cardioselective beta blockers:</li><li>\u27a4 Beta blockers with intrinsic sympathomimetic activity</li><li>\u27a4 Beta blockers with intrinsic sympathomimetic activity</li><li>\u27a4 Beta blockers with membrane stabilizing property</li><li>\u27a4 Beta blockers with membrane stabilizing property</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "00ac7b87",
      "audio": ""
    },
    {
      "text": "Which of the following drugs is associated with tachyphylaxis?",
      "options": [
        {
          "label": "A",
          "text": "Dopamine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ephedrine",
          "correct": true
        },
        {
          "label": "C",
          "text": "Haloperidol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Propranolol",
          "correct": false
        }
      ],
      "correct_answer": "B. Ephedrine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Ephedrine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Dopamine: While dopamine can see a decrease in effectiveness over time, particularly in the context of long-term treatment for conditions like heart failure, it is not typically associated with rapid tachyphylaxis. Dopamine acts directly on dopamine receptors and indirectly on adrenergic receptor s to increase heart rate and blood pressure, among other effects.</li><li>\u2022 Option A. Dopamine: While dopamine can see a decrease in effectiveness over time, particularly in the context of long-term treatment for conditions like heart failure, it is not typically associated with rapid tachyphylaxis. Dopamine acts directly on dopamine receptors and indirectly on adrenergic receptor s to increase heart rate and blood pressure, among other effects.</li><li>\u2022 Option A. Dopamine:</li><li>\u2022 decrease in effectiveness over time,</li><li>\u2022 long-term treatment</li><li>\u2022 heart failure,</li><li>\u2022 not</li><li>\u2022 rapid tachyphylaxis.</li><li>\u2022 Dopamine acts</li><li>\u2022 dopamine receptors</li><li>\u2022 indirectly on adrenergic receptor</li><li>\u2022 increase heart rate</li><li>\u2022 blood pressure,</li><li>\u2022 Option C. Haloperidol: Haloperidol is an antipsychotic medication used to treat schizophrenia and acute psychosis . It works primarily by blocking dopamine receptors in the brain . Tachyphylaxis is not commonly associated with haloperidol or other antipsychotic medications.</li><li>\u2022 Option C. Haloperidol: Haloperidol is an antipsychotic medication used to treat schizophrenia and acute psychosis . It works primarily by blocking dopamine receptors in the brain . Tachyphylaxis is not commonly associated with haloperidol or other antipsychotic medications.</li><li>\u2022 Option C. Haloperidol:</li><li>\u2022 antipsychotic medication</li><li>\u2022 schizophrenia and acute psychosis</li><li>\u2022 blocking dopamine receptors in the brain</li><li>\u2022 Tachyphylaxis</li><li>\u2022 not</li><li>\u2022 haloperidol or other antipsychotic medications.</li><li>\u2022 Option D. Propranolol: Propranolol is a beta-blocker used to manage hypertension, angina, and other conditions. It works by blocking beta-adrenergic receptors , reducing heart rate and blood pressure. T achyphylaxis is not a common issue with propranolol or most other beta-blockers.</li><li>\u2022 Option D. Propranolol: Propranolol is a beta-blocker used to manage hypertension, angina, and other conditions. It works by blocking beta-adrenergic receptors , reducing heart rate and blood pressure. T achyphylaxis is not a common issue with propranolol or most other beta-blockers.</li><li>\u2022 Option D. Propranolol:</li><li>\u2022 beta-blocker</li><li>\u2022 hypertension, angina,</li><li>\u2022 blocking beta-adrenergic receptors</li><li>\u2022 reducing heart rate and blood pressure.</li><li>\u2022 achyphylaxis</li><li>\u2022 not</li><li>\u2022 propranolol</li><li>\u2022 other beta-blockers.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The goal is to enhance understanding of pharmacodynamics, specifically the concept of tachyphylaxis, and to recognize which drugs are associated with this phenomenon. Examples of drugs acting by displacement include:</li><li>\u27a4 goal</li><li>\u27a4 enhance</li><li>\u27a4 pharmacodynamics,</li><li>\u27a4 concept of tachyphylaxis,</li><li>\u27a4 recognize which drugs</li><li>\u27a4 phenomenon.</li><li>\u27a4 drugs acting</li><li>\u27a4 Tyramine Ephedrine Pseudoephedrine Amphetamines</li><li>\u27a4 Tyramine</li><li>\u27a4 Ephedrine</li><li>\u27a4 Pseudoephedrine</li><li>\u27a4 Amphetamines</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3eedbb97",
      "audio": ""
    },
    {
      "text": "All of the following are findings of cholinergic toxidrome except?",
      "options": [
        {
          "label": "A",
          "text": "Salivation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Mydriasis",
          "correct": true
        },
        {
          "label": "C",
          "text": "Vomiting",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bradycardia",
          "correct": false
        }
      ],
      "correct_answer": "B. Mydriasis",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/30.jpg"
      ],
      "explanation": "<p><strong>Ans. B) Mydriasis</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Salivation: Increased salivation is a hallmark of cholinergic toxidrome due to stimulation of muscarinic receptors (M3).</li><li>\u2022 Option A. Salivation:</li><li>\u2022 Increased</li><li>\u2022 hallmark of cholinergic toxidrome</li><li>\u2022 stimulation of muscarinic receptors (M3).</li><li>\u2022 Option C. Vomiting: Another classic feature due to the a ctivation of the digestive system's muscarinic pathways.</li><li>\u2022 Option C. Vomiting:</li><li>\u2022 classic feature</li><li>\u2022 ctivation of the digestive system's muscarinic pathways.</li><li>\u2022 Option D. Bradycardia: Stimulation of muscarinic receptors (M2) in the heart slows the heart rate , leading to bradycardia.</li><li>\u2022 Option D. Bradycardia:</li><li>\u2022 Stimulation of muscarinic receptors (M2)</li><li>\u2022 slows the heart rate</li><li>\u2022 bradycardia.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 In cholinergic toxidrome , expect pinpoint pupils (miosis), not dilated pupils (mydriasis), along with excessive secretion such as salivation, sweating, lacrimation, symptoms of gastrointestinal upset like vomiting, and bradycardia. Mydriasis is typically associated with anticholinergic toxidrome, not cholinergic.</li><li>\u2022 In cholinergic toxidrome</li><li>\u2022 expect pinpoint pupils (miosis),</li><li>\u2022 excessive secretion</li><li>\u2022 salivation, sweating, lacrimation, symptoms of gastrointestinal upset</li><li>\u2022 vomiting, and bradycardia.</li><li>\u2022 anticholinergic toxidrome, not cholinergic.</li><li>\u2022 Symptoms of cholinergic overdose include:</li><li>\u2022 Symptoms of cholinergic overdose include:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7680d43d",
      "audio": ""
    },
    {
      "text": "All of the following are contraindications to the use of atropine except?",
      "options": [
        {
          "label": "A",
          "text": "Benign hyperplasia of prostate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Angle closure glaucoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "AV block",
          "correct": true
        },
        {
          "label": "D",
          "text": "Paralytic ileus",
          "correct": false
        }
      ],
      "correct_answer": "C. AV block",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/40.jpg"
      ],
      "explanation": "<p><strong>Ans. C) AV block</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Benign hyperplasia of prostate: Atropine can cause urinary retention, which is why it is contraindicated in patients with benign prostatic hyperplasia (BPH). A tropine's antimuscarinic effects reduce bladder muscle contraction, exacerbating t he difficulty in urination caused by prostate enlargement.</li><li>\u2022 Option A. Benign hyperplasia of prostate: Atropine can cause urinary retention, which is why it is contraindicated in patients with benign prostatic hyperplasia (BPH). A tropine's antimuscarinic effects reduce bladder muscle contraction, exacerbating t he difficulty in urination caused by prostate enlargement.</li><li>\u2022 Option A. Benign hyperplasia of prostate:</li><li>\u2022 Atropine</li><li>\u2022 urinary retention,</li><li>\u2022 contraindicated in</li><li>\u2022 benign prostatic hyperplasia (BPH).</li><li>\u2022 tropine's antimuscarinic effects reduce bladder muscle contraction,</li><li>\u2022 exacerbating t</li><li>\u2022 urination</li><li>\u2022 prostate enlargement.</li><li>\u2022 Option B. Angle closure glaucoma: Atropine is contraindicated in patients with angle closure glaucoma because it can increase intraocular pressure . Its antimuscarinic action dilates the pupil (mydriasis), which can block the drainage of aqueous humor through the trabecular meshwork, worsening the condition.</li><li>\u2022 Option B. Angle closure glaucoma: Atropine is contraindicated in patients with angle closure glaucoma because it can increase intraocular pressure . Its antimuscarinic action dilates the pupil (mydriasis), which can block the drainage of aqueous humor through the trabecular meshwork, worsening the condition.</li><li>\u2022 Option B. Angle closure glaucoma:</li><li>\u2022 Atropine is contraindicated</li><li>\u2022 angle closure glaucoma</li><li>\u2022 increase intraocular pressure</li><li>\u2022 antimuscarinic action dilates the pupil (mydriasis),</li><li>\u2022 block the drainage of</li><li>\u2022 aqueous humor</li><li>\u2022 trabecular meshwork,</li><li>\u2022 Option D. Paralytic ileus: Atropine is contraindicated in patients with paralytic ileus because its antimuscarinic effects can inhibit gastrointestinal motility, exacerbating the condition by further slowing or stopping the movement of the intestines.</li><li>\u2022 Option D. Paralytic ileus: Atropine is contraindicated in patients with paralytic ileus because its antimuscarinic effects can inhibit gastrointestinal motility, exacerbating the condition by further slowing or stopping the movement of the intestines.</li><li>\u2022 Option D. Paralytic ileus:</li><li>\u2022 Atropine is contraindicated</li><li>\u2022 paralytic ileus</li><li>\u2022 antimuscarinic effects</li><li>\u2022 inhibit gastrointestinal motility, exacerbating</li><li>\u2022 slowing or stopping the movement</li><li>\u2022 intestines.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to identify the contraindications of atropine use, focusing on its antimuscarinic effects on various organ systems. Here is a table listing the contraindications of atropine along with explanations for each:</li><li>\u27a4 identify the contraindications of atropine</li><li>\u27a4 antimuscarinic effects</li><li>\u27a4 various organ systems.</li><li>\u27a4 contraindications of atropine</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e3848f85",
      "audio": ""
    },
    {
      "text": "A 12-year-old female with an unremarkable past medical history presents with fever, sore throat, and a tender cervical lymphadenopathy. She is diagnosed with streptococcal Group A pharyngitis and is treated with IM penicillin. Within a few minutes of the injection, the patient is dyspneic, tachycardic, and hypotensive, and is noted to have wheezing on examination. She also complains of dysphagia. IM epinephrine is administered immediately. Which adrenoceptor primarily mediates the respiratory system response?",
      "options": [
        {
          "label": "A",
          "text": "Alpha 1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Alpha 2",
          "correct": false
        },
        {
          "label": "C",
          "text": "Beta 1",
          "correct": false
        },
        {
          "label": "D",
          "text": "Beta 2",
          "correct": true
        }
      ],
      "correct_answer": "D. Beta 2",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/111.jpg"
      ],
      "explanation": "<p><strong>Ans. D) Beta 2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Alpha 1: Alpha 1 adrenoceptors primarily mediate vasoconstriction and are involved in increasing peripheral vascular resistance , which can help in raising blood pressure . They are not directly involved in the mediation of the respiratory system's response to epinephrine in anaphylaxis.</li><li>\u2022 Option A. Alpha 1: Alpha 1 adrenoceptors primarily mediate vasoconstriction and are involved in increasing peripheral vascular resistance , which can help in raising blood pressure . They are not directly involved in the mediation of the respiratory system's response to epinephrine in anaphylaxis.</li><li>\u2022 Option A. Alpha 1:</li><li>\u2022 Alpha 1 adrenoceptors</li><li>\u2022 vasoconstriction</li><li>\u2022 increasing peripheral</li><li>\u2022 vascular resistance</li><li>\u2022 raising blood pressure</li><li>\u2022 not directly</li><li>\u2022 respiratory system's response</li><li>\u2022 epinephrine</li><li>\u2022 anaphylaxis.</li><li>\u2022 Option B. Alpha 2: Alpha 2 adrenoceptors are mainly involved in the feedback inhibition of norepinephrine release and do not play a direct role in the acute management of anaphylaxis or in mediating respiratory system responses such as bronchodilation.</li><li>\u2022 Option B. Alpha 2: Alpha 2 adrenoceptors are mainly involved in the feedback inhibition of norepinephrine release and do not play a direct role in the acute management of anaphylaxis or in mediating respiratory system responses such as bronchodilation.</li><li>\u2022 Option B. Alpha 2:</li><li>\u2022 Alpha 2 adrenoceptors</li><li>\u2022 feedback</li><li>\u2022 norepinephrine release</li><li>\u2022 do not</li><li>\u2022 acute management of anaphylaxis</li><li>\u2022 respiratory system</li><li>\u2022 bronchodilation.</li><li>\u2022 Option C. Beta 1: Beta 1 adrenoceptors are primarily found in the heart, where they increase heart rate and myocardial contractility. While beneficial in anaphylaxis for supporting cardiac output, they do not directly mediate the respiratory system's response to epinephrine.</li><li>\u2022 Option C. Beta 1: Beta 1 adrenoceptors are primarily found in the heart, where they increase heart rate and myocardial contractility. While beneficial in anaphylaxis for supporting cardiac output, they do not directly mediate the respiratory system's response to epinephrine.</li><li>\u2022 Option C. Beta 1:</li><li>\u2022 Beta 1 adrenoceptors</li><li>\u2022 heart,</li><li>\u2022 increase heart rate</li><li>\u2022 myocardial</li><li>\u2022 contractility.</li><li>\u2022 anaphylaxis for supporting cardiac output,</li><li>\u2022 do not</li><li>\u2022 respiratory</li><li>\u2022 system's response to epinephrine.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to understand the pharmacological effects of adrenoceptors, specifically the role of Beta 2 adrenoceptors in mediating bronchodilation in the context of anaphylaxis treatment. Recognizing the target receptors of emergency medications like epinephrine is crucial for effective clinical management of acute allergic reactions and anaphylaxis , ensuring prompt and appropriate intervention to alleviate life-threatening symptoms.</li><li>\u27a4 pharmacological effects of adrenoceptors,</li><li>\u27a4 Beta 2 adrenoceptors</li><li>\u27a4 mediating bronchodilation</li><li>\u27a4 anaphylaxis treatment.</li><li>\u27a4 target receptors</li><li>\u27a4 epinephrine is crucial</li><li>\u27a4 acute allergic reactions and anaphylaxis</li><li>\u27a4 ensuring prompt</li><li>\u27a4 intervention</li><li>\u27a4 alleviate life-threatening symptoms.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a599eced",
      "audio": ""
    },
    {
      "text": "Which of the following are uses of cholinergic drugs owing to their muscarinic actions? Sjogren\u2019s syndrome Alzheimer's disease Paralytic ileus Cobra bite",
      "options": [
        {
          "label": "A",
          "text": "If A,B,C are correct",
          "correct": true
        },
        {
          "label": "B",
          "text": "If A and C are correct",
          "correct": false
        },
        {
          "label": "C",
          "text": "If B and D are correct",
          "correct": false
        },
        {
          "label": "D",
          "text": "If all 4 are correct",
          "correct": false
        }
      ],
      "correct_answer": "A. If A,B,C are correct",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/121.jpg",
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/222.jpg"
      ],
      "explanation": "<p><strong>Ans. A) If A,B,C are correct</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A) Sjogren\u2019s syndrome: Cholinergic drugs are used to stimulate saliva and tear production in patients with Sjogren\u2019s syndrome, a condition characterized by dry mouth and dry eyes due to autoimmune destruction of the salivary and lacrimal glands. Their muscarinic actions enhance glandular secretion.</li><li>\u2022 Option A) Sjogren\u2019s syndrome: Cholinergic drugs are used to stimulate saliva and tear production in patients with Sjogren\u2019s syndrome, a condition characterized by dry mouth and dry eyes due to autoimmune destruction of the salivary and lacrimal glands. Their muscarinic actions enhance glandular secretion.</li><li>\u2022 Option A) Sjogren\u2019s syndrome:</li><li>\u2022 Cholinergic drugs</li><li>\u2022 stimulate saliva and tear production in patients</li><li>\u2022 Sjogren\u2019s syndrome,</li><li>\u2022 dry mouth and dry eyes</li><li>\u2022 autoimmune destruction</li><li>\u2022 salivary and lacrimal glands.</li><li>\u2022 muscarinic actions</li><li>\u2022 glandular secretion.</li><li>\u2022 Option B) Alzheimer's disease: Cholinergic drugs, specifically cholinesterase inhibitors, are used in Alzheimer's disease to increase acetylcholine levels in the brain and improve cognitive function. This acetylcholine works on muscarinic receptors to improve memory.</li><li>\u2022 Option B) Alzheimer's disease: Cholinergic drugs, specifically cholinesterase inhibitors, are used in Alzheimer's disease to increase acetylcholine levels in the brain and improve cognitive function. This acetylcholine works on muscarinic receptors to improve memory.</li><li>\u2022 Option B) Alzheimer's disease:</li><li>\u2022 cholinesterase inhibitors,</li><li>\u2022 Alzheimer's disease</li><li>\u2022 increase acetylcholine levels</li><li>\u2022 brain</li><li>\u2022 improve cognitive function.</li><li>\u2022 acetylcholine</li><li>\u2022 muscarinic</li><li>\u2022 receptors</li><li>\u2022 improve memory.</li><li>\u2022 Option C) Paralytic ileus: Cholinergic drug s are used to stimulate gastrointestinal motility in conditions like paralytic ileus by acting on muscarinic receptors in the gut, thereby alleviating the condition.</li><li>\u2022 Option C) Paralytic ileus: Cholinergic drug s are used to stimulate gastrointestinal motility in conditions like paralytic ileus by acting on muscarinic receptors in the gut, thereby alleviating the condition.</li><li>\u2022 Option C) Paralytic ileus:</li><li>\u2022 Cholinergic drug</li><li>\u2022 stimulate gastrointestinal motility</li><li>\u2022 paralytic</li><li>\u2022 ileus</li><li>\u2022 muscarinic receptors in the gut,</li><li>\u2022 alleviating the condition.</li><li>\u2022 Option D) Cobra bite: Treatment for a cobra bite primarily involves antivenom and supportive care. Cholinergic drugs like neostigmine is used to stimulate the Nm receptors and reverse the actions of the venom on neuromuscular junction. However the therapeutic approach does not center on muscarinic actions of cholinergic drugs in this condition.</li><li>\u2022 Option D) Cobra bite: Treatment for a cobra bite primarily involves antivenom and supportive care. Cholinergic drugs like neostigmine is used to stimulate the Nm receptors and reverse the actions of the venom on neuromuscular junction. However the therapeutic approach does not center on muscarinic actions of cholinergic drugs in this condition.</li><li>\u2022 Option D) Cobra bite:</li><li>\u2022 Treatment for a cobra bite</li><li>\u2022 antivenom and supportive care. Cholinergic drugs</li><li>\u2022 neostigmine</li><li>\u2022 stimulate the Nm receptors</li><li>\u2022 reverse</li><li>\u2022 venom on neuromuscular</li><li>\u2022 junction.</li><li>\u2022 therapeutic</li><li>\u2022 does not</li><li>\u2022 muscarinic actions of cholinergic drugs</li><li>\u2022 Option A (Sjogren\u2019s syndrome), Option B (Alzheimer's disease) and Option C (Paralytic ileus) are correct uses of cholinergic drugs due to their muscarinic actions.</li><li>\u2022 Option A (Sjogren\u2019s syndrome), Option B (Alzheimer's disease) and Option C (Paralytic ileus) are correct uses of cholinergic drugs due to their muscarinic actions.</li><li>\u2022 Option A (Sjogren\u2019s syndrome),</li><li>\u2022 Option B (Alzheimer's disease) and Option C (Paralytic ileus)</li><li>\u2022 cholinergic drugs</li><li>\u2022 muscarinic actions.</li><li>\u2022 Option D (Cobra bite) is use of cholinergic drugs due to action on nicotinic receptors and not muscarinic action.</li><li>\u2022 Option D (Cobra bite) is use of cholinergic drugs due to action on nicotinic receptors and not muscarinic action.</li><li>\u2022 Option D (Cobra bite)</li><li>\u2022 cholinergic drugs</li><li>\u2022 nicotinic receptors</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational objective is to understand the therapeutic applications of cholinergic drugs, particularly through their muscarinic actions , in various medical conditions. Recognizing how these drugs work can help in selecting appropriate treatment options for conditions like Sjogren\u2019s syndrome, Alzheimer\u2019s disease and paralytic ileus, while also understanding the limitations and specificity of their use in other disorders.</li><li>\u27a4 therapeutic applications of cholinergic drugs,</li><li>\u27a4 muscarinic</li><li>\u27a4 actions</li><li>\u27a4 help in selecting appropriate treatment</li><li>\u27a4 Sjogren\u2019s syndrome, Alzheimer\u2019s disease and paralytic ileus,</li><li>\u27a4 limitations and specificity</li><li>\u27a4 use</li><li>\u27a4 other disorders.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "02eb3b98",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman presents to your office for a regular check-up. Her only complaint is recurrent migraine headaches, which have increased in frequency over the years. On examination, her blood pressure is elevated at 150/70. Which of the following drug is an antihypertensive also and can be used prophylaxis of migraine?",
      "options": [
        {
          "label": "A",
          "text": "Clonidine",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prazosin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hydrochlorothiazide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Propranolol",
          "correct": true
        }
      ],
      "correct_answer": "D. Propranolol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Propranolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Clonidine: Clonidine is a centrally acting alpha-2 adrenergic agonist that lowers blood pressure by decreasing sympathetic outflow from the central nervous system . While it is effective for hypertension, it is not commonly used for migraine prophylaxis.</li><li>\u2022 Option A. Clonidine: Clonidine is a centrally acting alpha-2 adrenergic agonist that lowers blood pressure by decreasing sympathetic outflow from the central nervous system . While it is effective for hypertension, it is not commonly used for migraine prophylaxis.</li><li>\u2022 Option A. Clonidine:</li><li>\u2022 centrally acting alpha-2 adrenergic agonist</li><li>\u2022 lowers blood pressure</li><li>\u2022 decreasing</li><li>\u2022 sympathetic outflow</li><li>\u2022 central nervous system</li><li>\u2022 hypertension,</li><li>\u2022 not</li><li>\u2022 used for</li><li>\u2022 migraine prophylaxis.</li><li>\u2022 Option B. Prazosin: Prazosin is an alpha-1 adrenergic receptor blocker used primarily for treating hypertension and symptoms of benign prostatic hyperplasia. It is not indicated for the prophylaxis of migraines.</li><li>\u2022 Option B. Prazosin: Prazosin is an alpha-1 adrenergic receptor blocker used primarily for treating hypertension and symptoms of benign prostatic hyperplasia. It is not indicated for the prophylaxis of migraines.</li><li>\u2022 Option B. Prazosin:</li><li>\u2022 alpha-1 adrenergic receptor blocker</li><li>\u2022 hypertension</li><li>\u2022 benign prostatic hyperplasia.</li><li>\u2022 not</li><li>\u2022 prophylaxis of migraines.</li><li>\u2022 Option C. Hydrochlorothiazide: Hydrochlorothiazide is a thiazide diuretic used to treat hypertension by removing excess fluid from the body. It is not used for migraine prophylaxis.</li><li>\u2022 Option C. Hydrochlorothiazide: Hydrochlorothiazide is a thiazide diuretic used to treat hypertension by removing excess fluid from the body. It is not used for migraine prophylaxis.</li><li>\u2022 Option C. Hydrochlorothiazide:</li><li>\u2022 thiazide diuretic</li><li>\u2022 treat hypertension</li><li>\u2022 removing</li><li>\u2022 excess fluid</li><li>\u2022 not</li><li>\u2022 migraine prophylaxis.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to understand the dual use of certain antihypertensive medications, such as propranolol, in managing both elevated blood pressure and providing prophylactic treatment for migraine headaches. This case highlights the importance of selecting medications that can address multiple patient concerns simultaneously, thereby optimizing therapeutic outcomes.</li><li>\u27a4 dual use of certain antihypertensive medications,</li><li>\u27a4 propranolol,</li><li>\u27a4 both</li><li>\u27a4 elevated blood pressure</li><li>\u27a4 prophylactic treatment for migraine headaches.</li><li>\u27a4 highlights</li><li>\u27a4 selecting medications</li><li>\u27a4 multiple patient concerns simultaneously,</li><li>\u27a4 optimizing therapeutic outcomes.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b3fce780",
      "audio": ""
    },
    {
      "text": "A 60-year-old female patient started on a new antihypertensive medication recently. Her blood pressure seems to be under control, but she complains of fatigue, drowsiness, and fainting when she gets up from the bed. Which of the following drugs is she most likely taking?",
      "options": [
        {
          "label": "A",
          "text": "Metoprolol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Propranolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Prazosin",
          "correct": true
        },
        {
          "label": "D",
          "text": "Clonidine",
          "correct": false
        }
      ],
      "correct_answer": "C. Prazosin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Prazosin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Metoprolol: Metoprolol is a beta-1 selective adrenergic receptor blocker (beta-blocker) used to treat high blood pressure, heart pain (angina), and prevent heart attacks . While it can cause fatigue, it is less commonly associated with the severity of orthostatic hypotension described.</li><li>\u2022 Option A. Metoprolol: Metoprolol is a beta-1 selective adrenergic receptor blocker (beta-blocker) used to treat high blood pressure, heart pain (angina), and prevent heart attacks . While it can cause fatigue, it is less commonly associated with the severity of orthostatic hypotension described.</li><li>\u2022 Option A. Metoprolol:</li><li>\u2022 beta-1 selective adrenergic receptor blocker (beta-blocker)</li><li>\u2022 high</li><li>\u2022 blood pressure, heart pain (angina), and prevent heart attacks</li><li>\u2022 fatigue,</li><li>\u2022 less</li><li>\u2022 orthostatic hypotension</li><li>\u2022 Option B. Propranolol: Propranolol is a non-selective beta-adrenergic receptor blocke r that can treat high blood pressure, irregular heartbeats, and other conditions. Similar to metoprolol, while it might cause drowsiness or fatigue, pronounced orthostatic hypotension is not as characteristic as with alpha blockers.</li><li>\u2022 Option B. Propranolol: Propranolol is a non-selective beta-adrenergic receptor blocke r that can treat high blood pressure, irregular heartbeats, and other conditions. Similar to metoprolol, while it might cause drowsiness or fatigue, pronounced orthostatic hypotension is not as characteristic as with alpha blockers.</li><li>\u2022 Option B. Propranolol:</li><li>\u2022 non-selective beta-adrenergic receptor blocke</li><li>\u2022 high blood</li><li>\u2022 pressure, irregular heartbeats,</li><li>\u2022 Similar to metoprolol,</li><li>\u2022 drowsiness or fatigue,</li><li>\u2022 pronounced orthostatic hypotension</li><li>\u2022 not as characteristic</li><li>\u2022 alpha blockers.</li><li>\u2022 Option D. Clonidine: Clonidine is an alpha-2 adrenergic agonist that lowers blood pressure by decreasing the amoun t of certain chemicals in your blood. This allows your blood vessels to relax and your heart to beat more slowly and easily. It can cause drowsiness, but the specific symptoms of orthostatic hypotension upon standing are more closely associated with alpha-1 blockers like Prazosin.</li><li>\u2022 Option D. Clonidine: Clonidine is an alpha-2 adrenergic agonist that lowers blood pressure by decreasing the amoun t of certain chemicals in your blood. This allows your blood vessels to relax and your heart to beat more slowly and easily. It can cause drowsiness, but the specific symptoms of orthostatic hypotension upon standing are more closely associated with alpha-1 blockers like Prazosin.</li><li>\u2022 Option D. Clonidine:</li><li>\u2022 alpha-2 adrenergic agonist</li><li>\u2022 lowers blood pressure</li><li>\u2022 decreasing the amoun</li><li>\u2022 certain chemicals</li><li>\u2022 blood vessels to relax</li><li>\u2022 heart to beat more slowly and easily.</li><li>\u2022 drowsiness,</li><li>\u2022 orthostatic hypotension</li><li>\u2022 more closely</li><li>\u2022 alpha-1 blockers like Prazosin.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to identify the a ntihypertensive medication most likely to cause orthostatic hypotension among the options provided. Understanding the side effect profiles of antihypertensive agents, especially those that can impact patient safety and quality of life , such as orthostatic hypotension, is crucial in managing and monitoring treatment in hypertensive patients.</li><li>\u27a4 ntihypertensive medication</li><li>\u27a4 cause orthostatic hypotension</li><li>\u27a4 Understanding</li><li>\u27a4 side effect</li><li>\u27a4 antihypertensive agents,</li><li>\u27a4 impact patient safety and</li><li>\u27a4 quality of life</li><li>\u27a4 orthostatic hypotension,</li><li>\u27a4 managing and monitoring treatment in hypertensive patients.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "66bf2823",
      "audio": ""
    },
    {
      "text": "Regarding propranolol, find out the true statement?",
      "options": [
        {
          "label": "A",
          "text": "It is contraindicated in hypertrophic cardiomyopathy",
          "correct": false
        },
        {
          "label": "B",
          "text": "It can be given topically for treatment of glaucoma",
          "correct": false
        },
        {
          "label": "C",
          "text": "It is a lipid soluble non-selective beta blocker",
          "correct": true
        },
        {
          "label": "D",
          "text": "It inhibits the release of T3 and T4 and is therefore useful in hyperthyroidism.",
          "correct": false
        }
      ],
      "correct_answer": "C. It is a lipid soluble non-selective beta blocker",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) It is a lipid soluble non-selective beta blocker.</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. It is contraindicated in hypertrophic cardiomyopathy: This statement is false . Propranolol is actually drug of choice in the management of hypertrophic cardiomyopathy to help control heart rate and reduce left ventricular outflow obstruction .</li><li>\u2022 Option A. It is contraindicated in hypertrophic cardiomyopathy: This statement is false . Propranolol is actually drug of choice in the management of hypertrophic cardiomyopathy to help control heart rate and reduce left ventricular outflow obstruction .</li><li>\u2022 Option A. It is contraindicated in hypertrophic cardiomyopathy:</li><li>\u2022 false</li><li>\u2022 Propranolol</li><li>\u2022 drug of</li><li>\u2022 hypertrophic cardiomyopathy</li><li>\u2022 control heart rate and reduce left ventricular</li><li>\u2022 outflow obstruction</li><li>\u2022 Option B. It can be given topically for treatment of glaucoma: This statement is incorrect regarding propranolol. Beta-blockers like timolol, not propranolol , are used topically in the treatment of glaucoma to reduce intraocular pressure. Due to its membrane stabilizing property , propranolol is contra-indicated in glaucoma.</li><li>\u2022 Option B. It can be given topically for treatment of glaucoma: This statement is incorrect regarding propranolol. Beta-blockers like timolol, not propranolol , are used topically in the treatment of glaucoma to reduce intraocular pressure. Due to its membrane stabilizing property , propranolol is contra-indicated in glaucoma.</li><li>\u2022 Option B. It can be given topically for treatment of glaucoma:</li><li>\u2022 incorrect</li><li>\u2022 propranolol. Beta-blockers</li><li>\u2022 timolol,</li><li>\u2022 not propranolol</li><li>\u2022 topically</li><li>\u2022 glaucoma</li><li>\u2022 reduce intraocular pressure.</li><li>\u2022 membrane stabilizing property</li><li>\u2022 propranolol is contra-indicated in glaucoma.</li><li>\u2022 Option D. It inhibits the release of T3 and T4 and is therefore useful in hyperthyroidism: Propranolol does not directly inhibit the release of thyroid hormones (T3 and T4). However, it is useful in the symptomatic management of hyperthyroidism, such as controlling heart rate and tremors . Its usefulness in h yperthyroidism is due to its beta-blocking effects rather than a direct effect on thyroid hormone release. It can also inhibit peripheral conversion of T4 to T3.</li><li>\u2022 Option D. It inhibits the release of T3 and T4 and is therefore useful in hyperthyroidism: Propranolol does not directly inhibit the release of thyroid hormones (T3 and T4). However, it is useful in the symptomatic management of hyperthyroidism, such as controlling heart rate and tremors . Its usefulness in h yperthyroidism is due to its beta-blocking effects rather than a direct effect on thyroid hormone release. It can also inhibit peripheral conversion of T4 to T3.</li><li>\u2022 Option D. It inhibits the release of T3 and T4 and is therefore useful in hyperthyroidism:</li><li>\u2022 does not</li><li>\u2022 inhibit</li><li>\u2022 thyroid hormones (T3 and T4).</li><li>\u2022 symptomatic management of</li><li>\u2022 hyperthyroidism,</li><li>\u2022 controlling heart rate and tremors</li><li>\u2022 yperthyroidism</li><li>\u2022 its beta-blocking effects</li><li>\u2022 inhibit peripheral conversion of T4 to</li><li>\u2022 T3.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The educational goal is to clarify the properties and clinical applications of propranolol, a non-selective beta-blocker with lipid solubility, and to correct misconceptions regarding its use and mechanisms of action. Understanding the pharmacological characteristics and therapeutic implications of beta-blockers like propranolol is essential for their appropriate clinical use.</li><li>\u27a4 properties</li><li>\u27a4 clinical</li><li>\u27a4 propranolol,</li><li>\u27a4 non-selective beta-blocker</li><li>\u27a4 lipid</li><li>\u27a4 solubility,</li><li>\u27a4 correct misconceptions</li><li>\u27a4 use and mechanisms of action.</li><li>\u27a4 beta-blockers like propranolol</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "a641c1b1",
      "audio": ""
    },
    {
      "text": "Muscarinic receptor stimulation primarily causes which of the following actions?",
      "options": [
        {
          "label": "A",
          "text": "Erection",
          "correct": true
        },
        {
          "label": "B",
          "text": "Ejaculation",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dilation of bronchus",
          "correct": false
        },
        {
          "label": "D",
          "text": "Increased cardiac contractility",
          "correct": false
        }
      ],
      "correct_answer": "A. Erection",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Erection</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Ejaculation: This is primarily a function of the sympathetic nervous system, not muscarinic receptor stimulation.</li><li>\u2022 Option B. Ejaculation:</li><li>\u2022 Option C. Dilation of bronchus: Muscarinic receptor stimulation actually leads to bronchoconstriction, not dilation. The dilation of bronchi is mediated by the sympathetic nervous system through \u03b22-adrenergic receptors.</li><li>\u2022 Option C. Dilation of bronchus:</li><li>\u2022 Option D. Increased cardiac contractility: This is mainly mediated by \u03b21-adrenergic receptors under the influence of the sympathetic nervous system. Muscarinic receptor stimulation can decrease heart rate but does not directly increase contractility.</li><li>\u2022 Option D. Increased cardiac contractility:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 The parasympathetic nervous system, through muscarinic receptor stimulation, primarily causes erection due to vasodilation in erectile tissues, contrasting with the sympathetic nervous system's role in ejaculation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ef05857b",
      "audio": ""
    },
    {
      "text": "A patient who is on metoprolol for hypertension is given verapamil. What side effect is he likely to suffer from?",
      "options": [
        {
          "label": "A",
          "text": "Bradycardia and AV Block",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tachycardia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Torsades\u2019 de pointes",
          "correct": false
        },
        {
          "label": "D",
          "text": "Ventricular tachycardia",
          "correct": false
        }
      ],
      "correct_answer": "A. Bradycardia and AV Block",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Bradycardia and AV Block</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Tachycardia: Unlikely , since both drugs have a depressive effect on the heart.</li><li>\u2022 Option B.</li><li>\u2022 Tachycardia:</li><li>\u2022 Unlikely</li><li>\u2022 both drugs have a depressive effect on the heart.</li><li>\u2022 Option C. Torsades\u2019 de pointes: This is a specific form of ventricular tachycardia typically associated with drugs that prolong the QT interval, which is not a known effect of either verapamil or metoprolol.</li><li>\u2022 Option C.</li><li>\u2022 Torsades\u2019 de pointes:</li><li>\u2022 specific form of ventricular tachycardia</li><li>\u2022 QT</li><li>\u2022 interval,</li><li>\u2022 not a known effect of either verapamil or metoprolol.</li><li>\u2022 Option D. Ventricular tachycardia: This is not typically caused by the combination of a beta-blocker and a calcium channel blocker like verapamil .</li><li>\u2022 Option D.</li><li>\u2022 Ventricular tachycardia:</li><li>\u2022 not</li><li>\u2022 combination of a beta-blocker and a calcium channel blocker</li><li>\u2022 verapamil</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Combining metoprolol with verapamil can lead to an a dditive effect on the heart, potentially causing bradycardia and AV block. Therefore, such a combination should be used with caution or avoided.</li><li>\u2022 Combining</li><li>\u2022 metoprolol with verapamil</li><li>\u2022 lead</li><li>\u2022 dditive effect on the heart,</li><li>\u2022 bradycardia and AV block.</li><li>\u2022 combination</li><li>\u2022 caution or avoided.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e0b18c61",
      "audio": ""
    },
    {
      "text": "All of the following beta blockers can cross blood brain barrier except?",
      "options": [
        {
          "label": "A",
          "text": "Propranolol",
          "correct": false
        },
        {
          "label": "B",
          "text": "Atenolol",
          "correct": true
        },
        {
          "label": "C",
          "text": "Oxprenolol",
          "correct": false
        },
        {
          "label": "D",
          "text": "Timolol",
          "correct": false
        }
      ],
      "correct_answer": "B. Atenolol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Atenolol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Propranolol: A lipid-soluble beta-blocker that can cross the blood-brain barrier and may cause CNS side effects.</li><li>\u2022 Option A.</li><li>\u2022 Propranolol:</li><li>\u2022 lipid-soluble beta-blocker</li><li>\u2022 can cross the blood-brain barrier</li><li>\u2022 CNS side effects.</li><li>\u2022 Option C. Oxprenolol: A lipid-soluble beta-blocker with partial lipid solubility and can have some penetration into the CNS.</li><li>\u2022 Option C.</li><li>\u2022 Oxprenolol:</li><li>\u2022 lipid-soluble beta-blocker</li><li>\u2022 partial lipid solubility</li><li>\u2022 some penetration into the CNS.</li><li>\u2022 Option D. Timolol: A beta-blocker with some lipid solubility, which allows it to cross the blood-brain barrier.</li><li>\u2022 Option D.</li><li>\u2022 Timolol:</li><li>\u2022 beta-blocker</li><li>\u2022 lipid solubility,</li><li>\u2022 cross the blood-brain barrier.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Atenolol is a water-soluble beta-blocker that does not cross the blood-brain barrie r, making it a preferable option for patients at risk of CNS side effects and requiring careful use in patients with renal impairment due to its excretion predominantly via the kidneys.</li><li>\u2022 Atenolol is a water-soluble beta-blocker</li><li>\u2022 does not cross the blood-brain barrie</li><li>\u2022 risk</li><li>\u2022 CNS side effects</li><li>\u2022 patients with renal impairment</li><li>\u2022 excretion predominantly</li><li>\u2022 kidneys.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bb2486c5",
      "audio": ""
    },
    {
      "text": "All of the following are adverse effects of salmeterol except?",
      "options": [
        {
          "label": "A",
          "text": "Hypoglycemia",
          "correct": true
        },
        {
          "label": "B",
          "text": "Hypokalemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Tachycardia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tremors",
          "correct": false
        }
      ],
      "correct_answer": "A. Hypoglycemia",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Hypoglycemia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Hypokalemia: Can occur due to the intracellular shifting of potassium ions.</li><li>\u2022 Option B.</li><li>\u2022 Hypokalemia:</li><li>\u2022 due to the intracellular shifting of potassium ions.</li><li>\u2022 Option C. Tachycardia: Can result from beta-2 stimulation in the heart , leading to increased heart rate.</li><li>\u2022 Option C.</li><li>\u2022 Tachycardia:</li><li>\u2022 beta-2 stimulation in the heart</li><li>\u2022 increased heart rate.</li><li>\u2022 Option D. Tremors: Are a common side effect due to stimulation of beta-2 receptors in the skeletal muscles.</li><li>\u2022 Option D.</li><li>\u2022 Tremors:</li><li>\u2022 due to stimulation of beta-2 receptors</li><li>\u2022 skeletal muscles.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Salmeterol, as a beta-2 agonist, does not typically cause hypoglycemia; its adverse effects related to beta-2 stimulation include tremors, tachycardia, and hypokalemia. Always monitor these potential side effects when prescribing or using beta-2 agonists.</li><li>\u2022 Salmeterol,</li><li>\u2022 beta-2 agonist,</li><li>\u2022 does not</li><li>\u2022 hypoglycemia;</li><li>\u2022 beta-2 stimulation</li><li>\u2022 tremors, tachycardia, and hypokalemia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ab245e8c",
      "audio": ""
    },
    {
      "text": "Choose the 3 rd generation beta blockers among the following drugs? Labetalol Carvedilol Nebivolol Bisoprolol",
      "options": [
        {
          "label": "A",
          "text": "A,B,C are correct",
          "correct": true
        },
        {
          "label": "B",
          "text": "A and C are correct",
          "correct": false
        },
        {
          "label": "C",
          "text": "B and D are correct",
          "correct": false
        },
        {
          "label": "D",
          "text": "All 4 are correct",
          "correct": false
        }
      ],
      "correct_answer": "A. A,B,C are correct",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/44.jpg"
      ],
      "explanation": "<p><strong>Ans. A) A, B, C are correct</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Bisoprolol is a second-generation beta-blocker with selective beta-1 blocking properties. It does not cause vasodilation so it cannot be classified as third generation.</li><li>\u2022 Bisoprolol</li><li>\u2022 second-generation beta-blocker</li><li>\u2022 selective beta-1 blocking properties. It does not cause vasodilation so it cannot be classified as third generation.</li><li>\u2022 Labetalol: A non-selective beta-blocker with additional alpha-1 blocking properties, leading to vasodilation. Carvedilol: Another non-selective beta-blocker with alpha-1 blockade. It also has calcium channel blocking and antioxidant properties. Nebivolol: A selective beta-1 blocker with additional vasodilatory effects due to nitric oxide (NO) release.</li><li>\u2022 Labetalol: A non-selective beta-blocker with additional alpha-1 blocking properties, leading to vasodilation.</li><li>\u2022 Labetalol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 alpha-1 blocking properties,</li><li>\u2022 vasodilation.</li><li>\u2022 Carvedilol: Another non-selective beta-blocker with alpha-1 blockade. It also has calcium channel blocking and antioxidant properties.</li><li>\u2022 Carvedilol:</li><li>\u2022 non-selective beta-blocker</li><li>\u2022 alpha-1 blockade.</li><li>\u2022 calcium channel blocking and</li><li>\u2022 antioxidant properties.</li><li>\u2022 Nebivolol: A selective beta-1 blocker with additional vasodilatory effects due to nitric oxide (NO) release.</li><li>\u2022 Nebivolol:</li><li>\u2022 selective beta-1 blocker</li><li>\u2022 additional vasodilatory effects</li><li>\u2022 nitric oxide (NO) release.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Labetalol, carvedilol, and nebivolol are third-generation beta-blockers with additional vasodilatory properties. This classification is important for the tailored treatment of hypertension, heart failure, and other cardiovascular conditions, where the additional effects of these drugs on vasodilation can provide therapeutic advantages.</li><li>\u2022 Labetalol, carvedilol, and nebivolol</li><li>\u2022 third-generation beta-blockers</li><li>\u2022 additional vasodilatory properties.</li><li>\u2022 tailored</li><li>\u2022 treatment of hypertension, heart failure, and other cardiovascular conditions,</li><li>\u2022 additional</li><li>\u2022 effects</li><li>\u2022 vasodilation</li><li>\u2022 therapeutic advantages.</li><li>\u2022 Explanations :</li><li>\u2022 Explanations :</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a1f9c85",
      "audio": ""
    },
    {
      "text": "A patient with diabetes and COPD developed postoperative urinary retention. Which of the following drugs can be used for short-term treatment to relieve the symptoms of this person?",
      "options": [
        {
          "label": "A",
          "text": "Bethanechol",
          "correct": true
        },
        {
          "label": "B",
          "text": "Tamsolusin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Terazosin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Methacholine",
          "correct": false
        }
      ],
      "correct_answer": "A. Bethanechol",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Bethanechol</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation of options:</li><li>\u2022 Option A. Bethanechol : This drug is indeed used to treat urinary retention , as it stimulates muscarinic receptors in the bladder to induce contraction. Given that it is a direct cholinergic agonist, it could cause bronchoconstriction and would not be ideal for a patient with COPD, but it remains a treatment option specifically for urinary retention if the COPD is well-controlled and not severe.</li><li>\u2022 Option A. Bethanechol</li><li>\u2022 drug</li><li>\u2022 treat urinary retention</li><li>\u2022 stimulates muscarinic receptors</li><li>\u2022 bladder to</li><li>\u2022 induce contraction.</li><li>\u2022 direct cholinergic agonist,</li><li>\u2022 bronchoconstriction</li><li>\u2022 would not</li><li>\u2022 ideal</li><li>\u2022 COPD,</li><li>\u2022 urinary retention if the COPD</li><li>\u2022 well-controlled and not severe.</li><li>\u2022 Option B. Tamsulosin : While this drug is primarily used in the context of BPH, it does no t have a direct action to stimulate bladder emptying in the absence of BPH and is not used for postoperative urinary retention.</li><li>\u2022 Option B. Tamsulosin</li><li>\u2022 primarily used</li><li>\u2022 BPH,</li><li>\u2022 does no</li><li>\u2022 stimulate bladder</li><li>\u2022 emptying</li><li>\u2022 absence of BPH</li><li>\u2022 not used for postoperative urinary retention.</li><li>\u2022 Option C. Terazosin : Similar to tamsulosin, terazosin is an alpha-blocker used in BPH and is not used for postoperative urinary retention unless there is concurrent BPH.</li><li>\u2022 Option C. Terazosin</li><li>\u2022 Similar to tamsulosin, terazosin</li><li>\u2022 alpha-blocker</li><li>\u2022 BPH</li><li>\u2022 not used for postoperative urinary</li><li>\u2022 retention</li><li>\u2022 concurrent BPH.</li><li>\u2022 Option D.  Methacholine : This drug is primarily used for diagnostic purposes in conditions like asthma and is not used for treating urinary retention. Like bethanechol, it could potentially exacerbate COPD due to bronchoconstriction.</li><li>\u2022 Option D.  Methacholine</li><li>\u2022 primarily used for diagnostic purposes</li><li>\u2022 asthma</li><li>\u2022 not used for treating</li><li>\u2022 urinary retention.</li><li>\u2022 bethanechol,</li><li>\u2022 exacerbate COPD</li><li>\u2022 bronchoconstriction.</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 Bethanechol is the drug that is used for non-BPH related urinary retention, as it directly stimulates the detrusor muscle of the bladder . However, it would need to be used with caution in a patient with COPD. We need to weigh the benefits of using bethanechol for urinary retention against the risk of exacerbating the patient's COPD and monitor the patient closely.</li><li>\u2022 Bethanechol</li><li>\u2022 drug</li><li>\u2022 non-BPH</li><li>\u2022 urinary retention,</li><li>\u2022 stimulates the detrusor muscle of the</li><li>\u2022 bladder</li><li>\u2022 used with caution</li><li>\u2022 COPD.</li><li>\u2022 weigh the benefits</li><li>\u2022 bethanechol for urinary retention</li><li>\u2022 exacerbating the patient's COPD</li><li>\u2022 monitor the patient closely.</li><li>\u2022 Note: Among the given drugs, only bethanechol is useful for treatment of post operative urinary retention. Though it can worsen COPD by causing bronchoconstriction but still this should be the answer, as no other drug given in option s is useful in post operative retention.</li><li>\u2022 Note:</li><li>\u2022 only bethanechol</li><li>\u2022 post operative urinary retention.</li><li>\u2022 worsen</li><li>\u2022 COPD by causing bronchoconstriction</li><li>\u2022 no other drug given in option</li><li>\u2022 post operative retention.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8240d749",
      "audio": ""
    },
    {
      "text": "Anti-glaucoma drug that acts by increasing uveoscleral outflow is:",
      "options": [
        {
          "label": "A",
          "text": "Latanoprost",
          "correct": true
        },
        {
          "label": "B",
          "text": "Timolol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Dorzolamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Pilocarpine",
          "correct": false
        }
      ],
      "correct_answer": "A. Latanoprost",
      "question_images": [],
      "explanation_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/05/11/99.jpg"
      ],
      "explanation": "<p><strong>Ans. A) Latanoprost</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option B. Timolol: Timolol is a beta-blocke r used in the treatment of glaucoma, but it works by decreasing aqueous humor production in the eye, not by increasing uveoscleral outflow.</li><li>\u2022 Option B. Timolol: Timolol is a beta-blocke r used in the treatment of glaucoma, but it works by decreasing aqueous humor production in the eye, not by increasing uveoscleral outflow.</li><li>\u2022 Option B. Timolol:</li><li>\u2022 beta-blocke</li><li>\u2022 treatment of glaucoma,</li><li>\u2022 decreasing aqueous</li><li>\u2022 humor production in the eye,</li><li>\u2022 Option C. Dorzolamide: Dorzolamide is a carbonic anhydrase inhibitor that also reduces intraocular pressure by decreasing aqueous humor production . It does not act by increasing uveoscleral outflow.</li><li>\u2022 Option C. Dorzolamide: Dorzolamide is a carbonic anhydrase inhibitor that also reduces intraocular pressure by decreasing aqueous humor production . It does not act by increasing uveoscleral outflow.</li><li>\u2022 Option C. Dorzolamide:</li><li>\u2022 Dorzolamide is a carbonic anhydrase inhibitor</li><li>\u2022 reduces intraocular pressure</li><li>\u2022 decreasing aqueous humor production</li><li>\u2022 Option D. Pilocarpine: Pilocarpine is a muscarinic agonist that reduces i ntraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork, which is different from increasing uveoscleral outflow.</li><li>\u2022 Option D. Pilocarpine: Pilocarpine is a muscarinic agonist that reduces i ntraocular pressure by increasing the outflow of aqueous humor through the trabecular meshwork, which is different from increasing uveoscleral outflow.</li><li>\u2022 Option D. Pilocarpine:</li><li>\u2022 Pilocarpine is a muscarinic agonist</li><li>\u2022 ntraocular pressure by increasing the outflow of</li><li>\u2022 aqueous humor</li><li>\u2022 trabecular meshwork,</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The objective is to recognize the mechanism of action of different anti-glaucoma medications , particularly identifying latanoprost as a drug that reduces intraocular pressure by increasing uveoscleral outflow. Understanding how various anti-glaucoma drugs work is essential for selecting appropriate treatment options based on the individual needs and pathophysiology of the patient's glaucoma.</li><li>\u27a4 mechanism of action</li><li>\u27a4 anti-glaucoma medications</li><li>\u27a4 latanoprost as</li><li>\u27a4 reduces intraocular pressure</li><li>\u27a4 increasing uveoscleral outflow.</li><li>\u27a4 anti-glaucoma</li><li>\u27a4 Mechanism of action of anti-glaucoma drugs</li><li>\u27a4 Mechanism of action of anti-glaucoma drugs</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "812e4c43",
      "audio": ""
    },
    {
      "text": "A patient presented with acute glaucoma and painful red eye. Intraocular pressure was 38 mmHg. Slit lamp examination showed aqueous flare and keratic precipitates. Which of the following drugs should not be given in this patient for the control of glaucoma?",
      "options": [
        {
          "label": "A",
          "text": "Beta blockers",
          "correct": false
        },
        {
          "label": "B",
          "text": "Mannitol",
          "correct": false
        },
        {
          "label": "C",
          "text": "Acetazolamide",
          "correct": false
        },
        {
          "label": "D",
          "text": "Prostaglandin analogues",
          "correct": true
        }
      ],
      "correct_answer": "D. Prostaglandin analogues",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Prostaglandin analogues</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option Beta blockers (A. Beta blockers) reduce intraocular pressure by decreasing the production of aqueous humor. They do not directly address inflammation but can be used in conjunction with anti-inflammatory treatments.</li><li>\u2022 Option Beta blockers (A. Beta blockers) reduce intraocular pressure by decreasing the production of aqueous humor. They do not directly address inflammation but can be used in conjunction with anti-inflammatory treatments.</li><li>\u2022 Option Beta blockers</li><li>\u2022 reduce intraocular pressure</li><li>\u2022 decreasing</li><li>\u2022 aqueous humor.</li><li>\u2022 do not</li><li>\u2022 inflammation</li><li>\u2022 conjunction</li><li>\u2022 anti-inflammatory treatments.</li><li>\u2022 Option Mannitol (B. Mannitol), an osmotic diuretic , can rapidly reduce intraocular pressure by drawing fluid out of the eye, including in acute settings. It does not worsen the underlying inflammation.</li><li>\u2022 Option Mannitol (B. Mannitol), an osmotic diuretic , can rapidly reduce intraocular pressure by drawing fluid out of the eye, including in acute settings. It does not worsen the underlying inflammation.</li><li>\u2022 Option Mannitol</li><li>\u2022 osmotic diuretic</li><li>\u2022 rapidly reduce intraocular pressure</li><li>\u2022 drawing fluid out</li><li>\u2022 eye,</li><li>\u2022 acute settings.</li><li>\u2022 does not</li><li>\u2022 underlying inflammation.</li><li>\u2022 Option Acetazolamide (C. Acetazolamide) reduces aqueous humor production and, consequently, ientraocular pressure. These does not worsen inflammation and is used as part of a broader treatment regimen.</li><li>\u2022 Option Acetazolamide (C. Acetazolamide) reduces aqueous humor production and, consequently, ientraocular pressure. These does not worsen inflammation and is used as part of a broader treatment regimen.</li><li>\u2022 Option Acetazolamide</li><li>\u2022 reduces aqueous humor production</li><li>\u2022 ientraocular pressure.</li><li>\u2022 does not</li><li>\u2022 inflammation</li><li>\u2022 broader treatment regimen.</li><li>\u2022 For managing uveitis specifically, treatment often includes corticosteroids (either topical, periocular, or systemic) to reduce inflammation and immunosuppressive agent s in more severe cases . It\u2019s important to treat both the inflammation caused by uveitis and the elevated intraocular pressure to prevent vision loss.</li><li>\u2022 For managing uveitis</li><li>\u2022 treatment</li><li>\u2022 corticosteroids (either topical, periocular, or systemic)</li><li>\u2022 reduce</li><li>\u2022 inflammation and immunosuppressive agent</li><li>\u2022 more severe cases</li><li>\u2022 both the inflammation</li><li>\u2022 uveitis</li><li>\u2022 elevated intraocular pressure to prevent vision loss.</li></ul>\n<p><strong>Educational Objective:</strong></p><ul><li>\u27a4 Educational Objective:</li><li>\u27a4 The presence of uveitis in a patient with glaucoma significantly impacts the choice of treatment. Understanding the need to manage intraocular pressure while also addressing ocular inflammation is crucial. The goal is to select a treatment regimen that effectively lowers intraocular pressure without exacerbating uveitis , highlighting the importance of a comprehensive approach to patient care that considers the complexities introduced by overlapping ocular conditions.</li><li>\u27a4 presence of uveitis</li><li>\u27a4 glaucoma</li><li>\u27a4 impacts</li><li>\u27a4 manage</li><li>\u27a4 intraocular pressure</li><li>\u27a4 ocular inflammation is crucial.</li><li>\u27a4 lowers intraocular pressure without exacerbating uveitis</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "869b3eba",
      "audio": ""
    },
    {
      "text": "All of the following can be the mechanism for paradoxical bronchoconstriction seen with the use of ipratropium bromide Except?",
      "options": [
        {
          "label": "A",
          "text": "Presence of benzalkonium bromide in the preparation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prejunctional M2 receptor stimulation",
          "correct": true
        },
        {
          "label": "C",
          "text": "Associated use of hypertonic saline in nebulizer",
          "correct": false
        },
        {
          "label": "D",
          "text": "Presence of EDTA as impurity",
          "correct": false
        }
      ],
      "correct_answer": "B. Prejunctional M2 receptor stimulation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B. Prejunctional M2 receptor stimulation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation:</li><li>\u2022 Option A. Benzalkonium bromide: A preservative in some inhaler formulation s, which can cause airway irritation and constriction.</li><li>\u2022 Option A. Benzalkonium bromide: A preservative in some inhaler formulation s, which can cause airway irritation and constriction.</li><li>\u2022 Option A. Benzalkonium bromide:</li><li>\u2022 preservative</li><li>\u2022 inhaler formulation</li><li>\u2022 airway irritation and</li><li>\u2022 constriction.</li><li>\u2022 Option C. Hypertonic saline: Can also cause bronchoconstriction due to its osmotic effects on the airway.</li><li>\u2022 Option C. Hypertonic saline: Can also cause bronchoconstriction due to its osmotic effects on the airway.</li><li>\u2022 Option C. Hypertonic saline:</li><li>\u2022 bronchoconstriction</li><li>\u2022 osmotic effects on the airway.</li><li>\u2022 Option D. EDTA: Can act as an irritant leading to bronchoconstriction when included as an impurity in the formulation .</li><li>\u2022 Option D. EDTA: Can act as an irritant leading to bronchoconstriction when included as an impurity in the formulation .</li><li>\u2022 Option D. EDTA:</li><li>\u2022 irritant</li><li>\u2022 bronchoconstriction</li><li>\u2022 impurity in the formulation</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 While ipratropium bromide is typically used for its bronchodilatory effects, certain excipients or impurities in the formulation, like benzalkonium bromide or EDTA, as well as associated use of hypertonic saline, can lead to paradoxical bronchoconstriction. However, prejunctional M2 receptor stimulation would no t be the correct mechanism for this adverse effect , as ipratropium would block rather than stimulate these receptors.</li><li>\u2022 ipratropium bromide</li><li>\u2022 bronchodilatory effects,</li><li>\u2022 excipients or impurities</li><li>\u2022 benzalkonium bromide or EDTA,</li><li>\u2022 hypertonic saline,</li><li>\u2022 paradoxical bronchoconstriction.</li><li>\u2022 prejunctional M2 receptor stimulation</li><li>\u2022 no</li><li>\u2022 correct mechanism</li><li>\u2022 adverse effect</li><li>\u2022 ipratropium would</li><li>\u2022 block</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e28fe5e7",
      "audio": ""
    }
  ]
}